id	sid	tid	token	lemma	pos
admet-335	1	1	manuscript	manuscript	PROPN
admet-335	1	2	doi	doi	PROPN
admet-335	1	3	:	:	PUNCT
admet-335	1	4	10.5599	10.5599	NUM
admet-335	1	5	/	/	SYM
admet-335	1	6	admet.4.4.335	admet.4.4.335	PROPN
admet-335	1	7	327	327	NUM
admet-335	1	8	admet	admet	X
admet-335	1	9	&	&	CCONJ
admet-335	1	10	dmpk	dmpk	PROPN
admet-335	1	11	4(4	4(4	NUM
admet-335	1	12	)	)	PUNCT
admet-335	1	13	(	(	PUNCT
admet-335	1	14	2016	2016	NUM
admet-335	1	15	)	)	PUNCT
admet-335	1	16	327	327	NUM
admet-335	1	17	-	-	SYM
admet-335	1	18	334	334	NUM
admet-335	1	19	;	;	PUNCT
admet-335	1	20	doi	doi	NOUN
admet-335	1	21	:	:	PUNCT
admet-335	1	22	10.5599	10.5599	NUM
admet-335	1	23	/	/	SYM
admet-335	1	24	admet.4.4.335	admet.4.4.335	NOUN
admet-335	1	25	open	open	ADJ
admet-335	1	26	access	access	NOUN
admet-335	1	27	:	:	PUNCT
admet-335	1	28	issn	issn	PROPN
admet-335	1	29	:	:	PUNCT
admet-335	1	30	1848	1848	NUM
admet-335	1	31	-	-	SYM
admet-335	1	32	7718	7718	NUM
admet-335	1	33	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-335	1	34	original	original	ADJ
admet-335	1	35	scientific	scientific	ADJ
admet-335	1	36	paper	paper	NOUN
admet-335	1	37	tissue	tissue	NOUN
admet-335	1	38	distribution	distribution	NOUN
admet-335	1	39	of	of	ADP
admet-335	1	40	crizotinib	crizotinib	NOUN
admet-335	1	41	and	and	CCONJ
admet-335	1	42	gemcitabine	gemcitabine	NOUN
admet-335	1	43	combination	combination	NOUN
admet-335	1	44	in	in	ADP
admet-335	1	45	a	a	DET
admet-335	1	46	patient	patient	NOUN
admet-335	1	47	-	-	PUNCT
admet-335	1	48	derived	derive	VERB
admet-335	1	49	orthotopic	orthotopic	ADJ
admet-335	1	50	mouse	mouse	NOUN
admet-335	1	51	model	model	NOUN
admet-335	1	52	of	of	ADP
admet-335	1	53	pancreatic	pancreatic	ADJ
admet-335	1	54	cancer	cancer	NOUN
admet-335	1	55	richard	richard	PROPN
admet-335	1	56	j	j	PROPN
admet-335	1	57	honeywell1	honeywell1	PROPN
admet-335	1	58	,	,	PUNCT
admet-335	1	59	amir	amir	PROPN
admet-335	1	60	avan2	avan2	PROPN
admet-335	1	61	,	,	PUNCT
admet-335	1	62	elisa	elisa	PROPN
admet-335	1	63	giovannetti1,3	giovannetti1,3	PROPN
admet-335	1	64	and	and	CCONJ
admet-335	1	65	godefridus	godefridus	VERB
admet-335	1	66	j	j	PROPN
admet-335	1	67	peters1	peters1	NOUN
admet-335	1	68	,	,	PUNCT
admet-335	1	69	*	*	PROPN
admet-335	1	70	1	1	NUM
admet-335	1	71	department	department	NOUN
admet-335	1	72	of	of	ADP
admet-335	1	73	medical	medical	ADJ
admet-335	1	74	oncology	oncology	NOUN
admet-335	1	75	,	,	PUNCT
admet-335	1	76	vu	vu	PROPN
admet-335	1	77	university	university	PROPN
admet-335	1	78	medical	medical	ADJ
admet-335	1	79	center	center	NOUN
admet-335	1	80	,	,	PUNCT
admet-335	1	81	po	po	PROPN
admet-335	1	82	box	box	PROPN
admet-335	1	83	7057	7057	NUM
admet-335	1	84	,	,	PUNCT
admet-335	1	85	1007	1007	NUM
admet-335	1	86	mb	mb	ADP
admet-335	1	87	amsterdam	amsterdam	PROPN
admet-335	1	88	,	,	PUNCT
admet-335	1	89	the	the	DET
admet-335	1	90	netherlands	netherlands	PROPN
admet-335	1	91	2	2	NUM
admet-335	1	92	molecular	molecular	ADJ
admet-335	1	93	medicine	medicine	NOUN
admet-335	1	94	group	group	NOUN
admet-335	1	95	,	,	PUNCT
admet-335	1	96	department	department	NOUN
admet-335	1	97	of	of	ADP
admet-335	1	98	modern	modern	ADJ
admet-335	1	99	sciences	science	NOUN
admet-335	1	100	and	and	CCONJ
admet-335	1	101	technologies	technology	NOUN
admet-335	1	102	,	,	PUNCT
admet-335	1	103	faculty	faculty	NOUN
admet-335	1	104	of	of	ADP
admet-335	1	105	medicine	medicine	NOUN
admet-335	1	106	,	,	PUNCT
admet-335	1	107	mashhad	mashhad	PROPN
admet-335	1	108	university	university	PROPN
admet-335	1	109	of	of	ADP
admet-335	1	110	medical	medical	ADJ
admet-335	1	111	sciences	sciences	PROPN
admet-335	1	112	,	,	PUNCT
admet-335	1	113	mashhad	mashhad	PROPN
admet-335	1	114	,	,	PUNCT
admet-335	1	115	iran	iran	PROPN
admet-335	1	116	3	3	NUM
admet-335	1	117	cancer	cancer	NOUN
admet-335	1	118	pharmacology	pharmacology	NOUN
admet-335	1	119	lab	lab	NOUN
admet-335	1	120	,	,	PUNCT
admet-335	1	121	airc	airc	NOUN
admet-335	1	122	start	start	VERB
admet-335	1	123	-	-	PUNCT
admet-335	1	124	up	up	ADP
admet-335	1	125	unit	unit	NOUN
admet-335	1	126	,	,	PUNCT
admet-335	1	127	dipint	dipint	PROPN
admet-335	1	128	,	,	PUNCT
admet-335	1	129	pisa	pisa	PROPN
admet-335	1	130	,	,	PUNCT
admet-335	1	131	italy	italy	PROPN
admet-335	1	132	*	*	PUNCT
admet-335	1	133	corresponding	correspond	VERB
admet-335	1	134	author	author	NOUN
admet-335	1	135	:	:	PUNCT
admet-335	1	136	e	e	NOUN
admet-335	1	137	-	-	NOUN
admet-335	1	138	mail	mail	NOUN
admet-335	1	139	:	:	PUNCT
admet-335	1	140	gj.peters@vumc.nl	gj.peters@vumc.nl	PROPN
admet-335	1	141	.	.	PROPN
admet-335	1	142	received	receive	VERB
admet-335	1	143	:	:	PUNCT
admet-335	1	144	august	august	PROPN
admet-335	1	145	10	10	NUM
admet-335	1	146	,	,	PUNCT
admet-335	1	147	2016	2016	NUM
admet-335	1	148	;	;	PUNCT
admet-335	1	149	revised	revise	VERB
admet-335	1	150	:	:	PUNCT
admet-335	1	151	december	december	PROPN
admet-335	1	152	09	09	NUM
admet-335	1	153	,	,	PUNCT
admet-335	1	154	2016	2016	NUM
admet-335	1	155	;	;	PUNCT
admet-335	1	156	published	publish	VERB
admet-335	1	157	:	:	PUNCT
admet-335	1	158	december	december	PROPN
admet-335	1	159	26	26	NUM
admet-335	1	160	,	,	PUNCT
admet-335	1	161	2016	2016	NUM
admet-335	1	162	abstract	abstract	ADJ
admet-335	1	163	pharmacokinetics	pharmacokinetic	NOUN
admet-335	1	164	focuses	focus	VERB
admet-335	1	165	on	on	ADP
admet-335	1	166	the	the	DET
admet-335	1	167	question	question	NOUN
admet-335	1	168	whether	whether	SCONJ
admet-335	1	169	a	a	DET
admet-335	1	170	drug	drug	NOUN
admet-335	1	171	actually	actually	ADV
admet-335	1	172	reaches	reach	VERB
admet-335	1	173	its	its	PRON
admet-335	1	174	target	target	NOUN
admet-335	1	175	in	in	ADP
admet-335	1	176	therapeutic	therapeutic	ADJ
admet-335	1	177	concentrations	concentration	NOUN
admet-335	1	178	or	or	CCONJ
admet-335	1	179	accumulates	accumulate	VERB
admet-335	1	180	elsewhere	elsewhere	ADV
admet-335	1	181	,	,	PUNCT
admet-335	1	182	potentially	potentially	ADV
admet-335	1	183	causing	cause	VERB
admet-335	1	184	toxicological	toxicological	ADJ
admet-335	1	185	or	or	CCONJ
admet-335	1	186	unpredictable	unpredictable	ADJ
admet-335	1	187	side	side	NOUN
admet-335	1	188	effects	effect	NOUN
admet-335	1	189	.	.	PUNCT
admet-335	2	1	we	we	PRON
admet-335	2	2	determined	determine	VERB
admet-335	2	3	tissue	tissue	NOUN
admet-335	2	4	distribution	distribution	NOUN
admet-335	2	5	of	of	ADP
admet-335	2	6	gemcitabine	gemcitabine	NOUN
admet-335	2	7	,	,	PUNCT
admet-335	2	8	an	an	DET
admet-335	2	9	antimetabolite	antimetabolite	NOUN
admet-335	2	10	,	,	PUNCT
admet-335	2	11	and	and	CCONJ
admet-335	2	12	crizotinib	crizotinib	PROPN
admet-335	2	13	,	,	PUNCT
admet-335	2	14	a	a	DET
admet-335	2	15	tyrosine	tyrosine	NOUN
admet-335	2	16	-	-	PUNCT
admet-335	2	17	kinase	kinase	NOUN
admet-335	2	18	inhibitor	inhibitor	NOUN
admet-335	2	19	targeted	target	VERB
admet-335	2	20	against	against	ADP
admet-335	2	21	the	the	DET
admet-335	2	22	anaplastic	anaplastic	ADJ
admet-335	2	23	lymphoma	lymphoma	NOUN
admet-335	2	24	kinase	kinase	PROPN
admet-335	2	25	(	(	PUNCT
admet-335	2	26	alk	alk	PROPN
admet-335	2	27	)	)	PUNCT
admet-335	2	28	and	and	CCONJ
admet-335	2	29	mesenchymal	mesenchymal	ADJ
admet-335	2	30	-	-	ADJ
admet-335	2	31	epithelial	epithelial	ADJ
admet-335	2	32	transition	transition	NOUN
admet-335	2	33	factor	factor	NOUN
admet-335	2	34	(	(	PUNCT
admet-335	2	35	c	c	X
admet-335	2	36	-	-	PUNCT
admet-335	2	37	met	meet	VERB
admet-335	2	38	)	)	PUNCT
admet-335	2	39	receptors	receptor	NOUN
admet-335	2	40	,	,	PUNCT
admet-335	2	41	in	in	ADP
admet-335	2	42	a	a	DET
admet-335	2	43	validated	validate	VERB
admet-335	2	44	orthotopic	orthotopic	ADJ
admet-335	2	45	mouse	mouse	NOUN
admet-335	2	46	model	model	NOUN
admet-335	2	47	for	for	ADP
admet-335	2	48	pancreatic	pancreatic	ADJ
admet-335	2	49	cancer	cancer	NOUN
admet-335	2	50	.	.	PUNCT
admet-335	3	1	mice	mouse	NOUN
admet-335	3	2	with	with	ADP
admet-335	3	3	pancreatic	pancreatic	ADJ
admet-335	3	4	cancer	cancer	NOUN
admet-335	3	5	were	be	AUX
admet-335	3	6	treated	treat	VERB
admet-335	3	7	with	with	ADP
admet-335	3	8	either	either	CCONJ
admet-335	3	9	oral	oral	ADJ
admet-335	3	10	crizotinib	crizotinib	NOUN
admet-335	3	11	at	at	ADP
admet-335	3	12	25	25	NUM
admet-335	3	13	mg	mg	PROPN
admet-335	3	14	/	/	SYM
admet-335	3	15	kg	kg	PROPN
admet-335	3	16	,	,	PUNCT
admet-335	3	17	gemcitabine	gemcitabine	NOUN
admet-335	3	18	at	at	ADP
admet-335	3	19	100	100	NUM
admet-335	3	20	mg	mg	NOUN
admet-335	3	21	/	/	SYM
admet-335	3	22	kg	kg	NOUN
admet-335	3	23	or	or	CCONJ
admet-335	3	24	with	with	ADP
admet-335	3	25	their	their	PRON
admet-335	3	26	combination	combination	NOUN
admet-335	3	27	.	.	PUNCT
admet-335	4	1	two	two	NUM
admet-335	4	2	hours	hour	NOUN
admet-335	4	3	after	after	SCONJ
admet-335	4	4	the	the	DET
admet-335	4	5	last	last	ADJ
admet-335	4	6	gemcitabine	gemcitabine	NOUN
admet-335	4	7	dose	dose	NOUN
admet-335	4	8	mice	mouse	NOUN
admet-335	4	9	were	be	AUX
admet-335	4	10	sacrificed	sacrifice	VERB
admet-335	4	11	and	and	CCONJ
admet-335	4	12	all	all	DET
admet-335	4	13	available	available	ADJ
admet-335	4	14	blood	blood	NOUN
admet-335	4	15	/	/	SYM
admet-335	4	16	organs	organ	NOUN
admet-335	4	17	/	/	SYM
admet-335	4	18	tissues	tissue	NOUN
admet-335	4	19	were	be	AUX
admet-335	4	20	sampled	sample	VERB
admet-335	4	21	.	.	PUNCT
admet-335	5	1	tissue	tissue	NOUN
admet-335	5	2	was	be	AUX
admet-335	5	3	subsequently	subsequently	ADV
admet-335	5	4	analyzed	analyze	VERB
admet-335	5	5	for	for	ADP
admet-335	5	6	drug	drug	NOUN
admet-335	5	7	concentrations	concentration	NOUN
admet-335	5	8	using	use	VERB
admet-335	5	9	a	a	DET
admet-335	5	10	validated	validate	VERB
admet-335	5	11	liquid	liquid	ADJ
admet-335	5	12	chromatography	chromatography	NOUN
admet-335	5	13	-	-	PUNCT
admet-335	5	14	mass	mass	NOUN
admet-335	5	15	spectrometry	spectrometry	NOUN
admet-335	5	16	(	(	PUNCT
admet-335	5	17	lc	lc	PROPN
admet-335	5	18	-	-	PUNCT
admet-335	5	19	ms	ms	PROPN
admet-335	5	20	/	/	SYM
admet-335	5	21	ms	ms	NOUN
admet-335	5	22	)	)	PUNCT
admet-335	5	23	technique	technique	NOUN
admet-335	5	24	.	.	PUNCT
admet-335	6	1	in	in	ADP
admet-335	6	2	whole	whole	ADJ
admet-335	6	3	blood	blood	NOUN
admet-335	6	4	gemcitabine	gemcitabine	NOUN
admet-335	6	5	was	be	AUX
admet-335	6	6	about	about	ADV
admet-335	6	7	1.0	1.0	NUM
admet-335	6	8	µm	µm	NOUN
admet-335	6	9	and	and	CCONJ
admet-335	6	10	crizotinib	crizotinib	VERB
admet-335	6	11	2.4	2.4	NUM
admet-335	6	12	µm	µm	NOUN
admet-335	6	13	in	in	ADP
admet-335	6	14	the	the	DET
admet-335	6	15	single	single	ADJ
admet-335	6	16	treatment	treatment	NOUN
admet-335	6	17	,	,	PUNCT
admet-335	6	18	whereas	whereas	SCONJ
admet-335	6	19	in	in	SCONJ
admet-335	6	20	the	the	DET
admet-335	6	21	combination	combination	NOUN
admet-335	6	22	crizotinib	crizotinib	NOUN
admet-335	6	23	increased	increase	VERB
admet-335	6	24	the	the	DET
admet-335	6	25	levels	level	NOUN
admet-335	6	26	of	of	ADP
admet-335	6	27	gemcitabine	gemcitabine	NOUN
admet-335	6	28	.	.	PUNCT
admet-335	7	1	crizotinib	crizotinib	PROPN
admet-335	7	2	was	be	AUX
admet-335	7	3	found	find	VERB
admet-335	7	4	in	in	ADP
admet-335	7	5	all	all	DET
admet-335	7	6	major	major	ADJ
admet-335	7	7	tissues	tissue	NOUN
admet-335	7	8	,	,	PUNCT
admet-335	7	9	being	be	AUX
admet-335	7	10	highest	high	ADJ
admet-335	7	11	in	in	ADP
admet-335	7	12	the	the	DET
admet-335	7	13	intestine	intestine	NOUN
admet-335	7	14	.	.	PUNCT
admet-335	8	1	comparison	comparison	NOUN
admet-335	8	2	of	of	ADP
admet-335	8	3	crizotinib	crizotinib	NOUN
admet-335	8	4	alone	alone	ADV
admet-335	8	5	to	to	ADP
admet-335	8	6	the	the	DET
admet-335	8	7	gemcitabine	gemcitabine	NOUN
admet-335	8	8	-	-	PUNCT
admet-335	8	9	crizotinib	crizotinib	NOUN
admet-335	8	10	combination	combination	NOUN
admet-335	8	11	showed	show	VERB
admet-335	8	12	that	that	SCONJ
admet-335	8	13	crizotinib	crizotinib	VERB
admet-335	8	14	tissue	tissue	NOUN
admet-335	8	15	concentrations	concentration	NOUN
admet-335	8	16	were	be	AUX
admet-335	8	17	3	3	NUM
admet-335	8	18	-	-	SYM
admet-335	8	19	6	6	NUM
admet-335	8	20	fold	fold	ADV
admet-335	8	21	lower	lower	ADV
admet-335	8	22	in	in	ADP
admet-335	8	23	liver	liver	NOUN
admet-335	8	24	,	,	PUNCT
admet-335	8	25	lung	lung	NOUN
admet-335	8	26	,	,	PUNCT
admet-335	8	27	kidney	kidney	NOUN
admet-335	8	28	and	and	CCONJ
admet-335	8	29	spleen	spleen	NOUN
admet-335	8	30	,	,	PUNCT
admet-335	8	31	30	30	NUM
admet-335	8	32	-	-	NOUN
admet-335	8	33	fold	fold	VERB
admet-335	8	34	lower	lower	ADV
admet-335	8	35	in	in	ADP
admet-335	8	36	the	the	DET
admet-335	8	37	skin	skin	NOUN
admet-335	8	38	,	,	PUNCT
admet-335	8	39	heart	heart	NOUN
admet-335	8	40	and	and	CCONJ
admet-335	8	41	pancreas	pancrea	NOUN
admet-335	8	42	and	and	CCONJ
admet-335	8	43	200	200	NUM
admet-335	8	44	-	-	NUM
admet-335	8	45	fold	fold	VERB
admet-335	8	46	lower	lower	ADV
admet-335	8	47	in	in	ADP
admet-335	8	48	the	the	DET
admet-335	8	49	brain	brain	NOUN
admet-335	8	50	.	.	PUNCT
admet-335	9	1	tissue	tissue	NOUN
admet-335	9	2	gemcitabine	gemcitabine	NOUN
admet-335	9	3	was	be	AUX
admet-335	9	4	highest	high	ADJ
admet-335	9	5	in	in	ADP
admet-335	9	6	spleen	spleen	NOUN
admet-335	9	7	and	and	CCONJ
admet-335	9	8	skin	skin	NOUN
admet-335	9	9	,	,	PUNCT
admet-335	9	10	being	be	AUX
admet-335	9	11	about	about	ADV
admet-335	9	12	510	510	NUM
admet-335	9	13	fold	fold	ADV
admet-335	9	14	higher	high	ADJ
admet-335	9	15	than	than	ADP
admet-335	9	16	in	in	ADP
admet-335	9	17	the	the	DET
admet-335	9	18	other	other	ADJ
admet-335	9	19	tissues	tissue	NOUN
admet-335	9	20	,	,	PUNCT
admet-335	9	21	including	include	VERB
admet-335	9	22	brain	brain	NOUN
admet-335	9	23	,	,	PUNCT
admet-335	9	24	which	which	PRON
admet-335	9	25	still	still	ADV
admet-335	9	26	had	have	VERB
admet-335	9	27	a	a	DET
admet-335	9	28	relatively	relatively	ADV
admet-335	9	29	high	high	ADJ
admet-335	9	30	accumulation	accumulation	NOUN
admet-335	9	31	.	.	PUNCT
admet-335	10	1	in	in	ADP
admet-335	10	2	conclusion	conclusion	NOUN
admet-335	10	3	,	,	PUNCT
admet-335	10	4	both	both	PRON
admet-335	10	5	gemcitabine	gemcitabine	VERB
admet-335	10	6	and	and	CCONJ
admet-335	10	7	crizotinib	crizotinib	VERB
admet-335	10	8	accumulate	accumulate	VERB
admet-335	10	9	at	at	ADP
admet-335	10	10	clinically	clinically	ADV
admet-335	10	11	active	active	ADJ
admet-335	10	12	but	but	CCONJ
admet-335	10	13	variable	variable	ADJ
admet-335	10	14	levels	level	NOUN
admet-335	10	15	in	in	ADP
admet-335	10	16	tissues	tissue	NOUN
admet-335	10	17	,	,	PUNCT
admet-335	10	18	possibly	possibly	ADV
admet-335	10	19	relating	relate	VERB
admet-335	10	20	to	to	ADP
admet-335	10	21	the	the	DET
admet-335	10	22	effects	effect	NOUN
admet-335	10	23	exerted	exert	VERB
admet-335	10	24	by	by	ADP
admet-335	10	25	these	these	DET
admet-335	10	26	drugs	drug	NOUN
admet-335	10	27	.	.	PUNCT
admet-335	11	1	keywords	keyword	NOUN
admet-335	11	2	crizotinib	crizotinib	VERB
admet-335	11	3	;	;	PUNCT
admet-335	11	4	gemcitabine	gemcitabine	NOUN
admet-335	11	5	;	;	PUNCT
admet-335	11	6	tissue	tissue	NOUN
admet-335	11	7	distribution	distribution	NOUN
admet-335	11	8	introduction	introduction	NOUN
admet-335	11	9	pharmacokinetics	pharmacokinetic	NOUN
admet-335	11	10	usually	usually	ADV
admet-335	11	11	focuses	focus	VERB
admet-335	11	12	on	on	ADP
admet-335	11	13	the	the	DET
admet-335	11	14	behavior	behavior	NOUN
admet-335	11	15	of	of	ADP
admet-335	11	16	a	a	DET
admet-335	11	17	single	single	ADJ
admet-335	11	18	drug	drug	NOUN
admet-335	11	19	in	in	ADP
admet-335	11	20	plasma	plasma	NOUN
admet-335	11	21	in	in	ADP
admet-335	11	22	order	order	NOUN
admet-335	11	23	to	to	PART
admet-335	11	24	obtain	obtain	VERB
admet-335	11	25	information	information	NOUN
admet-335	11	26	on	on	ADP
admet-335	11	27	its	its	PRON
admet-335	11	28	uptake	uptake	NOUN
admet-335	11	29	,	,	PUNCT
admet-335	11	30	distribution	distribution	NOUN
admet-335	11	31	and	and	CCONJ
admet-335	11	32	elimination	elimination	NOUN
admet-335	12	1	[	[	X
admet-335	12	2	1	1	NUM
admet-335	12	3	]	]	PUNCT
admet-335	12	4	.	.	PUNCT
admet-335	13	1	in	in	ADP
admet-335	13	2	cancer	cancer	NOUN
admet-335	13	3	patients	patient	NOUN
admet-335	13	4	this	this	DET
admet-335	13	5	information	information	NOUN
admet-335	13	6	can	can	AUX
admet-335	13	7	give	give	VERB
admet-335	13	8	insight	insight	NOUN
admet-335	13	9	in	in	ADP
admet-335	13	10	the	the	DET
admet-335	13	11	mechanism	mechanism	NOUN
admet-335	13	12	of	of	ADP
admet-335	13	13	action	action	NOUN
admet-335	13	14	,	,	PUNCT
admet-335	13	15	the	the	DET
admet-335	13	16	relationship	relationship	NOUN
admet-335	13	17	between	between	ADP
admet-335	13	18	dose	dose	PROPN
admet-335	13	19	,	,	PUNCT
admet-335	13	20	systemic	systemic	ADJ
admet-335	13	21	concentration	concentration	NOUN
admet-335	13	22	and	and	CCONJ
admet-335	13	23	biological	biological	ADJ
admet-335	13	24	effect	effect	NOUN
admet-335	13	25	(	(	PUNCT
admet-335	13	26	beneficial	beneficial	ADJ
admet-335	13	27	or	or	CCONJ
admet-335	13	28	otherwise	otherwise	ADV
admet-335	13	29	)	)	PUNCT
admet-335	14	1	[	[	X
admet-335	14	2	2	2	NUM
admet-335	14	3	]	]	PUNCT
admet-335	14	4	.	.	PUNCT
admet-335	15	1	however	however	ADV
admet-335	15	2	,	,	PUNCT
admet-335	15	3	limited	limited	ADJ
admet-335	15	4	or	or	CCONJ
admet-335	15	5	insufficient	insufficient	ADJ
admet-335	15	6	attention	attention	NOUN
admet-335	15	7	is	be	AUX
admet-335	15	8	usually	usually	ADV
admet-335	15	9	given	give	VERB
admet-335	15	10	to	to	ADP
admet-335	15	11	the	the	DET
admet-335	15	12	question	question	NOUN
admet-335	15	13	whether	whether	SCONJ
admet-335	15	14	the	the	DET
admet-335	15	15	drug	drug	NOUN
admet-335	15	16	actually	actually	ADV
admet-335	15	17	reaches	reach	VERB
admet-335	15	18	its	its	PRON
admet-335	15	19	target	target	NOUN
admet-335	15	20	(	(	PUNCT
admet-335	15	21	the	the	DET
admet-335	15	22	tumor	tumor	NOUN
admet-335	15	23	)	)	PUNCT
admet-335	15	24	in	in	ADP
admet-335	15	25	therapeutic	therapeutic	ADJ
admet-335	15	26	concentrations	concentration	NOUN
admet-335	15	27	or	or	CCONJ
admet-335	15	28	accumulates	accumulate	VERB
admet-335	15	29	in	in	ADP
admet-335	15	30	normal	normal	ADJ
admet-335	15	31	tissues	tissue	NOUN
admet-335	15	32	potentially	potentially	ADV
admet-335	15	33	leading	lead	VERB
admet-335	15	34	to	to	ADP
admet-335	15	35	toxicity	toxicity	NOUN
admet-335	15	36	.	.	PUNCT
admet-335	16	1	usually	usually	ADV
admet-335	16	2	drug	drug	NOUN
admet-335	16	3	interactions	interaction	NOUN
admet-335	16	4	of	of	ADP
admet-335	16	5	combinations	combination	NOUN
admet-335	16	6	receive	receive	VERB
admet-335	16	7	limited	limited	ADJ
admet-335	16	8	interest	interest	NOUN
admet-335	16	9	.	.	PUNCT
admet-335	17	1	earlier	early	ADV
admet-335	17	2	we	we	PRON
admet-335	17	3	investigated	investigate	VERB
admet-335	17	4	the	the	DET
admet-335	17	5	interaction	interaction	NOUN
admet-335	17	6	between	between	ADP
admet-335	17	7	gemcitabine	gemcitabine	NOUN
admet-335	17	8	and	and	CCONJ
admet-335	17	9	crizotinib	crizotinib	VERB
admet-335	17	10	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	PROPN
admet-335	17	11	mailto:gj.peters@vumc.nl	mailto:gj.peters@vumc.nl	PROPN
admet-335	17	12	g.j	g.j	PROPN
admet-335	17	13	.	.	PROPN
admet-335	17	14	peters	peters	PROPN
admet-335	17	15	et	et	PROPN
admet-335	17	16	al	al	PROPN
admet-335	17	17	.	.	PROPN
admet-335	17	18	admet	admet	PROPN
admet-335	17	19	&	&	CCONJ
admet-335	17	20	dmpk	dmpk	PROPN
admet-335	17	21	4(4	4(4	NUM
admet-335	17	22	)	)	PUNCT
admet-335	17	23	(	(	PUNCT
admet-335	17	24	2016	2016	NUM
admet-335	17	25	)	)	PUNCT
admet-335	17	26	327	327	NUM
admet-335	17	27	-	-	SYM
admet-335	17	28	334	334	NUM
admet-335	17	29	328	328	NUM
admet-335	17	30	(	(	PUNCT
admet-335	17	31	figure	figure	NOUN
admet-335	17	32	1	1	NUM
admet-335	17	33	)	)	PUNCT
admet-335	17	34	and	and	CCONJ
admet-335	17	35	demonstrated	demonstrate	VERB
admet-335	17	36	a	a	DET
admet-335	17	37	synergistic	synergistic	ADJ
admet-335	17	38	effect	effect	NOUN
admet-335	17	39	between	between	ADP
admet-335	17	40	the	the	DET
admet-335	17	41	drugs	drug	NOUN
admet-335	17	42	in	in	ADP
admet-335	17	43	in	in	ADP
admet-335	17	44	vitro	vitro	X
admet-335	17	45	and	and	CCONJ
admet-335	17	46	in	in	ADP
admet-335	17	47	vivo	vivo	NOUN
admet-335	17	48	models	model	NOUN
admet-335	17	49	of	of	ADP
admet-335	17	50	pancreatic	pancreatic	ADJ
admet-335	17	51	ductal	ductal	ADJ
admet-335	17	52	adenocarcinoma	adenocarcinoma	NOUN
admet-335	17	53	(	(	PUNCT
admet-335	17	54	pdac	pdac	NOUN
admet-335	17	55	)	)	PUNCT
admet-335	18	1	[	[	X
admet-335	18	2	3	3	NUM
admet-335	18	3	]	]	PUNCT
admet-335	18	4	.	.	PUNCT
admet-335	19	1	in	in	ADP
admet-335	19	2	the	the	DET
admet-335	19	3	present	present	ADJ
admet-335	19	4	study	study	NOUN
admet-335	19	5	we	we	PRON
admet-335	19	6	aimed	aim	VERB
admet-335	19	7	to	to	PART
admet-335	19	8	analyze	analyze	VERB
admet-335	19	9	their	their	PRON
admet-335	19	10	interaction	interaction	NOUN
admet-335	19	11	in	in	ADP
admet-335	19	12	normal	normal	ADJ
admet-335	19	13	tissues	tissue	NOUN
admet-335	19	14	,	,	PUNCT
admet-335	19	15	in	in	ADP
admet-335	19	16	order	order	NOUN
admet-335	19	17	to	to	PART
admet-335	19	18	determine	determine	VERB
admet-335	19	19	whether	whether	SCONJ
admet-335	19	20	this	this	DET
admet-335	19	21	information	information	NOUN
admet-335	19	22	can	can	AUX
admet-335	19	23	give	give	VERB
admet-335	19	24	an	an	DET
admet-335	19	25	explanation	explanation	NOUN
admet-335	19	26	for	for	ADP
admet-335	19	27	toxic	toxic	ADJ
admet-335	19	28	side	side	NOUN
admet-335	19	29	effects	effect	NOUN
admet-335	19	30	seen	see	VERB
admet-335	19	31	with	with	ADP
admet-335	19	32	these	these	DET
admet-335	19	33	drugs	drug	NOUN
admet-335	19	34	in	in	ADP
admet-335	19	35	patients	patient	NOUN
admet-335	19	36	.	.	PUNCT
admet-335	20	1	crizotinib	crizotinib	PROPN
admet-335	20	2	is	be	AUX
admet-335	20	3	registered	register	VERB
admet-335	20	4	for	for	ADP
admet-335	20	5	the	the	DET
admet-335	20	6	treatment	treatment	NOUN
admet-335	20	7	of	of	ADP
admet-335	20	8	non	non	ADJ
admet-335	20	9	-	-	ADJ
admet-335	20	10	small	small	ADJ
admet-335	20	11	cell	cell	NOUN
admet-335	20	12	lung	lung	NOUN
admet-335	20	13	cancer	cancer	NOUN
admet-335	20	14	that	that	PRON
admet-335	20	15	expresses	express	VERB
admet-335	20	16	the	the	DET
admet-335	20	17	abnormal	abnormal	ADJ
admet-335	20	18	eml4	eml4	NOUN
admet-335	20	19	-	-	PUNCT
admet-335	20	20	alk	alk	NOUN
admet-335	20	21	fusion	fusion	NOUN
admet-335	20	22	gene	gene	NOUN
admet-335	20	23	,	,	PUNCT
admet-335	20	24	and	and	CCONJ
admet-335	20	25	has	have	AUX
admet-335	20	26	been	be	AUX
admet-335	20	27	evaluated	evaluate	VERB
admet-335	20	28	for	for	ADP
admet-335	20	29	use	use	NOUN
admet-335	20	30	with	with	ADP
admet-335	20	31	tumors	tumor	NOUN
admet-335	20	32	expressing	express	VERB
admet-335	20	33	high	high	ADJ
admet-335	20	34	c	c	NOUN
admet-335	20	35	-	-	PUNCT
admet-335	20	36	met	meet	VERB
admet-335	20	37	[	[	PUNCT
admet-335	20	38	4	4	NUM
admet-335	20	39	-	-	SYM
admet-335	20	40	6	6	NUM
admet-335	20	41	]	]	PUNCT
admet-335	20	42	.	.	PUNCT
admet-335	21	1	in	in	ADP
admet-335	21	2	turn	turn	NOUN
admet-335	21	3	,	,	PUNCT
admet-335	21	4	gemcitabine	gemcitabine	NOUN
admet-335	21	5	is	be	AUX
admet-335	21	6	standard	standard	ADJ
admet-335	21	7	first	first	ADJ
admet-335	21	8	line	line	NOUN
admet-335	21	9	treatment	treatment	NOUN
admet-335	21	10	in	in	ADP
admet-335	21	11	a	a	DET
admet-335	21	12	wide	wide	ADJ
admet-335	21	13	range	range	NOUN
admet-335	21	14	of	of	ADP
admet-335	21	15	carcinomas	carcinoma	NOUN
admet-335	21	16	including	include	VERB
admet-335	21	17	non	non	ADJ
admet-335	21	18	-	-	ADJ
admet-335	21	19	small	small	ADJ
admet-335	21	20	cell	cell	NOUN
admet-335	21	21	lung	lung	NOUN
admet-335	21	22	cancer	cancer	NOUN
admet-335	21	23	,	,	PUNCT
admet-335	21	24	pancreatic	pancreatic	ADJ
admet-335	21	25	cancer	cancer	NOUN
admet-335	21	26	,	,	PUNCT
admet-335	21	27	bladder	bladder	NOUN
admet-335	21	28	cancer	cancer	NOUN
admet-335	21	29	and	and	CCONJ
admet-335	21	30	breast	breast	NOUN
admet-335	21	31	cancer	cancer	NOUN
admet-335	21	32	[	[	X
admet-335	21	33	7	7	NUM
admet-335	21	34	]	]	PUNCT
admet-335	21	35	.	.	PUNCT
admet-335	22	1	in	in	ADP
admet-335	22	2	this	this	DET
admet-335	22	3	paper	paper	NOUN
admet-335	22	4	we	we	PRON
admet-335	22	5	describe	describe	VERB
admet-335	22	6	the	the	DET
admet-335	22	7	tissue	tissue	NOUN
admet-335	22	8	distribution	distribution	NOUN
admet-335	22	9	of	of	ADP
admet-335	22	10	both	both	PRON
admet-335	22	11	crizotinib	crizotinib	ADJ
admet-335	22	12	and	and	CCONJ
admet-335	22	13	gemcitabine	gemcitabine	NOUN
admet-335	22	14	,	,	PUNCT
admet-335	22	15	given	give	VERB
admet-335	22	16	alone	alone	ADV
admet-335	22	17	or	or	CCONJ
admet-335	22	18	together	together	ADV
admet-335	22	19	in	in	ADP
admet-335	22	20	a	a	DET
admet-335	22	21	patient	patient	NOUN
admet-335	22	22	-	-	PUNCT
admet-335	22	23	derived	derive	VERB
admet-335	22	24	orthotopic	orthotopic	ADJ
admet-335	22	25	mouse	mouse	PROPN
admet-335	22	26	pdac	pdac	PROPN
admet-335	22	27	model	model	NOUN
admet-335	22	28	.	.	PUNCT
admet-335	23	1	figure	figure	NOUN
admet-335	23	2	1	1	NUM
admet-335	23	3	.	.	PUNCT
admet-335	23	4	structural	structural	ADJ
admet-335	23	5	formulae	formulae	NOUN
admet-335	23	6	of	of	ADP
admet-335	23	7	crizotinib	crizotinib	NOUN
admet-335	23	8	(	(	PUNCT
admet-335	23	9	a	a	NOUN
admet-335	23	10	)	)	PUNCT
admet-335	23	11	and	and	CCONJ
admet-335	23	12	gemcitabine	gemcitabine	NOUN
admet-335	23	13	(	(	PUNCT
admet-335	23	14	b	b	NOUN
admet-335	23	15	)	)	PUNCT
admet-335	23	16	.	.	PUNCT
admet-335	24	1	model	model	NOUN
admet-335	24	2	and	and	CCONJ
admet-335	24	3	methods	method	NOUN
admet-335	24	4	mouse	mouse	PROPN
admet-335	24	5	model	model	PROPN
admet-335	24	6	orthotopic	orthotopic	ADJ
admet-335	24	7	primary	primary	ADJ
admet-335	24	8	-	-	PUNCT
admet-335	24	9	pdac	pdac	NOUN
admet-335	24	10	mouse	mouse	NOUN
admet-335	24	11	models	model	NOUN
admet-335	24	12	were	be	AUX
admet-335	24	13	developed	develop	VERB
admet-335	24	14	as	as	SCONJ
admet-335	24	15	reported	report	VERB
admet-335	24	16	by	by	ADP
admet-335	24	17	avan	avan	PROPN
admet-335	24	18	et	et	PROPN
admet-335	24	19	al	al	PROPN
admet-335	24	20	.	.	PUNCT
admet-335	25	1	[	[	X
admet-335	25	2	3	3	X
admet-335	25	3	]	]	PUNCT
admet-335	25	4	by	by	ADP
admet-335	25	5	implantation	implantation	NOUN
admet-335	25	6	of	of	ADP
admet-335	25	7	primary	primary	ADJ
admet-335	25	8	tumor	tumor	NOUN
admet-335	25	9	cells	cell	NOUN
admet-335	25	10	into	into	ADP
admet-335	25	11	6	6	NUM
admet-335	25	12	-	-	SYM
admet-335	25	13	8	8	NUM
admet-335	25	14	week	week	NOUN
admet-335	25	15	old	old	ADJ
admet-335	25	16	female	female	ADJ
admet-335	25	17	athymic	athymic	ADJ
admet-335	25	18	nude	nude	ADJ
admet-335	25	19	mice	mice	NOUN
admet-335	25	20	(	(	PUNCT
admet-335	25	21	harlan	harlan	PROPN
admet-335	25	22	,	,	PUNCT
admet-335	25	23	host	host	NOUN
admet-335	25	24	,	,	PUNCT
admet-335	25	25	the	the	DET
admet-335	25	26	netherlands	netherlands	PROPN
admet-335	25	27	)	)	PUNCT
admet-335	25	28	.	.	PUNCT
admet-335	26	1	tumor	tumor	NOUN
admet-335	26	2	growth	growth	NOUN
admet-335	26	3	was	be	AUX
admet-335	26	4	monitored	monitor	VERB
admet-335	26	5	via	via	ADP
admet-335	26	6	bioluminescence	bioluminescence	NOUN
admet-335	26	7	,	,	PUNCT
admet-335	26	8	as	as	SCONJ
admet-335	26	9	described	describe	VERB
admet-335	26	10	previously	previously	ADV
admet-335	26	11	[	[	X
admet-335	26	12	3	3	NUM
admet-335	26	13	]	]	PUNCT
admet-335	26	14	.	.	PUNCT
admet-335	27	1	the	the	DET
admet-335	27	2	mice	mouse	NOUN
admet-335	27	3	were	be	AUX
admet-335	27	4	treated	treat	VERB
admet-335	27	5	with	with	ADP
admet-335	27	6	oral	oral	ADJ
admet-335	27	7	crizotinib	crizotinib	NOUN
admet-335	27	8	at	at	ADP
admet-335	27	9	25	25	NUM
admet-335	27	10	mg	mg	PROPN
admet-335	27	11	/	/	SYM
admet-335	27	12	kg	kg	PROPN
admet-335	27	13	,	,	PUNCT
admet-335	27	14	or	or	CCONJ
admet-335	27	15	gemcitabine	gemcitabine	VERB
admet-335	27	16	at	at	ADP
admet-335	27	17	100	100	NUM
admet-335	27	18	mg	mg	NOUN
admet-335	27	19	/	/	SYM
admet-335	27	20	kg	kg	PROPN
admet-335	27	21	intraperitoneally	intraperitoneally	ADV
admet-335	27	22	4	4	NUM
admet-335	27	23	times	time	NOUN
admet-335	27	24	at	at	ADP
admet-335	27	25	3	3	NUM
admet-335	27	26	-	-	PUNCT
admet-335	27	27	day	day	NOUN
admet-335	27	28	intervals	interval	NOUN
admet-335	27	29	.	.	PUNCT
admet-335	28	1	the	the	DET
admet-335	28	2	third	third	ADJ
admet-335	28	3	group	group	NOUN
admet-335	28	4	received	receive	VERB
admet-335	28	5	a	a	DET
admet-335	28	6	combination	combination	NOUN
admet-335	28	7	of	of	ADP
admet-335	28	8	both	both	DET
admet-335	28	9	drugs	drug	NOUN
admet-335	28	10	.	.	PUNCT
admet-335	29	1	blood	blood	NOUN
admet-335	29	2	was	be	AUX
admet-335	29	3	taken	take	VERB
admet-335	29	4	via	via	ADP
admet-335	29	5	the	the	DET
admet-335	29	6	tail	tail	NOUN
admet-335	29	7	vein	vein	NOUN
admet-335	29	8	at	at	ADP
admet-335	29	9	1	1	NUM
admet-335	29	10	and	and	CCONJ
admet-335	29	11	2	2	NUM
admet-335	29	12	h	h	NOUN
admet-335	29	13	after	after	ADP
admet-335	29	14	drug	drug	NOUN
admet-335	29	15	administration	administration	NOUN
admet-335	29	16	.	.	PUNCT
admet-335	30	1	thereafter	thereafter	ADV
admet-335	30	2	mice	mouse	NOUN
admet-335	30	3	were	be	AUX
admet-335	30	4	sacrificed	sacrifice	VERB
admet-335	30	5	and	and	CCONJ
admet-335	30	6	all	all	DET
admet-335	30	7	available	available	ADJ
admet-335	30	8	organs	organ	NOUN
admet-335	30	9	/	/	SYM
admet-335	30	10	tissue	tissue	NOUN
admet-335	30	11	was	be	AUX
admet-335	30	12	sampled	sample	VERB
admet-335	30	13	.	.	PUNCT
admet-335	31	1	sampled	sample	VERB
admet-335	31	2	tissue	tissue	NOUN
admet-335	31	3	was	be	AUX
admet-335	31	4	immediately	immediately	ADV
admet-335	31	5	frozen	freeze	VERB
admet-335	31	6	in	in	ADP
admet-335	31	7	liquid	liquid	ADJ
admet-335	31	8	nitrogen	nitrogen	NOUN
admet-335	31	9	and	and	CCONJ
admet-335	31	10	stored	store	VERB
admet-335	31	11	at	at	ADP
admet-335	31	12	-80	-80	NOUN
admet-335	31	13	°	°	PROPN
admet-335	31	14	c	c	NOUN
admet-335	31	15	.	.	PUNCT
admet-335	32	1	drug	drug	NOUN
admet-335	32	2	analysis	analysis	NOUN
admet-335	32	3	and	and	CCONJ
admet-335	32	4	equipment	equipment	NOUN
admet-335	32	5	tissue	tissue	NOUN
admet-335	32	6	and	and	CCONJ
admet-335	32	7	whole	whole	ADJ
admet-335	32	8	blood	blood	NOUN
admet-335	32	9	concentrations	concentration	NOUN
admet-335	32	10	of	of	ADP
admet-335	32	11	gemcitabine	gemcitabine	NOUN
admet-335	32	12	and	and	CCONJ
admet-335	32	13	crizotinib	crizotinib	NOUN
admet-335	32	14	were	be	AUX
admet-335	32	15	determined	determine	VERB
admet-335	32	16	by	by	ADP
admet-335	32	17	adaptation	adaptation	NOUN
admet-335	32	18	of	of	ADP
admet-335	32	19	a	a	DET
admet-335	32	20	validated	validate	VERB
admet-335	32	21	liquid	liquid	ADJ
admet-335	32	22	chromatography	chromatography	NOUN
admet-335	32	23	-	-	PUNCT
admet-335	32	24	mass	mass	NOUN
admet-335	32	25	spectrometry	spectrometry	NOUN
admet-335	32	26	(	(	PUNCT
admet-335	32	27	lc	lc	PROPN
admet-335	32	28	-	-	PUNCT
admet-335	32	29	ms	ms	PROPN
admet-335	32	30	/	/	SYM
admet-335	32	31	ms	ms	PROPN
admet-335	32	32	)	)	PUNCT
admet-335	32	33	methodology	methodology	NOUN
admet-335	32	34	previously	previously	ADV
admet-335	32	35	reported	report	VERB
admet-335	32	36	[	[	X
admet-335	32	37	8,9	8,9	NUM
admet-335	32	38	]	]	PUNCT
admet-335	32	39	using	use	VERB
admet-335	32	40	a	a	DET
admet-335	32	41	sciex	sciex	NOUN
admet-335	32	42	api3000	api3000	PROPN
admet-335	32	43	mass	mass	PROPN
admet-335	32	44	spectrometer	spectrometer	NOUN
admet-335	32	45	coupled	couple	VERB
admet-335	32	46	with	with	ADP
admet-335	32	47	a	a	DET
admet-335	32	48	dionex	dionex	ADV
admet-335	32	49	ultimate	ultimate	ADJ
admet-335	32	50	3000	3000	NUM
admet-335	32	51	capillary	capillary	ADJ
admet-335	32	52	lc	lc	NOUN
admet-335	32	53	system	system	NOUN
admet-335	32	54	.	.	PUNCT
admet-335	33	1	precision	precision	NOUN
admet-335	33	2	,	,	PUNCT
admet-335	33	3	accuracy	accuracy	NOUN
admet-335	33	4	,	,	PUNCT
admet-335	33	5	robustness	robustness	NOUN
admet-335	33	6	and	and	CCONJ
admet-335	33	7	stability	stability	NOUN
admet-335	33	8	were	be	AUX
admet-335	33	9	established	establish	VERB
admet-335	33	10	for	for	ADP
admet-335	33	11	crizotinib	crizotinib	NOUN
admet-335	33	12	and	and	CCONJ
admet-335	33	13	gemcitabine	gemcitabine	NOUN
admet-335	33	14	prior	prior	ADV
admet-335	33	15	to	to	ADP
admet-335	33	16	tissue	tissue	NOUN
admet-335	33	17	analysis	analysis	NOUN
admet-335	33	18	in	in	ADP
admet-335	33	19	whole	whole	ADJ
admet-335	33	20	blood	blood	NOUN
admet-335	33	21	,	,	PUNCT
admet-335	33	22	plasma	plasma	NOUN
admet-335	33	23	,	,	PUNCT
admet-335	33	24	serum	serum	NOUN
admet-335	33	25	and	and	CCONJ
admet-335	33	26	cell	cell	NOUN
admet-335	33	27	culture	culture	NOUN
admet-335	33	28	medium	medium	NOUN
admet-335	34	1	[	[	X
admet-335	34	2	8	8	NUM
admet-335	34	3	]	]	PUNCT
admet-335	34	4	.	.	PUNCT
admet-335	35	1	parameters	parameter	NOUN
admet-335	35	2	were	be	AUX
admet-335	35	3	determined	determine	VERB
admet-335	35	4	with	with	ADP
admet-335	35	5	software	software	NOUN
admet-335	35	6	“	"	PUNCT
admet-335	35	7	analyst	analyst	NOUN
admet-335	35	8	”	"	PUNCT
admet-335	35	9	version	version	NOUN
admet-335	35	10	6.2	6.2	NUM
admet-335	35	11	(	(	PUNCT
admet-335	35	12	sciex	sciex	NOUN
admet-335	35	13	bv	bv	PROPN
admet-335	35	14	,	,	PUNCT
admet-335	35	15	breda	breda	NOUN
admet-335	35	16	)	)	PUNCT
admet-335	35	17	and	and	CCONJ
admet-335	35	18	dmslink	dmslink	VERB
admet-335	35	19	ver	ver	PROPN
admet-335	35	20	2.10	2.10	NUM
admet-335	35	21	(	(	PUNCT
admet-335	35	22	thermo	thermo	NOUN
admet-335	35	23	scientific	scientific	ADJ
admet-335	35	24	dionex	dionex	NOUN
admet-335	35	25	,	,	PUNCT
admet-335	35	26	breda	breda	NOUN
admet-335	35	27	)	)	PUNCT
admet-335	35	28	.	.	PUNCT
admet-335	36	1	whole	whole	ADJ
admet-335	36	2	blood	blood	NOUN
admet-335	36	3	,	,	PUNCT
admet-335	36	4	plasma	plasma	NOUN
admet-335	36	5	and	and	CCONJ
admet-335	36	6	serum	serum	NOUN
admet-335	36	7	were	be	AUX
admet-335	36	8	extracted	extract	VERB
admet-335	36	9	by	by	ADP
admet-335	36	10	adding	add	VERB
admet-335	36	11	20	20	NUM
admet-335	36	12	µl	µl	ADP
admet-335	36	13	whole	whole	ADJ
admet-335	36	14	blood	blood	NOUN
admet-335	36	15	aliquots	aliquot	NOUN
admet-335	36	16	to	to	ADP
admet-335	36	17	80	80	NUM
admet-335	36	18	µl	µl	ADP
admet-335	36	19	acetonitrile	acetonitrile	NOUN
admet-335	36	20	and	and	CCONJ
admet-335	36	21	sonicating	sonicate	VERB
admet-335	36	22	for	for	ADP
admet-335	36	23	15	15	NUM
admet-335	36	24	seconds	second	NOUN
admet-335	36	25	.	.	PUNCT
admet-335	37	1	after	after	ADP
admet-335	37	2	centrifugation	centrifugation	NOUN
admet-335	37	3	at	at	ADP
admet-335	37	4	2500	2500	NUM
admet-335	37	5	g	g	NOUN
admet-335	37	6	for	for	ADP
admet-335	37	7	10	10	NUM
admet-335	37	8	minutes	minute	NOUN
admet-335	37	9	/	/	SYM
admet-335	37	10	4	4	NUM
admet-335	37	11	°	°	NOUN
admet-335	37	12	c	c	NOUN
admet-335	37	13	,	,	PUNCT
admet-335	37	14	the	the	DET
admet-335	37	15	supernatant	supernatant	NOUN
admet-335	37	16	was	be	AUX
admet-335	37	17	taken	take	VERB
admet-335	37	18	and	and	CCONJ
admet-335	37	19	analyzed	analyze	VERB
admet-335	37	20	by	by	ADP
admet-335	37	21	lc	lc	PROPN
admet-335	37	22	-	-	PUNCT
admet-335	37	23	ms	ms	PROPN
admet-335	37	24	/	/	SYM
admet-335	37	25	ms	ms	PROPN
admet-335	37	26	.	.	PROPN
admet-335	37	27	tissue	tissue	NOUN
admet-335	37	28	sample	sample	NOUN
admet-335	37	29	preparation	preparation	NOUN
admet-335	37	30	was	be	AUX
admet-335	37	31	performed	perform	VERB
admet-335	37	32	by	by	ADP
admet-335	37	33	taking	take	VERB
admet-335	37	34	triplicate	triplicate	NOUN
admet-335	37	35	portions	portion	NOUN
admet-335	37	36	of	of	ADP
admet-335	37	37	each	each	DET
admet-335	37	38	tissue	tissue	NOUN
admet-335	37	39	(	(	PUNCT
admet-335	37	40	5	5	NUM
admet-335	37	41	-	-	SYM
admet-335	37	42	30	30	NUM
admet-335	37	43	mg	mg	NUM
admet-335	37	44	)	)	PUNCT
admet-335	37	45	,	,	PUNCT
admet-335	37	46	weighed	weigh	VERB
admet-335	37	47	into	into	ADP
admet-335	37	48	1.5	1.5	NUM
admet-335	37	49	ml	ml	NOUN
admet-335	37	50	cryogenic	cryogenic	NOUN
admet-335	37	51	vials	vial	NOUN
admet-335	37	52	which	which	PRON
admet-335	37	53	were	be	AUX
admet-335	37	54	subsequently	subsequently	ADV
admet-335	37	55	desiccated	desiccate	VERB
admet-335	37	56	using	use	VERB
admet-335	37	57	the	the	DET
admet-335	37	58	freeze	freeze	NOUN
admet-335	37	59	drying	dry	VERB
admet-335	37	60	processes	process	NOUN
admet-335	37	61	for	for	ADP
admet-335	37	62	48	48	NUM
admet-335	37	63	h.	h.	NOUN
admet-335	37	64	samples	sample	NOUN
admet-335	37	65	were	be	AUX
admet-335	37	66	then	then	ADV
admet-335	37	67	homogenized	homogenize	VERB
admet-335	37	68	for	for	ADP
admet-335	37	69	10	10	NUM
admet-335	37	70	min	min	NOUN
admet-335	37	71	with	with	ADP
admet-335	37	72	acetonitrile	acetonitrile	NOUN
admet-335	37	73	:	:	PUNCT
admet-335	37	74	water	water	NOUN
admet-335	37	75	(	(	PUNCT
admet-335	37	76	5:1	5:1	NUM
admet-335	37	77	)	)	PUNCT
admet-335	37	78	,	,	PUNCT
admet-335	37	79	sonicated	sonicate	VERB
admet-335	37	80	and	and	CCONJ
admet-335	37	81	centrifuged	centrifuge	VERB
admet-335	37	82	.	.	PUNCT
admet-335	38	1	the	the	DET
admet-335	38	2	subsequent	subsequent	ADJ
admet-335	38	3	supernatant	supernatant	NOUN
admet-335	38	4	was	be	AUX
admet-335	38	5	then	then	ADV
admet-335	38	6	analyzed	analyze	VERB
admet-335	38	7	by	by	ADP
admet-335	38	8	lcms	lcms	PROPN
admet-335	38	9	/	/	SYM
admet-335	38	10	ms	ms	PROPN
admet-335	38	11	.	.	PROPN
admet-335	38	12	(	(	PUNCT
admet-335	38	13	a	a	X
admet-335	38	14	)	)	PUNCT
admet-335	38	15	(	(	PUNCT
admet-335	38	16	b	b	X
admet-335	38	17	)	)	PUNCT
admet-335	38	18	admet	admet	PROPN
admet-335	38	19	&	&	CCONJ
admet-335	38	20	dmpk	dmpk	PROPN
admet-335	38	21	4(4	4(4	NUM
admet-335	38	22	)	)	PUNCT
admet-335	38	23	(	(	PUNCT
admet-335	38	24	2016	2016	NUM
admet-335	38	25	)	)	PUNCT
admet-335	38	26	327	327	NUM
admet-335	38	27	-	-	PUNCT
admet-335	38	28	334	334	NUM
admet-335	38	29	tissue	tissue	NOUN
admet-335	38	30	distribution	distribution	NOUN
admet-335	38	31	of	of	ADP
admet-335	38	32	crizotinib	crizotinib	NOUN
admet-335	38	33	and	and	CCONJ
admet-335	38	34	gemcitabine	gemcitabine	NOUN
admet-335	38	35	in	in	ADP
admet-335	38	36	mouse	mouse	NOUN
admet-335	38	37	model	model	NOUN
admet-335	38	38	doi	doi	PROPN
admet-335	38	39	:	:	PUNCT
admet-335	38	40	10.5599	10.5599	NUM
admet-335	38	41	/	/	SYM
admet-335	38	42	admet.4.4.335	admet.4.4.335	NOUN
admet-335	38	43	329	329	NUM
admet-335	38	44	crizotinib	crizotinib	VERB
admet-335	38	45	optimization	optimization	NOUN
admet-335	38	46	crizotinib	crizotinib	VERB
admet-335	38	47	analysis	analysis	NOUN
admet-335	38	48	was	be	AUX
admet-335	38	49	optimized	optimize	VERB
admet-335	38	50	for	for	ADP
admet-335	38	51	mass	mass	ADJ
admet-335	38	52	spectroscopic	spectroscopic	ADJ
admet-335	38	53	detection	detection	NOUN
admet-335	38	54	as	as	SCONJ
admet-335	38	55	described	describe	VERB
admet-335	38	56	earlier	early	ADV
admet-335	38	57	for	for	ADP
admet-335	38	58	tyrosine	tyrosine	NOUN
admet-335	38	59	kinase	kinase	PROPN
admet-335	38	60	inhibitors	inhibitor	NOUN
admet-335	38	61	.	.	PUNCT
admet-335	39	1	briefly	briefly	ADV
admet-335	39	2	,	,	PUNCT
admet-335	39	3	1	1	NUM
admet-335	39	4	µg	µg	NOUN
admet-335	39	5	/	/	SYM
admet-335	39	6	ml	ml	NOUN
admet-335	39	7	solution	solution	NOUN
admet-335	39	8	was	be	AUX
admet-335	39	9	infused	infuse	VERB
admet-335	39	10	at	at	ADP
admet-335	39	11	3	3	NUM
admet-335	39	12	µl	µl	NOUN
admet-335	39	13	per	per	ADP
admet-335	39	14	min	min	NOUN
admet-335	39	15	into	into	ADP
admet-335	39	16	the	the	DET
admet-335	39	17	turbo	turbo	NOUN
admet-335	39	18	ionisation	ionisation	NOUN
admet-335	39	19	source	source	NOUN
admet-335	39	20	,	,	PUNCT
admet-335	39	21	the	the	DET
admet-335	39	22	parent	parent	NOUN
admet-335	39	23	ion	ion	NOUN
admet-335	39	24	for	for	ADP
admet-335	39	25	crizotinib	crizotinib	NOUN
admet-335	39	26	(	(	PUNCT
admet-335	39	27	mw-449	mw-449	PROPN
admet-335	39	28	)	)	PUNCT
admet-335	39	29	was	be	AUX
admet-335	39	30	established	establish	VERB
admet-335	39	31	as	as	ADP
admet-335	39	32	450	450	NUM
admet-335	39	33	,	,	PUNCT
admet-335	39	34	451	451	NUM
admet-335	39	35	and	and	CCONJ
admet-335	39	36	452	452	NUM
admet-335	39	37	amu	amu	NOUN
admet-335	39	38	with	with	ADP
admet-335	39	39	characteristic	characteristic	ADJ
admet-335	39	40	pattern	pattern	NOUN
admet-335	39	41	of	of	ADP
admet-335	39	42	a	a	DET
admet-335	39	43	chlorine	chlorine	NOUN
admet-335	39	44	containing	contain	VERB
admet-335	39	45	molecule	molecule	NOUN
admet-335	39	46	(	(	PUNCT
admet-335	39	47	figure	figure	NOUN
admet-335	39	48	2a	2a	NUM
admet-335	39	49	)	)	PUNCT
admet-335	39	50	.	.	PUNCT
admet-335	40	1	the	the	DET
admet-335	40	2	major	major	ADJ
admet-335	40	3	fragment	fragment	NOUN
admet-335	40	4	of	of	ADP
admet-335	40	5	the	the	DET
admet-335	40	6	450	450	NUM
admet-335	40	7	amu	amu	PROPN
admet-335	40	8	response	response	NOUN
admet-335	40	9	was	be	AUX
admet-335	40	10	259.9	259.9	NUM
admet-335	40	11	(	(	PUNCT
admet-335	40	12	figure	figure	NOUN
admet-335	40	13	2a	2a	NUM
admet-335	40	14	)	)	PUNCT
admet-335	40	15	.	.	PUNCT
admet-335	41	1	mass	mass	PROPN
admet-335	41	2	spectrometric	spectrometric	ADJ
admet-335	41	3	parameters	parameter	NOUN
admet-335	41	4	for	for	ADP
admet-335	41	5	the	the	DET
admet-335	41	6	transition	transition	NOUN
admet-335	41	7	quadrupole	quadrupole	NOUN
admet-335	41	8	pairing	pairing	NOUN
admet-335	41	9	(	(	PUNCT
admet-335	41	10	q1	q1	PROPN
admet-335	41	11	/	/	SYM
admet-335	41	12	q3	q3	PROPN
admet-335	41	13	)	)	PUNCT
admet-335	41	14	of	of	ADP
admet-335	41	15	450.0/259.1	450.0/259.1	NUM
admet-335	41	16	are	be	AUX
admet-335	41	17	:	:	PUNCT
admet-335	41	18	declustering	declustere	VERB
admet-335	41	19	potential	potential	ADJ
admet-335	41	20	(	(	PUNCT
admet-335	41	21	dp	dp	NOUN
admet-335	41	22	)	)	PUNCT
admet-335	41	23	,	,	PUNCT
admet-335	41	24	61	61	NUM
admet-335	41	25	v	v	NOUN
admet-335	41	26	;	;	PUNCT
admet-335	41	27	focusing	focus	VERB
admet-335	41	28	potential	potential	NOUN
admet-335	41	29	,	,	PUNCT
admet-335	41	30	270	270	NUM
admet-335	41	31	v	v	NOUN
admet-335	41	32	;	;	PUNCT
admet-335	41	33	entrance	entrance	NOUN
admet-335	41	34	potential	potential	NOUN
admet-335	41	35	,	,	PUNCT
admet-335	41	36	10	10	NUM
admet-335	41	37	v	v	NOUN
admet-335	41	38	;	;	PUNCT
admet-335	41	39	collision	collision	NOUN
admet-335	41	40	energy	energy	NOUN
admet-335	41	41	,	,	PUNCT
admet-335	41	42	31	31	NUM
admet-335	41	43	v	v	NOUN
admet-335	41	44	;	;	PUNCT
admet-335	41	45	cell	cell	NOUN
admet-335	41	46	exit	exit	NOUN
admet-335	41	47	potential	potential	NOUN
admet-335	41	48	,	,	PUNCT
admet-335	41	49	18	18	NUM
admet-335	41	50	v.	v.	ADP
admet-335	41	51	crizotinib	crizotinib	NOUN
admet-335	41	52	0	0	NUM
admet-335	41	53	1	1	NUM
admet-335	41	54	2	2	NUM
admet-335	41	55	3	3	NUM
admet-335	41	56	0	0	NUM
admet-335	41	57	500	500	NUM
admet-335	41	58	1000	1000	NUM
admet-335	41	59	1500	1500	NUM
admet-335	41	60	time	time	NOUN
admet-335	41	61	(	(	PUNCT
admet-335	41	62	min	min	NOUN
admet-335	41	63	)	)	PUNCT
admet-335	41	64	c	c	NOUN
admet-335	41	65	o	o	PUNCT
admet-335	41	66	u	u	NOUN
admet-335	41	67	n	n	X
admet-335	41	68	ts	ts	ADP
admet-335	41	69	p	p	PROPN
admet-335	41	70	e	e	PROPN
admet-335	41	71	r	r	NOUN
admet-335	41	72	s	s	NUM
admet-335	41	73	e	e	NOUN
admet-335	41	74	c	c	NOUN
admet-335	41	75	o	o	X
admet-335	41	76	n	n	X
admet-335	41	77	d	d	X
admet-335	41	78	gemcitabine	gemcitabine	NOUN
admet-335	41	79	0	0	NUM
admet-335	41	80	1	1	NUM
admet-335	41	81	2	2	NUM
admet-335	41	82	3	3	NUM
admet-335	41	83	0	0	NUM
admet-335	41	84	50	50	NUM
admet-335	41	85	100	100	NUM
admet-335	41	86	150	150	NUM
admet-335	41	87	200	200	NUM
admet-335	41	88	time	time	NOUN
admet-335	41	89	(	(	PUNCT
admet-335	41	90	min	min	NOUN
admet-335	41	91	)	)	PUNCT
admet-335	41	92	deoxycytidine	deoxycytidine	NOUN
admet-335	41	93	0	0	NUM
admet-335	41	94	1	1	NUM
admet-335	41	95	2	2	NUM
admet-335	41	96	3	3	NUM
admet-335	41	97	0	0	NUM
admet-335	41	98	500	500	NUM
admet-335	41	99	1000	1000	NUM
admet-335	41	100	1500	1500	NUM
admet-335	41	101	time	time	NOUN
admet-335	41	102	(	(	PUNCT
admet-335	41	103	min	min	NOUN
admet-335	41	104	)	)	PUNCT
admet-335	41	105	crizotinib	crizotinib	NOUN
admet-335	41	106	extracted	extract	VERB
admet-335	41	107	from	from	ADP
admet-335	41	108	whole	whole	ADJ
admet-335	41	109	blood	blood	NOUN
admet-335	41	110	0	0	NUM
admet-335	41	111	2000	2000	NUM
admet-335	41	112	4000	4000	NUM
admet-335	41	113	6000	6000	NUM
admet-335	41	114	0	0	NUM
admet-335	41	115	50000	50000	NUM
admet-335	41	116	100000	100000	NUM
admet-335	41	117	150000	150000	NUM
admet-335	41	118	200000	200000	NUM
admet-335	41	119	250000	250000	NUM
admet-335	41	120	mouse	mouse	NOUN
admet-335	41	121	whole	whole	ADJ
admet-335	41	122	blood	blood	NOUN
admet-335	41	123	human	human	ADJ
admet-335	41	124	whole	whole	ADJ
admet-335	41	125	blood	blood	NOUN
admet-335	41	126	concentration	concentration	NOUN
admet-335	41	127	(	(	PUNCT
admet-335	41	128	ng	ng	NOUN
admet-335	41	129	/	/	SYM
admet-335	41	130	ml	ml	PROPN
admet-335	41	131	)	)	PUNCT
admet-335	41	132	i	i	PRON
admet-335	41	133	n	n	VERB
admet-335	41	134	t	t	X
admet-335	41	135	e	e	NOUN
admet-335	41	136	n	n	X
admet-335	41	137	s	s	X
admet-335	42	1	i	i	PRON
admet-335	42	2	t	t	NOUN
admet-335	42	3	y	y	PROPN
admet-335	42	4	(	(	PUNCT
admet-335	42	5	c	c	PROPN
admet-335	42	6	p	p	X
admet-335	42	7	s	s	PROPN
admet-335	42	8	)	)	PUNCT
admet-335	43	1	+	+	NUM
admet-335	43	2	q1	q1	NOUN
admet-335	43	3	spectrum	spectrum	NOUN
admet-335	43	4	of	of	ADP
admet-335	43	5	crizotinib	crizotinib	NOUN
admet-335	43	6	in	in	ADP
admet-335	43	7	mobile	mobile	ADJ
admet-335	43	8	phase	phase	NOUN
admet-335	43	9	420	420	NUM
admet-335	43	10	440	440	NUM
admet-335	43	11	460	460	NUM
admet-335	43	12	480	480	NUM
admet-335	43	13	0.0	0.0	NUM
admet-335	43	14	5000000.0	5000000.0	NUM
admet-335	43	15	1.01007	1.01007	NUM
admet-335	43	16	1.51007	1.51007	NUM
admet-335	43	17	2.01007	2.01007	NUM
admet-335	43	18	2.51007	2.51007	NUM
admet-335	43	19	450.0	450.0	NUM
admet-335	43	20	451.0	451.0	NUM
admet-335	43	21	452.0	452.0	NUM
admet-335	43	22	n	n	NOUN
admet-335	43	23	nh	nh	PROPN
admet-335	43	24	2	2	NUM
admet-335	43	25	o	o	NOUN
admet-335	43	26	cl	cl	NOUN
admet-335	43	27	cl	cl	NOUN
admet-335	43	28	f	f	PROPN
admet-335	43	29	n	n	CCONJ
admet-335	43	30	n	n	ADV
admet-335	44	1	hn	hn	PROPN
admet-335	44	2	c	c	PROPN
admet-335	44	3	p	p	NOUN
admet-335	44	4	s	s	PROPN
admet-335	44	5	product	product	NOUN
admet-335	44	6	ion	ion	NOUN
admet-335	44	7	spectrum	spectrum	NOUN
admet-335	44	8	crizotinib	crizotinib	VERB
admet-335	44	9	250	250	NUM
admet-335	44	10	300	300	NUM
admet-335	44	11	350	350	NUM
admet-335	44	12	400	400	NUM
admet-335	44	13	4500	4500	NUM
admet-335	44	14	500000	500000	NUM
admet-335	44	15	1000000	1000000	NUM
admet-335	44	16	1500000	1500000	NUM
admet-335	44	17	2000000	2000000	NUM
admet-335	44	18	259.9	259.9	NUM
admet-335	44	19	450.0	450.0	NUM
admet-335	44	20	369.9	369.9	NUM
admet-335	45	1	c	c	NOUN
admet-335	46	1	p	p	X
admet-335	46	2	s	s	PROPN
admet-335	46	3	a	a	DET
admet-335	46	4	b	b	NOUN
admet-335	46	5	c	c	X
admet-335	46	6	figure	figure	NOUN
admet-335	46	7	2	2	NUM
admet-335	46	8	.	.	PUNCT
admet-335	46	9	ionisation	ionisation	NOUN
admet-335	46	10	spectrum	spectrum	NOUN
admet-335	46	11	and	and	CCONJ
admet-335	46	12	chromatography	chromatography	NOUN
admet-335	46	13	of	of	ADP
admet-335	46	14	crizotinib	crizotinib	PROPN
admet-335	46	15	,	,	PUNCT
admet-335	46	16	gemcitabine	gemcitabine	NOUN
admet-335	46	17	and	and	CCONJ
admet-335	46	18	of	of	ADP
admet-335	46	19	the	the	DET
admet-335	46	20	internal	internal	ADJ
admet-335	46	21	control	control	NOUN
admet-335	46	22	deoxycytidine	deoxycytidine	NOUN
admet-335	46	23	.	.	PUNCT
admet-335	47	1	(	(	PUNCT
admet-335	47	2	a	a	X
admet-335	47	3	)	)	PUNCT
admet-335	47	4	ionisation	ionisation	NOUN
admet-335	47	5	spectrum	spectrum	NOUN
admet-335	47	6	of	of	ADP
admet-335	47	7	the	the	DET
admet-335	47	8	parent	parent	NOUN
admet-335	47	9	compound	compound	NOUN
admet-335	47	10	(	(	PUNCT
admet-335	47	11	crizotinib	crizotinib	PROPN
admet-335	47	12	)	)	PUNCT
admet-335	47	13	and	and	CCONJ
admet-335	47	14	the	the	DET
admet-335	47	15	product	product	NOUN
admet-335	47	16	ion	ion	NOUN
admet-335	47	17	spectrum	spectrum	NOUN
admet-335	47	18	of	of	ADP
admet-335	47	19	the	the	DET
admet-335	47	20	[	[	X
admet-335	47	21	m+h	m+h	X
admet-335	47	22	]	]	X
admet-335	48	1	+	+	CCONJ
admet-335	48	2	ion	ion	NOUN
admet-335	48	3	for	for	ADP
admet-335	48	4	crizotinib	crizotinib	NOUN
admet-335	48	5	in	in	ADP
admet-335	48	6	chromatographic	chromatographic	ADJ
admet-335	48	7	mobile	mobile	ADJ
admet-335	48	8	phase	phase	NOUN
admet-335	48	9	,	,	PUNCT
admet-335	48	10	consisting	consist	VERB
admet-335	48	11	of	of	ADP
admet-335	48	12	acetonitrile	acetonitrile	NOUN
admet-335	48	13	,	,	PUNCT
admet-335	48	14	methanol	methanol	NOUN
admet-335	48	15	,	,	PUNCT
admet-335	48	16	isopropyl	isopropyl	NOUN
admet-335	48	17	alcohol	alcohol	NOUN
admet-335	48	18	and	and	CCONJ
admet-335	48	19	aqueous	aqueous	ADJ
admet-335	48	20	ammonium	ammonium	NOUN
admet-335	48	21	acetate	acetate	NOUN
admet-335	48	22	at	at	ADP
admet-335	48	23	ph	ph	PROPN
admet-335	48	24	7.80	7.80	NUM
admet-335	48	25	.	.	PUNCT
admet-335	49	1	(	(	PUNCT
admet-335	49	2	b	b	X
admet-335	49	3	)	)	PUNCT
admet-335	49	4	chromatography	chromatography	NOUN
admet-335	49	5	of	of	ADP
admet-335	49	6	crizotinib	crizotinib	PROPN
admet-335	49	7	,	,	PUNCT
admet-335	49	8	gemcitabine	gemcitabine	NOUN
admet-335	49	9	and	and	CCONJ
admet-335	49	10	deoxycytidine	deoxycytidine	ADJ
admet-335	49	11	.	.	PUNCT
admet-335	50	1	(	(	PUNCT
admet-335	50	2	c	c	X
admet-335	50	3	)	)	PUNCT
admet-335	50	4	linearity	linearity	NOUN
admet-335	50	5	of	of	ADP
admet-335	50	6	crizotinib	crizotinib	VERB
admet-335	50	7	analysis	analysis	NOUN
admet-335	50	8	in	in	ADP
admet-335	50	9	mouse	mouse	NOUN
admet-335	50	10	and	and	CCONJ
admet-335	50	11	human	human	ADJ
admet-335	50	12	whole	whole	ADJ
admet-335	50	13	blood	blood	NOUN
admet-335	50	14	.	.	PUNCT
admet-335	51	1	extraction	extraction	NOUN
admet-335	51	2	and	and	CCONJ
admet-335	51	3	chromatography	chromatography	NOUN
admet-335	51	4	crizotinib	crizotinib	NOUN
admet-335	51	5	chromatography	chromatography	NOUN
admet-335	51	6	was	be	AUX
admet-335	51	7	performed	perform	VERB
admet-335	51	8	using	use	VERB
admet-335	51	9	the	the	DET
admet-335	51	10	optimized	optimize	VERB
admet-335	51	11	chromatographic	chromatographic	ADJ
admet-335	51	12	system	system	NOUN
admet-335	51	13	for	for	ADP
admet-335	51	14	the	the	DET
admet-335	51	15	multiple	multiple	ADJ
admet-335	51	16	tyrosine	tyrosine	NOUN
admet-335	51	17	kinase	kinase	PROPN
admet-335	51	18	inhibitors	inhibitor	NOUN
admet-335	51	19	(	(	PUNCT
admet-335	51	20	figure	figure	NOUN
admet-335	51	21	2b	2b	NOUN
admet-335	51	22	)	)	PUNCT
admet-335	52	1	[	[	X
admet-335	52	2	8	8	NUM
admet-335	52	3	]	]	PUNCT
admet-335	52	4	.	.	PUNCT
admet-335	53	1	under	under	ADP
admet-335	53	2	these	these	DET
admet-335	53	3	set	set	VERB
admet-335	53	4	conditions	condition	NOUN
admet-335	53	5	crizotinib	crizotinib	NOUN
admet-335	53	6	exhibited	exhibit	VERB
admet-335	53	7	less	less	ADJ
admet-335	53	8	sensitivity	sensitivity	NOUN
admet-335	53	9	g.j	g.j	PROPN
admet-335	53	10	.	.	PUNCT
admet-335	54	1	peters	peters	PROPN
admet-335	54	2	et	et	PROPN
admet-335	54	3	al	al	PROPN
admet-335	54	4	.	.	PROPN
admet-335	54	5	admet	admet	PROPN
admet-335	54	6	&	&	CCONJ
admet-335	54	7	dmpk	dmpk	PROPN
admet-335	54	8	4(4	4(4	NUM
admet-335	54	9	)	)	PUNCT
admet-335	54	10	(	(	PUNCT
admet-335	54	11	2016	2016	NUM
admet-335	54	12	)	)	PUNCT
admet-335	54	13	327	327	NUM
admet-335	54	14	-	-	SYM
admet-335	54	15	334	334	NUM
admet-335	54	16	330	330	NUM
admet-335	54	17	when	when	SCONJ
admet-335	54	18	compared	compare	VERB
admet-335	54	19	to	to	ADP
admet-335	54	20	erlotinib	erlotinib	PROPN
admet-335	54	21	,	,	PUNCT
admet-335	54	22	sunitinib	sunitinib	NOUN
admet-335	54	23	and	and	CCONJ
admet-335	54	24	gefitinib	gefitinib	NOUN
admet-335	54	25	.	.	PUNCT
admet-335	55	1	however	however	ADV
admet-335	55	2	,	,	PUNCT
admet-335	55	3	the	the	DET
admet-335	55	4	crizotinib	crizotinib	NOUN
admet-335	55	5	assay	assay	VERB
admet-335	55	6	was	be	AUX
admet-335	55	7	linear	linear	ADJ
admet-335	55	8	up	up	ADP
admet-335	55	9	to	to	PART
admet-335	55	10	30	30	NUM
admet-335	55	11	µg	µg	NOUN
admet-335	55	12	/	/	SYM
admet-335	55	13	ml	ml	NOUN
admet-335	55	14	in	in	ADP
admet-335	55	15	both	both	DET
admet-335	55	16	plasma	plasma	NOUN
admet-335	55	17	and	and	CCONJ
admet-335	55	18	serum	serum	NOUN
admet-335	55	19	(	(	PUNCT
admet-335	55	20	r2	r2	PROPN
admet-335	55	21	=	=	SYM
admet-335	55	22	0.986	0.986	NUM
admet-335	55	23	,	,	PUNCT
admet-335	55	24	n=	n=	ADJ
admet-335	55	25	10	10	NUM
admet-335	55	26	)	)	PUNCT
admet-335	55	27	,	,	PUNCT
admet-335	55	28	and	and	CCONJ
admet-335	55	29	reproducible	reproducible	VERB
admet-335	55	30	over	over	ADP
admet-335	55	31	a	a	DET
admet-335	55	32	3	3	NUM
admet-335	55	33	day	day	NOUN
admet-335	55	34	period	period	NOUN
admet-335	55	35	.	.	PUNCT
admet-335	56	1	crizotinib	crizotinib	PROPN
admet-335	56	2	was	be	AUX
admet-335	56	3	more	more	ADV
admet-335	56	4	soluble	soluble	ADJ
admet-335	56	5	in	in	ADP
admet-335	56	6	aqueous	aqueous	ADJ
admet-335	56	7	solutions	solution	NOUN
admet-335	56	8	than	than	SCONJ
admet-335	56	9	other	other	ADJ
admet-335	56	10	reported	report	VERB
admet-335	56	11	tkis	tkis	PROPN
admet-335	56	12	.	.	PUNCT
admet-335	57	1	for	for	ADP
admet-335	57	2	whole	whole	ADJ
admet-335	57	3	blood	blood	NOUN
admet-335	57	4	the	the	DET
admet-335	57	5	extraction	extraction	NOUN
admet-335	57	6	was	be	AUX
admet-335	57	7	best	well	ADV
admet-335	57	8	performed	perform	VERB
admet-335	57	9	in	in	ADP
admet-335	57	10	reverse	reverse	NOUN
admet-335	57	11	,	,	PUNCT
admet-335	57	12	where	where	SCONJ
admet-335	57	13	the	the	DET
admet-335	57	14	20	20	NUM
admet-335	57	15	µl	µl	ADP
admet-335	57	16	sample	sample	NOUN
admet-335	57	17	of	of	ADP
admet-335	57	18	whole	whole	ADJ
admet-335	57	19	blood	blood	NOUN
admet-335	57	20	was	be	AUX
admet-335	57	21	pipetted	pipette	VERB
admet-335	57	22	directly	directly	ADV
admet-335	57	23	into	into	ADP
admet-335	57	24	round	round	NOUN
admet-335	57	25	bottomed	bottom	VERB
admet-335	57	26	96	96	NUM
admet-335	57	27	well	well	INTJ
admet-335	57	28	already	already	ADV
admet-335	57	29	containing	contain	VERB
admet-335	57	30	80	80	NUM
admet-335	57	31	µl	µl	NOUN
admet-335	57	32	of	of	ADP
admet-335	57	33	acetonitrile	acetonitrile	NOUN
admet-335	57	34	.	.	PUNCT
admet-335	58	1	this	this	PRON
admet-335	58	2	ensured	ensure	VERB
admet-335	58	3	each	each	DET
admet-335	58	4	sample	sample	NOUN
admet-335	58	5	was	be	AUX
admet-335	58	6	homogeneously	homogeneously	ADV
admet-335	58	7	mixed	mixed	ADJ
admet-335	58	8	prior	prior	ADV
admet-335	58	9	to	to	ADP
admet-335	58	10	centrifugation	centrifugation	NOUN
admet-335	58	11	and	and	CCONJ
admet-335	58	12	transfer	transfer	NOUN
admet-335	58	13	of	of	ADP
admet-335	58	14	the	the	DET
admet-335	58	15	supernatant	supernatant	NOUN
admet-335	58	16	for	for	ADP
admet-335	58	17	lc	lc	PROPN
admet-335	58	18	-	-	PUNCT
admet-335	58	19	ms	ms	PROPN
admet-335	58	20	/	/	SYM
admet-335	58	21	ms	ms	NOUN
admet-335	58	22	analysis	analysis	NOUN
admet-335	58	23	.	.	PUNCT
admet-335	59	1	linearity	linearity	NOUN
admet-335	59	2	linear	linear	PROPN
admet-335	59	3	regression	regression	NOUN
admet-335	59	4	for	for	ADP
admet-335	59	5	whole	whole	ADJ
admet-335	59	6	blood	blood	NOUN
admet-335	59	7	preparations	preparation	NOUN
admet-335	59	8	was	be	AUX
admet-335	59	9	similar	similar	ADJ
admet-335	59	10	to	to	ADP
admet-335	59	11	plasma	plasma	NOUN
admet-335	59	12	/	/	SYM
admet-335	59	13	serum	serum	NOUN
admet-335	59	14	/	/	SYM
admet-335	59	15	cell	cell	NOUN
admet-335	59	16	culture	culture	NOUN
admet-335	59	17	medium	medium	NOUN
admet-335	59	18	in	in	ADP
admet-335	59	19	the	the	DET
admet-335	59	20	1	1	NUM
admet-335	59	21	–	–	SYM
admet-335	59	22	5000	5000	NUM
admet-335	59	23	ng	ng	NOUN
admet-335	59	24	/	/	SYM
admet-335	59	25	ml	ml	PROPN
admet-335	59	26	and	and	CCONJ
admet-335	59	27	was	be	AUX
admet-335	59	28	acceptable	acceptable	ADJ
admet-335	59	29	(	(	PUNCT
admet-335	59	30	r2>0.98	r2>0.98	PROPN
admet-335	59	31	)	)	PUNCT
admet-335	59	32	.	.	PUNCT
admet-335	60	1	the	the	DET
admet-335	60	2	standard	standard	ADJ
admet-335	60	3	error	error	NOUN
admet-335	60	4	was	be	AUX
admet-335	60	5	within	within	ADP
admet-335	60	6	±	±	NUM
admet-335	60	7	15	15	NUM
admet-335	60	8	%	%	NOUN
admet-335	60	9	for	for	ADP
admet-335	60	10	each	each	DET
admet-335	60	11	calibration	calibration	NOUN
admet-335	60	12	point	point	NOUN
admet-335	60	13	used	use	VERB
admet-335	60	14	.	.	PUNCT
admet-335	61	1	the	the	DET
admet-335	61	2	limit	limit	NOUN
admet-335	61	3	of	of	ADP
admet-335	61	4	quantitation	quantitation	NOUN
admet-335	61	5	for	for	ADP
admet-335	61	6	crizotinib	crizotinib	NOUN
admet-335	61	7	was	be	AUX
admet-335	61	8	50	50	NUM
admet-335	61	9	ng	ng	NOUN
admet-335	61	10	/	/	SYM
admet-335	61	11	ml	ml	ADP
admet-335	61	12	,	,	PUNCT
admet-335	61	13	due	due	ADP
admet-335	61	14	to	to	ADP
admet-335	61	15	lack	lack	NOUN
admet-335	61	16	of	of	ADP
admet-335	61	17	stock	stock	NOUN
admet-335	61	18	mouse	mouse	PROPN
admet-335	61	19	whole	whole	ADJ
admet-335	61	20	blood	blood	NOUN
admet-335	61	21	preparations	preparation	NOUN
admet-335	61	22	of	of	ADP
admet-335	61	23	human	human	ADJ
admet-335	61	24	whole	whole	ADJ
admet-335	61	25	blood	blood	NOUN
admet-335	61	26	were	be	AUX
admet-335	61	27	compared	compare	VERB
admet-335	61	28	to	to	PART
admet-335	61	29	mouse	mouse	VERB
admet-335	61	30	whole	whole	ADJ
admet-335	61	31	blood	blood	NOUN
admet-335	61	32	standard	standard	ADJ
admet-335	61	33	curves	curve	NOUN
admet-335	61	34	.	.	PUNCT
admet-335	62	1	no	no	DET
admet-335	62	2	difference	difference	NOUN
admet-335	62	3	was	be	AUX
admet-335	62	4	observed	observe	VERB
admet-335	62	5	in	in	ADP
admet-335	62	6	the	the	DET
admet-335	62	7	linear	linear	ADJ
admet-335	62	8	regression	regression	NOUN
admet-335	62	9	parameters	parameter	NOUN
admet-335	62	10	determined	determine	VERB
admet-335	62	11	(	(	PUNCT
admet-335	62	12	figure	figure	NOUN
admet-335	62	13	2c	2c	NUM
admet-335	62	14	)	)	PUNCT
admet-335	62	15	,	,	PUNCT
admet-335	62	16	hence	hence	ADV
admet-335	62	17	human	human	ADJ
admet-335	62	18	whole	whole	ADJ
admet-335	62	19	blood	blood	NOUN
admet-335	62	20	was	be	AUX
admet-335	62	21	used	use	VERB
admet-335	62	22	as	as	ADP
admet-335	62	23	an	an	DET
admet-335	62	24	alternative	alternative	ADJ
admet-335	62	25	stock	stock	NOUN
admet-335	62	26	matrix	matrix	NOUN
admet-335	62	27	for	for	SCONJ
admet-335	62	28	the	the	DET
admet-335	62	29	samples	sample	NOUN
admet-335	62	30	to	to	PART
admet-335	62	31	be	be	AUX
admet-335	62	32	analyzed	analyze	VERB
admet-335	62	33	.	.	PUNCT
admet-335	63	1	to	to	PART
admet-335	63	2	limit	limit	VERB
admet-335	63	3	the	the	DET
admet-335	63	4	standard	standard	ADJ
admet-335	63	5	requirements	requirement	NOUN
admet-335	63	6	per	per	ADP
admet-335	63	7	analytical	analytical	ADJ
admet-335	63	8	run	run	NOUN
admet-335	63	9	,	,	PUNCT
admet-335	63	10	standard	standard	ADJ
admet-335	63	11	curves	curve	NOUN
admet-335	63	12	for	for	ADP
admet-335	63	13	crizotinib	crizotinib	NOUN
admet-335	63	14	and	and	CCONJ
admet-335	63	15	gemcitabine	gemcitabine	NOUN
admet-335	63	16	,	,	PUNCT
admet-335	63	17	and	and	CCONJ
admet-335	63	18	its	its	PRON
admet-335	63	19	metabolite	metabolite	NOUN
admet-335	63	20	difluorodeoxyuridine	difluorodeoxyuridine	NOUN
admet-335	63	21	(	(	PUNCT
admet-335	63	22	dfdu	dfdu	ADJ
admet-335	63	23	)	)	PUNCT
admet-335	63	24	were	be	AUX
admet-335	63	25	prepared	prepare	VERB
admet-335	63	26	in	in	ADP
admet-335	63	27	either	either	CCONJ
admet-335	63	28	whole	whole	ADJ
admet-335	63	29	blood	blood	NOUN
admet-335	63	30	or	or	CCONJ
admet-335	63	31	cell	cell	NOUN
admet-335	63	32	culture	culture	NOUN
admet-335	63	33	medium	medium	NOUN
admet-335	63	34	.	.	PUNCT
admet-335	64	1	separate	separate	ADJ
admet-335	64	2	extractions	extraction	NOUN
admet-335	64	3	for	for	ADP
admet-335	64	4	gemcitabine	gemcitabine	NOUN
admet-335	64	5	/	/	SYM
admet-335	64	6	dfdu	dfdu	ADJ
admet-335	64	7	and	and	CCONJ
admet-335	64	8	crizotinib	crizotinib	NOUN
admet-335	64	9	were	be	AUX
admet-335	64	10	just	just	ADV
admet-335	64	11	not	not	PART
admet-335	64	12	possible	possible	ADJ
admet-335	64	13	because	because	SCONJ
admet-335	64	14	the	the	DET
admet-335	64	15	sample	sample	NOUN
admet-335	64	16	volume	volume	NOUN
admet-335	64	17	available	available	ADJ
admet-335	64	18	for	for	SCONJ
admet-335	64	19	the	the	DET
admet-335	64	20	mouse	mouse	NOUN
admet-335	64	21	blood	blood	NOUN
admet-335	64	22	samples	sample	NOUN
admet-335	64	23	ranged	range	VERB
admet-335	64	24	from	from	ADP
admet-335	64	25	5	5	NUM
admet-335	64	26	-	-	SYM
admet-335	64	27	20	20	NUM
admet-335	64	28	µl	µl	NOUN
admet-335	64	29	per	per	ADP
admet-335	64	30	time	time	NOUN
admet-335	64	31	point	point	NOUN
admet-335	64	32	.	.	PUNCT
admet-335	65	1	therefore	therefore	ADV
admet-335	65	2	,	,	PUNCT
admet-335	65	3	extraction	extraction	NOUN
admet-335	65	4	using	use	VERB
admet-335	65	5	acetonitrile	acetonitrile	ADJ
admet-335	65	6	precipitation	precipitation	NOUN
admet-335	65	7	was	be	AUX
admet-335	65	8	used	use	VERB
admet-335	65	9	for	for	ADP
admet-335	65	10	gemcitabine	gemcitabine	NOUN
admet-335	65	11	and	and	CCONJ
admet-335	65	12	dfdu	dfdu	ADJ
admet-335	65	13	.	.	PUNCT
admet-335	66	1	gemcitabine/	gemcitabine/	PROPN
admet-335	66	2	dfdu	dfdu	ADJ
admet-335	66	3	sensitivity	sensitivity	NOUN
admet-335	66	4	was	be	AUX
admet-335	66	5	lower	low	ADJ
admet-335	66	6	(	(	PUNCT
admet-335	66	7	especially	especially	ADV
admet-335	66	8	for	for	ADP
admet-335	66	9	dfdu	dfdu	ADJ
admet-335	66	10	in	in	ADP
admet-335	66	11	tissues	tissue	NOUN
admet-335	66	12	)	)	PUNCT
admet-335	66	13	compared	compare	VERB
admet-335	66	14	to	to	ADP
admet-335	66	15	the	the	DET
admet-335	66	16	previously	previously	ADV
admet-335	66	17	published	publish	VERB
admet-335	66	18	procedure	procedure	NOUN
admet-335	66	19	but	but	CCONJ
admet-335	66	20	was	be	AUX
admet-335	66	21	linear	linear	ADJ
admet-335	66	22	in	in	ADP
admet-335	66	23	response	response	NOUN
admet-335	66	24	across	across	ADP
admet-335	66	25	multiple	multiple	ADJ
admet-335	66	26	days	day	NOUN
admet-335	66	27	.	.	PUNCT
admet-335	67	1	the	the	DET
admet-335	67	2	limit	limit	NOUN
admet-335	67	3	of	of	ADP
admet-335	67	4	quantification	quantification	NOUN
admet-335	67	5	for	for	ADP
admet-335	67	6	gemcitabine	gemcitabine	NOUN
admet-335	67	7	was	be	AUX
admet-335	67	8	10	10	NUM
admet-335	67	9	ng	ng	PROPN
admet-335	67	10	/	/	SYM
admet-335	67	11	ml	ml	PROPN
admet-335	67	12	.	.	PUNCT
admet-335	68	1	linear	linear	ADJ
admet-335	68	2	regression	regression	NOUN
admet-335	68	3	for	for	ADP
admet-335	68	4	gemcitabine	gemcitabine	NOUN
admet-335	68	5	was	be	AUX
admet-335	68	6	not	not	PART
admet-335	68	7	affected	affect	VERB
admet-335	68	8	by	by	ADP
admet-335	68	9	the	the	DET
admet-335	68	10	presence	presence	NOUN
admet-335	68	11	of	of	ADP
admet-335	68	12	crizotinib	crizotinib	NOUN
admet-335	68	13	and	and	CCONJ
admet-335	68	14	chromatographically	chromatographically	ADV
admet-335	68	15	all	all	DET
admet-335	68	16	compounds	compound	NOUN
admet-335	68	17	were	be	AUX
admet-335	68	18	separated	separate	VERB
admet-335	68	19	(	(	PUNCT
admet-335	68	20	figure	figure	NOUN
admet-335	68	21	2c	2c	NUM
admet-335	68	22	)	)	PUNCT
admet-335	68	23	.	.	PUNCT
admet-335	69	1	tissue	tissue	NOUN
admet-335	69	2	analysis	analysis	NOUN
admet-335	69	3	preparation	preparation	NOUN
admet-335	69	4	of	of	ADP
admet-335	69	5	a	a	DET
admet-335	69	6	standard	standard	ADJ
admet-335	69	7	curve	curve	NOUN
admet-335	69	8	within	within	ADP
admet-335	69	9	a	a	DET
admet-335	69	10	tissue	tissue	NOUN
admet-335	69	11	matrix	matrix	NOUN
admet-335	69	12	was	be	AUX
admet-335	69	13	not	not	PART
admet-335	69	14	always	always	ADV
admet-335	69	15	feasible	feasible	ADJ
admet-335	69	16	due	due	ADP
admet-335	69	17	to	to	ADP
admet-335	69	18	the	the	DET
admet-335	69	19	lack	lack	NOUN
admet-335	69	20	of	of	ADP
admet-335	69	21	sufficient	sufficient	ADJ
admet-335	69	22	tissue	tissue	NOUN
admet-335	69	23	from	from	ADP
admet-335	69	24	untreated	untreated	ADJ
admet-335	69	25	mice	mouse	NOUN
admet-335	69	26	.	.	PUNCT
admet-335	70	1	therefore	therefore	ADV
admet-335	70	2	cell	cell	NOUN
admet-335	70	3	culture	culture	NOUN
admet-335	70	4	medium	medium	NOUN
admet-335	70	5	was	be	AUX
admet-335	70	6	compared	compare	VERB
admet-335	70	7	with	with	ADP
admet-335	70	8	blank	blank	ADJ
admet-335	70	9	mouse	mouse	NOUN
admet-335	70	10	tissue	tissue	NOUN
admet-335	70	11	(	(	PUNCT
admet-335	70	12	heart	heart	NOUN
admet-335	70	13	)	)	PUNCT
admet-335	70	14	,	,	PUNCT
admet-335	70	15	which	which	PRON
admet-335	70	16	was	be	AUX
admet-335	70	17	available	available	ADJ
admet-335	70	18	in	in	ADP
admet-335	70	19	sufficient	sufficient	ADJ
admet-335	70	20	quantity	quantity	NOUN
admet-335	70	21	for	for	ADP
admet-335	70	22	the	the	DET
admet-335	70	23	validation	validation	NOUN
admet-335	70	24	procedure	procedure	NOUN
admet-335	70	25	.	.	PUNCT
admet-335	71	1	both	both	PRON
admet-335	71	2	were	be	AUX
admet-335	71	3	prepared	prepare	VERB
admet-335	71	4	as	as	ADP
admet-335	71	5	per	per	ADP
admet-335	71	6	protocol	protocol	NOUN
admet-335	71	7	.	.	PUNCT
admet-335	72	1	separate	separate	ADJ
admet-335	72	2	standard	standard	ADJ
admet-335	72	3	curves	curve	NOUN
admet-335	72	4	were	be	AUX
admet-335	72	5	prepared	prepare	VERB
admet-335	72	6	by	by	ADP
admet-335	72	7	spiking	spike	VERB
admet-335	72	8	with	with	ADP
admet-335	72	9	crizotinib	crizotinib	NOUN
admet-335	72	10	and	and	CCONJ
admet-335	72	11	gemcitabine	gemcitabine	NOUN
admet-335	72	12	dilutions	dilution	NOUN
admet-335	72	13	in	in	ADP
admet-335	72	14	acetonitrile	acetonitrile	NOUN
admet-335	72	15	:	:	PUNCT
admet-335	72	16	water	water	NOUN
admet-335	72	17	(	(	PUNCT
admet-335	72	18	5:1	5:1	NUM
admet-335	72	19	)	)	PUNCT
admet-335	72	20	.	.	PUNCT
admet-335	73	1	no	no	DET
admet-335	73	2	difference	difference	NOUN
admet-335	73	3	was	be	AUX
admet-335	73	4	observed	observe	VERB
admet-335	73	5	.	.	PUNCT
admet-335	74	1	therefore	therefore	ADV
admet-335	74	2	,	,	PUNCT
admet-335	74	3	for	for	ADP
admet-335	74	4	all	all	DET
admet-335	74	5	tissue	tissue	NOUN
admet-335	74	6	analysis	analysis	NOUN
admet-335	74	7	cell	cell	NOUN
admet-335	74	8	culture	culture	NOUN
admet-335	74	9	medium	medium	NOUN
admet-335	74	10	was	be	AUX
admet-335	74	11	used	use	VERB
admet-335	74	12	for	for	ADP
admet-335	74	13	the	the	DET
admet-335	74	14	standard	standard	ADJ
admet-335	74	15	matrix	matrix	NOUN
admet-335	74	16	.	.	PUNCT
admet-335	75	1	recovery	recovery	NOUN
admet-335	75	2	of	of	ADP
admet-335	75	3	crizotinib	crizotinib	NOUN
admet-335	75	4	,	,	PUNCT
admet-335	75	5	gemcitabine	gemcitabine	NOUN
admet-335	75	6	and	and	CCONJ
admet-335	75	7	dfdu	dfdu	ADJ
admet-335	75	8	was	be	AUX
admet-335	75	9	verified	verify	VERB
admet-335	75	10	using	use	VERB
admet-335	75	11	the	the	DET
admet-335	75	12	extracted	extract	VERB
admet-335	75	13	tissue	tissue	NOUN
admet-335	75	14	of	of	ADP
admet-335	75	15	the	the	DET
admet-335	75	16	combination	combination	NOUN
admet-335	75	17	treated	treat	VERB
admet-335	75	18	animal	animal	NOUN
admet-335	75	19	,	,	PUNCT
admet-335	75	20	by	by	ADP
admet-335	75	21	testing	test	VERB
admet-335	75	22	whether	whether	SCONJ
admet-335	75	23	subsequent	subsequent	ADJ
admet-335	75	24	extraction	extraction	NOUN
admet-335	75	25	would	would	AUX
admet-335	75	26	yield	yield	VERB
admet-335	75	27	any	any	DET
admet-335	75	28	detectable	detectable	ADJ
admet-335	75	29	drug	drug	NOUN
admet-335	75	30	.	.	PUNCT
admet-335	76	1	therefore	therefore	ADV
admet-335	76	2	,	,	PUNCT
admet-335	76	3	tissues	tissue	NOUN
admet-335	76	4	were	be	AUX
admet-335	76	5	extracted	extract	VERB
admet-335	76	6	with	with	ADP
admet-335	76	7	acetonitrile	acetonitrile	NOUN
admet-335	76	8	:	:	PUNCT
admet-335	76	9	water	water	NOUN
admet-335	76	10	(	(	PUNCT
admet-335	76	11	5:1	5:1	NUM
admet-335	76	12	)	)	PUNCT
admet-335	76	13	for	for	ADP
admet-335	76	14	a	a	DET
admet-335	76	15	second	second	ADJ
admet-335	76	16	and	and	CCONJ
admet-335	76	17	third	third	ADJ
admet-335	76	18	time	time	NOUN
admet-335	76	19	.	.	PUNCT
admet-335	77	1	after	after	ADP
admet-335	77	2	analysis	analysis	NOUN
admet-335	77	3	no	no	DET
admet-335	77	4	crizotinib	crizotinib	NOUN
admet-335	77	5	,	,	PUNCT
admet-335	77	6	gemcitabine	gemcitabine	NOUN
admet-335	77	7	or	or	CCONJ
admet-335	77	8	dfdu	dfdu	ADJ
admet-335	77	9	could	could	AUX
admet-335	77	10	be	be	AUX
admet-335	77	11	observed	observe	VERB
admet-335	77	12	within	within	ADP
admet-335	77	13	the	the	DET
admet-335	77	14	second	second	ADJ
admet-335	77	15	and	and	CCONJ
admet-335	77	16	third	third	ADJ
admet-335	77	17	extracts	extract	NOUN
admet-335	77	18	,	,	PUNCT
admet-335	77	19	indicating	indicate	VERB
admet-335	77	20	that	that	SCONJ
admet-335	77	21	close	close	ADJ
admet-335	77	22	to	to	PART
admet-335	77	23	100	100	NUM
admet-335	77	24	%	%	NOUN
admet-335	77	25	had	have	AUX
admet-335	77	26	been	be	AUX
admet-335	77	27	recovered	recover	VERB
admet-335	77	28	on	on	ADP
admet-335	77	29	the	the	DET
admet-335	77	30	first	first	ADJ
admet-335	77	31	extraction	extraction	NOUN
admet-335	77	32	(	(	PUNCT
admet-335	77	33	data	datum	NOUN
admet-335	77	34	not	not	PART
admet-335	77	35	shown	show	VERB
admet-335	77	36	)	)	PUNCT
admet-335	77	37	.	.	PUNCT
admet-335	78	1	results	result	VERB
admet-335	78	2	whole	whole	ADJ
admet-335	78	3	blood	blood	NOUN
admet-335	78	4	analysis	analysis	NOUN
admet-335	78	5	limited	limited	ADJ
admet-335	78	6	sampling	sampling	NOUN
admet-335	78	7	was	be	AUX
admet-335	78	8	performed	perform	VERB
admet-335	78	9	at	at	ADP
admet-335	78	10	1	1	NUM
admet-335	78	11	and	and	CCONJ
admet-335	78	12	2	2	NUM
admet-335	78	13	hour	hour	NOUN
admet-335	78	14	,	,	PUNCT
admet-335	78	15	since	since	SCONJ
admet-335	78	16	the	the	DET
admet-335	78	17	peak	peak	NOUN
admet-335	78	18	concentration	concentration	NOUN
admet-335	78	19	of	of	ADP
admet-335	78	20	gemcitabine	gemcitabine	NOUN
admet-335	78	21	was	be	AUX
admet-335	78	22	expected	expect	VERB
admet-335	78	23	around	around	ADP
admet-335	78	24	these	these	DET
admet-335	78	25	time	time	NOUN
admet-335	78	26	intervals	interval	NOUN
admet-335	78	27	[	[	X
admet-335	78	28	10,11	10,11	NOUN
admet-335	78	29	]	]	PUNCT
admet-335	78	30	.	.	PUNCT
admet-335	79	1	whole	whole	ADJ
admet-335	79	2	blood	blood	NOUN
admet-335	79	3	analysis	analysis	NOUN
admet-335	79	4	of	of	ADP
admet-335	79	5	the	the	DET
admet-335	79	6	treated	treat	VERB
admet-335	79	7	animals	animal	NOUN
admet-335	79	8	demonstrated	demonstrate	VERB
admet-335	79	9	measurable	measurable	ADJ
admet-335	79	10	concentrations	concentration	NOUN
admet-335	79	11	for	for	ADP
admet-335	79	12	gemcitabine	gemcitabine	NOUN
admet-335	79	13	(	(	PUNCT
admet-335	79	14	2	2	NUM
admet-335	79	15	h	h	NOUN
admet-335	79	16	:	:	PUNCT
admet-335	79	17	1.0	1.0	NUM
admet-335	79	18	±	±	NUM
admet-335	79	19	0.3	0.3	NUM
admet-335	79	20	µm	µm	NOUN
admet-335	79	21	)	)	PUNCT
admet-335	79	22	,	,	PUNCT
admet-335	79	23	dfdu	dfdu	ADJ
admet-335	79	24	(	(	PUNCT
admet-335	79	25	2	2	NUM
admet-335	79	26	h	h	NOUN
admet-335	79	27	:	:	PUNCT
admet-335	79	28	5.6	5.6	NUM
admet-335	79	29	±	±	NUM
admet-335	79	30	1.4	1.4	NUM
admet-335	79	31	µm	µm	NOUN
admet-335	79	32	)	)	PUNCT
admet-335	79	33	and	and	CCONJ
admet-335	79	34	crizotinib	crizotinib	X
admet-335	79	35	(	(	PUNCT
admet-335	79	36	2	2	NUM
admet-335	79	37	h	h	NOUN
admet-335	79	38	:	:	PUNCT
admet-335	79	39	2.4	2.4	NUM
admet-335	79	40	±	±	NUM
admet-335	79	41	0.8	0.8	NUM
admet-335	79	42	µm	µm	NUM
admet-335	79	43	)	)	PUNCT
admet-335	79	44	(	(	PUNCT
admet-335	79	45	figure	figure	NOUN
admet-335	79	46	3	3	NUM
admet-335	79	47	)	)	PUNCT
admet-335	79	48	.	.	PUNCT
admet-335	80	1	admet	admet	PROPN
admet-335	80	2	&	&	CCONJ
admet-335	80	3	dmpk	dmpk	PROPN
admet-335	80	4	4(4	4(4	NUM
admet-335	80	5	)	)	PUNCT
admet-335	80	6	(	(	PUNCT
admet-335	80	7	2016	2016	NUM
admet-335	80	8	)	)	PUNCT
admet-335	80	9	327	327	NUM
admet-335	80	10	-	-	PUNCT
admet-335	80	11	334	334	NUM
admet-335	80	12	tissue	tissue	NOUN
admet-335	80	13	distribution	distribution	NOUN
admet-335	80	14	of	of	ADP
admet-335	80	15	crizotinib	crizotinib	NOUN
admet-335	80	16	and	and	CCONJ
admet-335	80	17	gemcitabine	gemcitabine	NOUN
admet-335	80	18	in	in	ADP
admet-335	80	19	mouse	mouse	NOUN
admet-335	80	20	model	model	NOUN
admet-335	80	21	doi	doi	PROPN
admet-335	80	22	:	:	PUNCT
admet-335	80	23	10.5599	10.5599	NUM
admet-335	80	24	/	/	SYM
admet-335	80	25	admet.4.4.335	admet.4.4.335	NOUN
admet-335	80	26	331	331	NUM
admet-335	80	27	tissue	tissue	NOUN
admet-335	80	28	analysis	analysis	NOUN
admet-335	80	29	gemcitabine	gemcitabine	NOUN
admet-335	80	30	was	be	AUX
admet-335	80	31	found	find	VERB
admet-335	80	32	in	in	ADP
admet-335	80	33	all	all	DET
admet-335	80	34	tissues	tissue	NOUN
admet-335	80	35	that	that	PRON
admet-335	80	36	could	could	AUX
admet-335	80	37	be	be	AUX
admet-335	80	38	analyzed	analyze	VERB
admet-335	80	39	,	,	PUNCT
admet-335	80	40	when	when	SCONJ
admet-335	80	41	given	give	VERB
admet-335	80	42	alone	alone	ADV
admet-335	80	43	or	or	CCONJ
admet-335	80	44	in	in	ADP
admet-335	80	45	combination	combination	NOUN
admet-335	80	46	.	.	PUNCT
admet-335	81	1	the	the	DET
admet-335	81	2	highest	high	ADJ
admet-335	81	3	levels	level	NOUN
admet-335	81	4	were	be	AUX
admet-335	81	5	found	find	VERB
admet-335	81	6	in	in	ADP
admet-335	81	7	skin	skin	NOUN
admet-335	81	8	and	and	CCONJ
admet-335	81	9	spleen	spleen	NOUN
admet-335	81	10	.	.	PUNCT
admet-335	82	1	the	the	DET
admet-335	82	2	concentration	concentration	NOUN
admet-335	82	3	in	in	ADP
admet-335	82	4	the	the	DET
admet-335	82	5	brain	brain	NOUN
admet-335	82	6	was	be	AUX
admet-335	82	7	relatively	relatively	ADV
admet-335	82	8	high	high	ADJ
admet-335	82	9	compared	compare	VERB
admet-335	82	10	to	to	ADP
admet-335	82	11	the	the	DET
admet-335	82	12	other	other	ADJ
admet-335	82	13	tissue	tissue	NOUN
admet-335	82	14	types	type	NOUN
admet-335	82	15	and	and	CCONJ
admet-335	82	16	even	even	ADV
admet-335	82	17	comparable	comparable	ADJ
admet-335	82	18	to	to	ADP
admet-335	82	19	liver	liver	NOUN
admet-335	82	20	(	(	PUNCT
admet-335	82	21	figure	figure	NOUN
admet-335	82	22	4	4	NUM
admet-335	82	23	)	)	PUNCT
admet-335	82	24	,	,	PUNCT
admet-335	82	25	showing	show	VERB
admet-335	82	26	a	a	DET
admet-335	82	27	good	good	ADJ
admet-335	82	28	brain	brain	NOUN
admet-335	82	29	penetration	penetration	NOUN
admet-335	82	30	of	of	ADP
admet-335	82	31	gemcitabine	gemcitabine	NOUN
admet-335	82	32	.	.	PUNCT
admet-335	83	1	however	however	ADV
admet-335	83	2	,	,	PUNCT
admet-335	83	3	the	the	DET
admet-335	83	4	primary	primary	ADJ
admet-335	83	5	metabolite	metabolite	NOUN
admet-335	83	6	of	of	ADP
admet-335	83	7	gemcitabine	gemcitabine	NOUN
admet-335	83	8	,	,	PUNCT
admet-335	83	9	dfdu	dfdu	ADJ
admet-335	83	10	,	,	PUNCT
admet-335	83	11	was	be	AUX
admet-335	83	12	not	not	PART
admet-335	83	13	detectable	detectable	ADJ
admet-335	83	14	for	for	ADP
admet-335	83	15	this	this	DET
admet-335	83	16	group	group	NOUN
admet-335	83	17	of	of	ADP
admet-335	83	18	samples	sample	NOUN
admet-335	83	19	.	.	PUNCT
admet-335	84	1	this	this	PRON
admet-335	84	2	was	be	AUX
admet-335	84	3	most	most	ADV
admet-335	84	4	likely	likely	ADJ
admet-335	84	5	due	due	ADP
admet-335	84	6	to	to	ADP
admet-335	84	7	the	the	DET
admet-335	84	8	lack	lack	NOUN
admet-335	84	9	of	of	ADP
admet-335	84	10	sensitivity	sensitivity	NOUN
admet-335	84	11	of	of	ADP
admet-335	84	12	uridine	uridine	NOUN
admet-335	84	13	based	base	VERB
admet-335	84	14	compounds	compound	NOUN
admet-335	84	15	to	to	ADP
admet-335	84	16	mass	mass	NOUN
admet-335	84	17	spectrometric	spectrometric	ADJ
admet-335	84	18	detection	detection	NOUN
admet-335	84	19	under	under	ADP
admet-335	84	20	the	the	DET
admet-335	84	21	chromatographic	chromatographic	ADJ
admet-335	84	22	conditions	condition	NOUN
admet-335	84	23	used	use	VERB
admet-335	84	24	,	,	PUNCT
admet-335	84	25	since	since	SCONJ
admet-335	84	26	we	we	PRON
admet-335	84	27	did	do	AUX
admet-335	84	28	not	not	PART
admet-335	84	29	use	use	VERB
admet-335	84	30	the	the	DET
admet-335	84	31	optimal	optimal	ADJ
admet-335	84	32	lcms	lcms	PROPN
admet-335	84	33	conditions	condition	NOUN
admet-335	84	34	as	as	SCONJ
admet-335	84	35	used	use	VERB
admet-335	84	36	earlier	early	ADV
admet-335	84	37	for	for	ADP
admet-335	84	38	tissues	tissue	NOUN
admet-335	84	39	[	[	X
admet-335	84	40	14	14	NUM
admet-335	84	41	]	]	PUNCT
admet-335	84	42	.	.	PUNCT
admet-335	85	1	in	in	ADP
admet-335	85	2	the	the	DET
admet-335	85	3	combination	combination	NOUN
admet-335	85	4	the	the	DET
admet-335	85	5	highest	high	ADJ
admet-335	85	6	levels	level	NOUN
admet-335	85	7	of	of	ADP
admet-335	85	8	gemcitabine	gemcitabine	NOUN
admet-335	85	9	were	be	AUX
admet-335	85	10	found	find	VERB
admet-335	85	11	in	in	ADP
admet-335	85	12	the	the	DET
admet-335	85	13	same	same	ADJ
admet-335	85	14	tissues	tissue	NOUN
admet-335	85	15	as	as	ADP
admet-335	85	16	at	at	ADP
admet-335	85	17	single	single	ADJ
admet-335	85	18	drug	drug	NOUN
admet-335	85	19	treatment	treatment	NOUN
admet-335	85	20	,	,	PUNCT
admet-335	85	21	with	with	ADP
admet-335	85	22	increased	increase	VERB
admet-335	85	23	drug	drug	NOUN
admet-335	85	24	levels	level	NOUN
admet-335	85	25	in	in	ADP
admet-335	85	26	blood	blood	NOUN
admet-335	85	27	,	,	PUNCT
admet-335	85	28	but	but	CCONJ
admet-335	85	29	lower	low	ADJ
admet-335	85	30	levels	level	NOUN
admet-335	85	31	in	in	ADP
admet-335	85	32	lung	lung	NOUN
admet-335	85	33	and	and	CCONJ
admet-335	85	34	brain	brain	NOUN
admet-335	85	35	(	(	PUNCT
admet-335	85	36	figure	figure	NOUN
admet-335	85	37	4	4	NUM
admet-335	85	38	)	)	PUNCT
admet-335	85	39	.	.	PUNCT
admet-335	86	1	d	d	NOUN
admet-335	86	2	ru	ru	NOUN
admet-335	86	3	g	g	PROPN
admet-335	86	4	c	c	PROPN
admet-335	86	5	o	o	NOUN
admet-335	86	6	n	n	ADP
admet-335	86	7	c	c	NOUN
admet-335	86	8	e	e	X
admet-335	86	9	n	n	X
admet-335	86	10	tr	tr	DET
admet-335	86	11	a	a	DET
admet-335	86	12	ti	ti	NOUN
admet-335	86	13	o	o	NOUN
admet-335	86	14	n	n	PROPN
admet-335	86	15	(	(	PUNCT
admet-335	86	16	µ	µ	X
admet-335	86	17	m	m	NOUN
admet-335	86	18	)	)	PUNCT
admet-335	86	19	crizotinib	crizotinib	VERB
admet-335	86	20	  	  	SPACE
admet-335	86	21	gemcitabine	gemcitabine	NOUN
admet-335	86	22	dfdu	dfdu	ADJ
admet-335	86	23	0	0	NUM
admet-335	86	24	5	5	NUM
admet-335	86	25	10	10	NUM
admet-335	86	26	gemcitabine	gemcitabine	NOUN
admet-335	86	27	+	+	CCONJ
admet-335	86	28	crizotinib	crizotinib	VERB
admet-335	86	29	gemicitabine	gemicitabine	NOUN
admet-335	86	30	alone	alone	ADV
admet-335	86	31	crizotinib	crizotinib	VERB
admet-335	86	32	alone	alone	ADV
admet-335	86	33	nd	nd	PRON
admet-335	86	34	nd	nd	INTJ
admet-335	86	35	nd	nd	PROPN
admet-335	86	36	d	d	NOUN
admet-335	86	37	ru	ru	NOUN
admet-335	86	38	g	g	PROPN
admet-335	86	39	c	c	PROPN
admet-335	86	40	o	o	NOUN
admet-335	86	41	n	n	ADP
admet-335	86	42	c	c	NOUN
admet-335	86	43	e	e	X
admet-335	86	44	n	n	X
admet-335	86	45	tr	tr	DET
admet-335	86	46	a	a	DET
admet-335	86	47	ti	ti	NOUN
admet-335	86	48	o	o	NOUN
admet-335	86	49	n	n	PROPN
admet-335	86	50	(	(	PUNCT
admet-335	86	51	µ	µ	X
admet-335	86	52	m	m	NOUN
admet-335	86	53	)	)	PUNCT
admet-335	86	54	crizotinib	crizotinib	VERB
admet-335	86	55	  	  	SPACE
admet-335	86	56	gemcitabine	gemcitabine	NOUN
admet-335	86	57	dfdu	dfdu	ADJ
admet-335	86	58	0	0	NUM
admet-335	86	59	5	5	NUM
admet-335	86	60	10	10	NUM
admet-335	86	61	gemcitabine	gemcitabine	NOUN
admet-335	86	62	+	+	CCONJ
admet-335	86	63	crizotinib	crizotinib	VERB
admet-335	86	64	gemicitabine	gemicitabine	NOUN
admet-335	86	65	alone	alone	ADV
admet-335	86	66	crizotinib	crizotinib	VERB
admet-335	86	67	alone	alone	ADV
admet-335	86	68	nd	nd	PRON
admet-335	86	69	nd	nd	NOUN
admet-335	86	70	nd	nd	ADV
admet-335	86	71	1	1	NUM
admet-335	86	72	hr	hr	NOUN
admet-335	86	73	2	2	NUM
admet-335	86	74	hr	hr	NOUN
admet-335	86	75	figure	figure	NOUN
admet-335	86	76	3	3	NUM
admet-335	86	77	.	.	PUNCT
admet-335	86	78	concentrations	concentration	NOUN
admet-335	86	79	of	of	ADP
admet-335	86	80	crizotinib	crizotinib	NOUN
admet-335	86	81	,	,	PUNCT
admet-335	86	82	gemcitabine	gemcitabine	NOUN
admet-335	86	83	and	and	CCONJ
admet-335	86	84	dfdu	dfdu	ADJ
admet-335	86	85	in	in	ADP
admet-335	86	86	whole	whole	ADJ
admet-335	86	87	mouse	mouse	NOUN
admet-335	86	88	blood	blood	NOUN
admet-335	86	89	.	.	PUNCT
admet-335	87	1	blood	blood	NOUN
admet-335	87	2	was	be	AUX
admet-335	87	3	taken	take	VERB
admet-335	87	4	at	at	ADP
admet-335	87	5	1	1	NUM
admet-335	87	6	and	and	CCONJ
admet-335	87	7	2	2	NUM
admet-335	87	8	h	h	NOUN
admet-335	87	9	after	after	ADP
admet-335	87	10	drug	drug	NOUN
admet-335	87	11	administration	administration	NOUN
admet-335	87	12	.	.	PUNCT
admet-335	88	1	values	value	NOUN
admet-335	88	2	are	be	AUX
admet-335	88	3	means	mean	VERB
admet-335	88	4	±	±	NUM
admet-335	88	5	sd	sd	NOUN
admet-335	88	6	of	of	ADP
admet-335	88	7	3	3	NUM
admet-335	88	8	animals	animal	NOUN
admet-335	88	9	.	.	PUNCT
admet-335	89	1	p	p	X
admet-335	89	2	m	m	VERB
admet-335	89	3	o	o	NOUN
admet-335	89	4	l/	l/	NOUN
admet-335	89	5	m	m	VERB
admet-335	89	6	g	g	PROPN
admet-335	89	7	t	t	PROPN
admet-335	89	8	is	be	AUX
admet-335	89	9	s	s	NOUN
admet-335	89	10	u	u	NOUN
admet-335	89	11	e	e	NOUN
admet-335	89	12	g	g	NOUN
admet-335	89	13	e	e	X
admet-335	89	14	m	m	NOUN
admet-335	89	15	c	c	VERB
admet-335	89	16	it	it	PRON
admet-335	89	17	a	a	DET
admet-335	89	18	b	b	NOUN
admet-335	89	19	in	in	ADP
admet-335	89	20	e	e	PROPN
admet-335	89	21	p	p	X
admet-335	89	22	an	an	DET
admet-335	89	23	cr	cr	NOUN
admet-335	89	24	ea	ea	PROPN
admet-335	89	25	s	s	PART
admet-335	89	26	liv	liv	PROPN
admet-335	89	27	er	er	INTJ
admet-335	89	28	lung	lung	PROPN
admet-335	89	29	b	b	PROPN
admet-335	89	30	ra	ra	PROPN
admet-335	89	31	in	in	ADP
admet-335	89	32	in	in	ADP
admet-335	89	33	te	te	PROPN
admet-335	89	34	st	st	PROPN
admet-335	89	35	in	in	ADP
admet-335	89	36	e	e	PROPN
admet-335	89	37	k	k	PROPN
admet-335	89	38	i	i	PROPN
admet-335	89	39	d	d	PROPN
admet-335	89	40	ney	ney	PROPN
admet-335	89	41	s	s	VERB
admet-335	89	42	ki	ki	PROPN
admet-335	90	1	n	n	PROPN
admet-335	90	2	h	h	NOUN
admet-335	91	1	ea	ea	INTJ
admet-335	91	2	rt	rt	PROPN
admet-335	91	3	s	s	PROPN
admet-335	91	4	ple	ple	PROPN
admet-335	91	5	en	en	PROPN
admet-335	91	6	0	0	NUM
admet-335	91	7	5	5	NUM
admet-335	91	8	10	10	NUM
admet-335	91	9	20	20	NUM
admet-335	91	10	30	30	NUM
admet-335	91	11	40	40	NUM
admet-335	91	12	50	50	NUM
admet-335	92	1	p	p	NOUN
admet-335	92	2	m	m	NOUN
admet-335	92	3	o	o	NOUN
admet-335	92	4	l/	l/	NOUN
admet-335	92	5	m	m	VERB
admet-335	92	6	g	g	PROPN
admet-335	92	7	t	t	PROPN
admet-335	92	8	is	be	AUX
admet-335	92	9	s	s	NOUN
admet-335	92	10	u	u	NOUN
admet-335	92	11	e	e	NOUN
admet-335	92	12	g	g	NOUN
admet-335	92	13	e	e	X
admet-335	92	14	m	m	NOUN
admet-335	92	15	c	c	VERB
admet-335	92	16	it	it	PRON
admet-335	92	17	a	a	DET
admet-335	92	18	b	b	NOUN
admet-335	92	19	in	in	ADP
admet-335	92	20	e	e	PROPN
admet-335	92	21	p	p	X
admet-335	92	22	an	an	DET
admet-335	92	23	cr	cr	NOUN
admet-335	92	24	ea	ea	PROPN
admet-335	92	25	s	s	PART
admet-335	92	26	liv	liv	PROPN
admet-335	92	27	er	er	INTJ
admet-335	92	28	lung	lung	PROPN
admet-335	92	29	b	b	PROPN
admet-335	92	30	ra	ra	PROPN
admet-335	92	31	in	in	ADP
admet-335	92	32	s	s	PROPN
admet-335	92	33	ki	ki	PROPN
admet-335	92	34	n	n	PROPN
admet-335	92	35	0	0	NUM
admet-335	92	36	10	10	NUM
admet-335	92	37	20	20	NUM
admet-335	92	38	30	30	NUM
admet-335	92	39	40	40	NUM
admet-335	92	40	a	a	DET
admet-335	92	41	b	b	NOUN
admet-335	92	42	figure	figure	NOUN
admet-335	92	43	4	4	NUM
admet-335	92	44	.	.	PUNCT
admet-335	92	45	tissue	tissue	NOUN
admet-335	92	46	analysis	analysis	NOUN
admet-335	92	47	(	(	PUNCT
admet-335	92	48	at	at	ADP
admet-335	92	49	2	2	NUM
admet-335	92	50	hour	hour	NOUN
admet-335	92	51	after	after	ADP
admet-335	92	52	drug	drug	NOUN
admet-335	92	53	administration	administration	NOUN
admet-335	92	54	)	)	PUNCT
admet-335	92	55	of	of	ADP
admet-335	92	56	gemcitabine	gemcitabine	NOUN
admet-335	92	57	at	at	ADP
admet-335	92	58	single	single	ADJ
admet-335	92	59	drug	drug	NOUN
admet-335	92	60	administration	administration	NOUN
admet-335	92	61	(	(	PUNCT
admet-335	92	62	a	a	NOUN
admet-335	92	63	)	)	PUNCT
admet-335	92	64	and	and	CCONJ
admet-335	92	65	in	in	ADP
admet-335	92	66	combination	combination	NOUN
admet-335	92	67	with	with	ADP
admet-335	92	68	crizotinib	crizotinib	NOUN
admet-335	92	69	(	(	PUNCT
admet-335	92	70	b	b	NOUN
admet-335	92	71	)	)	PUNCT
admet-335	92	72	.	.	PUNCT
admet-335	93	1	values	value	NOUN
admet-335	93	2	are	be	AUX
admet-335	93	3	means	mean	VERB
admet-335	93	4	±	±	NUM
admet-335	93	5	sd	sd	NOUN
admet-335	93	6	of	of	ADP
admet-335	93	7	3	3	NUM
admet-335	93	8	animals	animal	NOUN
admet-335	93	9	.	.	PUNCT
admet-335	94	1	at	at	ADP
admet-335	94	2	single	single	ADJ
admet-335	94	3	treatment	treatment	NOUN
admet-335	94	4	crizotinib	crizotinib	NOUN
admet-335	94	5	accumulated	accumulate	VERB
admet-335	94	6	at	at	ADP
admet-335	94	7	high	high	ADJ
admet-335	94	8	levels	level	NOUN
admet-335	94	9	in	in	ADP
admet-335	94	10	lung	lung	NOUN
admet-335	94	11	,	,	PUNCT
admet-335	94	12	liver	liver	NOUN
admet-335	94	13	and	and	CCONJ
admet-335	94	14	pancreatic	pancreatic	ADJ
admet-335	94	15	tissues	tissue	NOUN
admet-335	94	16	,	,	PUNCT
admet-335	94	17	and	and	CCONJ
admet-335	94	18	at	at	ADP
admet-335	94	19	very	very	ADV
admet-335	94	20	low	low	ADJ
admet-335	94	21	levels	level	NOUN
admet-335	94	22	in	in	ADP
admet-335	94	23	the	the	DET
admet-335	94	24	brain	brain	NOUN
admet-335	94	25	(	(	PUNCT
admet-335	94	26	100	100	NUM
admet-335	94	27	-	-	ADJ
admet-335	94	28	fold	fold	VERB
admet-335	94	29	lower	lower	ADV
admet-335	94	30	)	)	PUNCT
admet-335	94	31	(	(	PUNCT
admet-335	94	32	figure	figure	NOUN
admet-335	94	33	5a	5a	NUM
admet-335	94	34	)	)	PUNCT
admet-335	94	35	.	.	PUNCT
admet-335	95	1	in	in	ADP
admet-335	95	2	the	the	DET
admet-335	95	3	combined	combine	VERB
admet-335	95	4	treatment	treatment	NOUN
admet-335	95	5	crizotinib	crizotinib	NOUN
admet-335	95	6	(	(	PUNCT
admet-335	95	7	pmol	pmol	PROPN
admet-335	95	8	/	/	SYM
admet-335	95	9	mg	mg	NOUN
admet-335	95	10	tissue	tissue	NOUN
admet-335	95	11	)	)	PUNCT
admet-335	95	12	was	be	AUX
admet-335	95	13	also	also	ADV
admet-335	95	14	found	find	VERB
admet-335	95	15	in	in	ADP
admet-335	95	16	all	all	DET
admet-335	95	17	major	major	ADJ
admet-335	95	18	tissues	tissue	NOUN
admet-335	95	19	at	at	ADP
admet-335	95	20	varying	vary	VERB
admet-335	95	21	concentrations	concentration	NOUN
admet-335	95	22	;	;	PUNCT
admet-335	95	23	intestine	intestine	NOUN
admet-335	95	24	demonstrated	demonstrate	VERB
admet-335	95	25	the	the	DET
admet-335	95	26	highest	high	ADJ
admet-335	95	27	levels	level	NOUN
admet-335	95	28	g.j	g.j	PROPN
admet-335	95	29	.	.	PROPN
admet-335	95	30	peters	peters	PROPN
admet-335	95	31	et	et	PROPN
admet-335	95	32	al	al	PROPN
admet-335	95	33	.	.	PROPN
admet-335	95	34	admet	admet	PROPN
admet-335	95	35	&	&	CCONJ
admet-335	95	36	dmpk	dmpk	PROPN
admet-335	95	37	4(4	4(4	NUM
admet-335	95	38	)	)	PUNCT
admet-335	95	39	(	(	PUNCT
admet-335	95	40	2016	2016	NUM
admet-335	95	41	)	)	PUNCT
admet-335	95	42	327	327	NUM
admet-335	95	43	-	-	SYM
admet-335	95	44	334	334	NUM
admet-335	95	45	332	332	NUM
admet-335	95	46	(	(	PUNCT
admet-335	95	47	1084	1084	NUM
admet-335	95	48	)	)	PUNCT
admet-335	95	49	followed	follow	VERB
admet-335	95	50	by	by	ADP
admet-335	95	51	liver	liver	NOUN
admet-335	95	52	(	(	PUNCT
admet-335	95	53	215	215	NUM
admet-335	95	54	)	)	PUNCT
admet-335	95	55	,	,	PUNCT
admet-335	95	56	lung	lung	NOUN
admet-335	95	57	(	(	PUNCT
admet-335	95	58	172	172	NUM
admet-335	95	59	)	)	PUNCT
admet-335	95	60	and	and	CCONJ
admet-335	95	61	kidney	kidney	NOUN
admet-335	95	62	(	(	PUNCT
admet-335	95	63	167	167	NUM
admet-335	95	64	)	)	PUNCT
admet-335	95	65	.	.	PUNCT
admet-335	96	1	in	in	ADP
admet-335	96	2	addition	addition	NOUN
admet-335	96	3	,	,	PUNCT
admet-335	96	4	crizotinib	crizotinib	NOUN
admet-335	96	5	was	be	AUX
admet-335	96	6	found	find	VERB
admet-335	96	7	in	in	ADP
admet-335	96	8	the	the	DET
admet-335	96	9	spleen	spleen	NOUN
admet-335	96	10	(	(	PUNCT
admet-335	96	11	133	133	NUM
admet-335	96	12	)	)	PUNCT
admet-335	96	13	,	,	PUNCT
admet-335	96	14	skin	skin	NOUN
admet-335	96	15	(	(	PUNCT
admet-335	96	16	28	28	NUM
admet-335	96	17	)	)	PUNCT
admet-335	96	18	,	,	PUNCT
admet-335	96	19	heart	heart	NOUN
admet-335	96	20	(	(	PUNCT
admet-335	96	21	34	34	NUM
admet-335	96	22	)	)	PUNCT
admet-335	96	23	,	,	PUNCT
admet-335	96	24	pancreas	pancreas	NOUN
admet-335	96	25	(	(	PUNCT
admet-335	96	26	48	48	NUM
admet-335	96	27	)	)	PUNCT
admet-335	96	28	and	and	CCONJ
admet-335	96	29	brain	brain	NOUN
admet-335	96	30	(	(	PUNCT
admet-335	96	31	4	4	NUM
admet-335	96	32	)	)	PUNCT
admet-335	96	33	.	.	PUNCT
admet-335	97	1	crizotinib	crizotinib	PROPN
admet-335	97	2	demonstrated	demonstrate	VERB
admet-335	97	3	an	an	DET
admet-335	97	4	increased	increase	VERB
admet-335	97	5	accumulation	accumulation	NOUN
admet-335	97	6	compared	compare	VERB
admet-335	97	7	to	to	ADP
admet-335	97	8	the	the	DET
admet-335	97	9	single	single	ADJ
admet-335	97	10	treatment	treatment	NOUN
admet-335	97	11	in	in	ADP
admet-335	97	12	4	4	NUM
admet-335	97	13	of	of	ADP
admet-335	97	14	5	5	NUM
admet-335	97	15	tissues	tissue	NOUN
admet-335	97	16	tested	test	VERB
admet-335	97	17	(	(	PUNCT
admet-335	97	18	figure	figure	NOUN
admet-335	97	19	5b	5b	NOUN
admet-335	97	20	and	and	CCONJ
admet-335	97	21	table	table	NOUN
admet-335	97	22	1	1	NUM
admet-335	97	23	)	)	PUNCT
admet-335	97	24	.	.	PUNCT
admet-335	98	1	p	p	NOUN
admet-335	98	2	m	m	VERB
admet-335	98	3	o	o	NOUN
admet-335	98	4	l/	l/	NOUN
admet-335	98	5	m	m	VERB
admet-335	98	6	g	g	PROPN
admet-335	98	7	t	t	PROPN
admet-335	98	8	is	be	AUX
admet-335	98	9	s	s	NOUN
admet-335	98	10	u	u	NOUN
admet-335	98	11	e	e	X
admet-335	98	12	c	c	X
admet-335	98	13	ri	ri	PROPN
admet-335	98	14	z	z	NOUN
admet-335	98	15	o	o	NOUN
admet-335	98	16	ti	ti	X
admet-335	99	1	n	n	PROPN
admet-335	99	2	ib	ib	PROPN
admet-335	99	3	pan	pan	PROPN
admet-335	99	4	cr	cr	PROPN
admet-335	99	5	ea	ea	PROPN
admet-335	99	6	s	s	PART
admet-335	99	7	liv	liv	PROPN
admet-335	99	8	er	er	INTJ
admet-335	99	9	lung	lung	PROPN
admet-335	99	10	b	b	PROPN
admet-335	99	11	ra	ra	PROPN
admet-335	99	12	in	in	ADP
admet-335	99	13	ski	ski	PROPN
admet-335	99	14	n	n	PROPN
admet-335	99	15	0	0	NUM
admet-335	99	16	5	5	NUM
admet-335	99	17	10	10	NUM
admet-335	99	18	15	15	NUM
admet-335	99	19	20	20	NUM
admet-335	99	20	50	50	NUM
admet-335	99	21	100	100	NUM
admet-335	99	22	150	150	NUM
admet-335	99	23	200	200	NUM
admet-335	99	24	250	250	NUM
admet-335	99	25	p	p	NOUN
admet-335	99	26	m	m	PROPN
admet-335	99	27	o	o	NOUN
admet-335	99	28	l/	l/	NOUN
admet-335	99	29	m	m	VERB
admet-335	99	30	g	g	PROPN
admet-335	99	31	t	t	PROPN
admet-335	99	32	is	be	AUX
admet-335	99	33	s	s	NOUN
admet-335	99	34	u	u	NOUN
admet-335	99	35	e	e	X
admet-335	99	36	c	c	X
admet-335	99	37	ri	ri	PROPN
admet-335	99	38	z	z	NOUN
admet-335	99	39	o	o	NOUN
admet-335	99	40	ti	ti	X
admet-335	99	41	n	n	PROPN
admet-335	99	42	ib	ib	PROPN
admet-335	99	43	pan	pan	PROPN
admet-335	99	44	cr	cr	PROPN
admet-335	99	45	ea	ea	PROPN
admet-335	99	46	s	s	PART
admet-335	99	47	liv	liv	PROPN
admet-335	99	48	er	er	INTJ
admet-335	99	49	lung	lung	PROPN
admet-335	99	50	b	b	PROPN
admet-335	99	51	ra	ra	PROPN
admet-335	99	52	in	in	ADP
admet-335	99	53	in	in	ADP
admet-335	99	54	te	te	PROPN
admet-335	99	55	st	st	PROPN
admet-335	99	56	in	in	ADP
admet-335	99	57	e	e	PROPN
admet-335	99	58	k	k	PROPN
admet-335	99	59	i	i	PROPN
admet-335	99	60	d	d	PROPN
admet-335	99	61	ney	ney	PROPN
admet-335	99	62	ski	ski	NOUN
admet-335	100	1	n	n	CCONJ
admet-335	100	2	h	h	NOUN
admet-335	101	1	ea	ea	PROPN
admet-335	102	1	rt	rt	PROPN
admet-335	102	2	sple	sple	PROPN
admet-335	102	3	en	en	PROPN
admet-335	102	4	0	0	NUM
admet-335	102	5	2	2	NUM
admet-335	102	6	4	4	NUM
admet-335	102	7	6	6	NUM
admet-335	102	8	500	500	NUM
admet-335	102	9	1000	1000	NUM
admet-335	102	10	100	100	NUM
admet-335	102	11	a	a	DET
admet-335	102	12	b	b	NOUN
admet-335	102	13	figure	figure	NOUN
admet-335	102	14	5	5	NUM
admet-335	102	15	.	.	PUNCT
admet-335	102	16	tissue	tissue	NOUN
admet-335	102	17	analysis	analysis	NOUN
admet-335	102	18	(	(	PUNCT
admet-335	102	19	at	at	ADP
admet-335	102	20	2	2	NUM
admet-335	102	21	hour	hour	NOUN
admet-335	102	22	after	after	ADP
admet-335	102	23	drug	drug	NOUN
admet-335	102	24	administration	administration	NOUN
admet-335	102	25	)	)	PUNCT
admet-335	102	26	of	of	ADP
admet-335	102	27	crizotinib	crizotinib	NOUN
admet-335	102	28	at	at	ADP
admet-335	102	29	single	single	ADJ
admet-335	102	30	drug	drug	NOUN
admet-335	102	31	administration	administration	NOUN
admet-335	102	32	(	(	PUNCT
admet-335	102	33	a	a	NOUN
admet-335	102	34	)	)	PUNCT
admet-335	102	35	and	and	CCONJ
admet-335	102	36	in	in	ADP
admet-335	102	37	combination	combination	NOUN
admet-335	102	38	with	with	ADP
admet-335	102	39	gemcitabine	gemcitabine	NOUN
admet-335	102	40	(	(	PUNCT
admet-335	102	41	b	b	NOUN
admet-335	102	42	)	)	PUNCT
admet-335	102	43	.	.	PUNCT
admet-335	103	1	values	value	NOUN
admet-335	103	2	are	be	AUX
admet-335	103	3	means	mean	VERB
admet-335	103	4	±	±	NUM
admet-335	103	5	sd	sd	NOUN
admet-335	103	6	of	of	ADP
admet-335	103	7	3	3	NUM
admet-335	103	8	animals	animal	NOUN
admet-335	103	9	.	.	PUNCT
admet-335	104	1	table	table	NOUN
admet-335	104	2	1	1	NUM
admet-335	104	3	.	.	PUNCT
admet-335	104	4	effect	effect	NOUN
admet-335	104	5	of	of	ADP
admet-335	104	6	combination	combination	NOUN
admet-335	104	7	treatment	treatment	NOUN
admet-335	104	8	on	on	ADP
admet-335	104	9	drug	drug	NOUN
admet-335	104	10	levels	level	NOUN
admet-335	104	11	in	in	ADP
admet-335	104	12	normal	normal	ADJ
admet-335	104	13	tissues	tissue	NOUN
admet-335	104	14	,	,	PUNCT
admet-335	104	15	the	the	DET
admet-335	104	16	pancreatic	pancreatic	ADJ
admet-335	104	17	tumor	tumor	NOUN
admet-335	104	18	and	and	CCONJ
admet-335	104	19	blood	blood	NOUN
admet-335	104	20	.	.	PUNCT
admet-335	105	1	blood	blood	NOUN
admet-335	105	2	pancreas	pancreas	PROPN
admet-335	105	3	liver	liver	NOUN
admet-335	105	4	lung	lung	NOUN
admet-335	105	5	brain	brain	NOUN
admet-335	105	6	skin	skin	NOUN
admet-335	105	7	tumor	tumor	NOUN
admet-335	105	8	crizotinib	crizotinib	VERB
admet-335	105	9	1.4	1.4	NUM
admet-335	105	10	1.4	1.4	NUM
admet-335	105	11	2.0	2.0	NUM
admet-335	105	12	0.8	0.8	NUM
admet-335	105	13	4.5	4.5	NUM
admet-335	105	14	1.6	1.6	NUM
admet-335	105	15	1.4	1.4	NUM
admet-335	105	16	gemcitabine	gemcitabine	NOUN
admet-335	105	17	2.0	2.0	NUM
admet-335	105	18	1.3	1.3	NUM
admet-335	105	19	0.4	0.4	NUM
admet-335	105	20	0.2	0.2	NUM
admet-335	105	21	0.2	0.2	NUM
admet-335	105	22	1.2	1.2	NUM
admet-335	105	23	1.3	1.3	NUM
admet-335	105	24	values	value	NOUN
admet-335	105	25	are	be	AUX
admet-335	105	26	ratios	ratio	NOUN
admet-335	105	27	of	of	ADP
admet-335	105	28	the	the	DET
admet-335	105	29	combination	combination	NOUN
admet-335	105	30	versus	versus	ADP
admet-335	105	31	single	single	ADJ
admet-335	105	32	drug	drug	NOUN
admet-335	105	33	.	.	PUNCT
admet-335	106	1	tumor	tumor	NOUN
admet-335	106	2	data	datum	NOUN
admet-335	106	3	are	be	AUX
admet-335	106	4	from	from	ADP
admet-335	106	5	[	[	X
admet-335	106	6	7	7	NUM
admet-335	106	7	]	]	PUNCT
admet-335	106	8	discussion	discussion	NOUN
admet-335	106	9	tissue	tissue	NOUN
admet-335	106	10	distribution	distribution	NOUN
admet-335	106	11	of	of	ADP
admet-335	106	12	crizotinib	crizotinib	NOUN
admet-335	106	13	alone	alone	ADV
admet-335	106	14	and	and	CCONJ
admet-335	106	15	of	of	ADP
admet-335	106	16	the	the	DET
admet-335	106	17	gemcitabine	gemcitabine	NOUN
admet-335	106	18	and	and	CCONJ
admet-335	106	19	crizotinib	crizotinib	VERB
admet-335	106	20	combination	combination	NOUN
admet-335	106	21	has	have	AUX
admet-335	106	22	not	not	PART
admet-335	106	23	been	be	AUX
admet-335	106	24	reported	report	VERB
admet-335	106	25	previously	previously	ADV
admet-335	106	26	.	.	PUNCT
admet-335	107	1	only	only	ADV
admet-335	107	2	limited	limited	ADJ
admet-335	107	3	data	datum	NOUN
admet-335	107	4	are	be	AUX
admet-335	107	5	available	available	ADJ
admet-335	107	6	for	for	ADP
admet-335	107	7	gemcitabine	gemcitabine	NOUN
admet-335	107	8	distribution	distribution	NOUN
admet-335	107	9	in	in	ADP
admet-335	107	10	the	the	DET
admet-335	107	11	range	range	NOUN
admet-335	107	12	of	of	ADP
admet-335	107	13	tissues	tissue	NOUN
admet-335	107	14	we	we	PRON
admet-335	107	15	have	have	AUX
admet-335	107	16	tested	test	VERB
admet-335	107	17	.	.	PUNCT
admet-335	108	1	early	early	ADJ
admet-335	108	2	data	datum	NOUN
admet-335	108	3	on	on	ADP
admet-335	108	4	gemcitabine	gemcitabine	NOUN
admet-335	108	5	tissue	tissue	NOUN
admet-335	108	6	accumulation	accumulation	NOUN
admet-335	108	7	were	be	AUX
admet-335	108	8	obtained	obtain	VERB
admet-335	108	9	using	use	VERB
admet-335	108	10	radioactively	radioactively	NOUN
admet-335	108	11	labeled	label	VERB
admet-335	108	12	drug	drug	NOUN
admet-335	108	13	[	[	X
admet-335	108	14	12,13	12,13	NUM
admet-335	108	15	]	]	PUNCT
admet-335	108	16	;	;	PUNCT
admet-335	108	17	however	however	ADV
admet-335	108	18	,	,	PUNCT
admet-335	108	19	these	these	DET
admet-335	108	20	data	datum	NOUN
admet-335	108	21	does	do	AUX
admet-335	108	22	not	not	PART
admet-335	108	23	differentiate	differentiate	VERB
admet-335	108	24	between	between	ADP
admet-335	108	25	gemcitabine	gemcitabine	NOUN
admet-335	108	26	and	and	CCONJ
admet-335	108	27	dfdu	dfdu	ADJ
admet-335	108	28	,	,	PUNCT
admet-335	108	29	which	which	PRON
admet-335	108	30	could	could	AUX
admet-335	108	31	overestimate	overestimate	VERB
admet-335	108	32	the	the	DET
admet-335	108	33	tissues	tissue	NOUN
admet-335	108	34	exposure	exposure	NOUN
admet-335	108	35	to	to	ADP
admet-335	108	36	gemcitabine	gemcitabine	NOUN
admet-335	108	37	.	.	PUNCT
admet-335	109	1	as	as	SCONJ
admet-335	109	2	expected	expect	VERB
admet-335	109	3	,	,	PUNCT
admet-335	109	4	gemcitabine	gemcitabine	NOUN
admet-335	109	5	is	be	AUX
admet-335	109	6	accumulated	accumulate	VERB
admet-335	109	7	into	into	ADP
admet-335	109	8	all	all	DET
admet-335	109	9	tested	test	VERB
admet-335	109	10	tissues	tissue	NOUN
admet-335	109	11	,	,	PUNCT
admet-335	109	12	in	in	ADP
admet-335	109	13	agreement	agreement	NOUN
admet-335	109	14	with	with	ADP
admet-335	109	15	previous	previous	ADJ
admet-335	109	16	results	result	NOUN
admet-335	109	17	in	in	ADP
admet-335	109	18	humans	human	NOUN
admet-335	109	19	and	and	CCONJ
admet-335	109	20	animals	animal	NOUN
admet-335	109	21	[	[	X
admet-335	109	22	14	14	NUM
admet-335	109	23	-	-	SYM
admet-335	109	24	17	17	NUM
admet-335	109	25	]	]	PUNCT
admet-335	109	26	,	,	PUNCT
admet-335	109	27	as	as	SCONJ
admet-335	109	28	also	also	ADV
admet-335	109	29	shown	show	VERB
admet-335	109	30	with	with	ADP
admet-335	109	31	19f	19f	PROPN
admet-335	109	32	-	-	PUNCT
admet-335	109	33	nmr15	nmr15	NOUN
admet-335	109	34	.	.	PUNCT
admet-335	110	1	the	the	DET
admet-335	110	2	use	use	NOUN
admet-335	110	3	of	of	ADP
admet-335	110	4	the	the	DET
admet-335	110	5	sensitive	sensitive	ADJ
admet-335	110	6	lc	lc	PROPN
admet-335	110	7	-	-	PUNCT
admet-335	110	8	ms	ms	PROPN
admet-335	110	9	/	/	SYM
admet-335	110	10	ms	ms	NOUN
admet-335	110	11	technique	technique	NOUN
admet-335	110	12	enabled	enable	VERB
admet-335	110	13	acquisition	acquisition	NOUN
admet-335	110	14	of	of	ADP
admet-335	110	15	reproducible	reproducible	ADJ
admet-335	110	16	blood	blood	NOUN
admet-335	110	17	pharmacokinetics	pharmacokinetic	NOUN
admet-335	110	18	for	for	ADP
admet-335	110	19	all	all	DET
admet-335	110	20	three	three	NUM
admet-335	110	21	compounds	compound	NOUN
admet-335	110	22	(	(	PUNCT
admet-335	110	23	crizotinib	crizotinib	PROPN
admet-335	110	24	,	,	PUNCT
admet-335	110	25	gemcitabine	gemcitabine	NOUN
admet-335	110	26	and	and	CCONJ
admet-335	110	27	dfdu	dfdu	ADJ
admet-335	110	28	)	)	PUNCT
admet-335	110	29	simultaneously	simultaneously	ADV
admet-335	110	30	without	without	ADP
admet-335	110	31	interference	interference	NOUN
admet-335	110	32	[	[	X
admet-335	110	33	8,9	8,9	NUM
admet-335	110	34	]	]	PUNCT
admet-335	110	35	,	,	PUNCT
admet-335	110	36	but	but	CCONJ
admet-335	110	37	tissue	tissue	NOUN
admet-335	110	38	analysis	analysis	NOUN
admet-335	110	39	of	of	ADP
admet-335	110	40	dfdu	dfdu	ADJ
admet-335	110	41	was	be	AUX
admet-335	110	42	not	not	PART
admet-335	110	43	possible	possible	ADJ
admet-335	110	44	since	since	SCONJ
admet-335	110	45	we	we	PRON
admet-335	110	46	had	have	VERB
admet-335	110	47	to	to	PART
admet-335	110	48	adapt	adapt	VERB
admet-335	110	49	the	the	DET
admet-335	110	50	protocol	protocol	NOUN
admet-335	110	51	to	to	PART
admet-335	110	52	have	have	VERB
admet-335	110	53	one	one	NUM
admet-335	110	54	extraction	extraction	NOUN
admet-335	110	55	procedure	procedure	NOUN
admet-335	110	56	for	for	ADP
admet-335	110	57	all	all	DET
admet-335	110	58	drugs	drug	NOUN
admet-335	110	59	.	.	PUNCT
admet-335	111	1	using	use	VERB
admet-335	111	2	the	the	DET
admet-335	111	3	optimal	optimal	ADJ
admet-335	111	4	lc	lc	NOUN
admet-335	111	5	-	-	PUNCT
admet-335	111	6	ms	ms	PROPN
admet-335	111	7	/	/	SYM
admet-335	111	8	ms	ms	NOUN
admet-335	111	9	procedure	procedure	NOUN
admet-335	111	10	for	for	ADP
admet-335	111	11	dfdu	dfdu	ADJ
admet-335	111	12	we	we	PRON
admet-335	111	13	could	could	AUX
admet-335	111	14	demonstrate	demonstrate	VERB
admet-335	111	15	accumulation	accumulation	NOUN
admet-335	111	16	of	of	ADP
admet-335	111	17	dfdu	dfdu	ADJ
admet-335	111	18	in	in	ADP
admet-335	111	19	human	human	ADJ
admet-335	111	20	tissue	tissue	NOUN
admet-335	111	21	[	[	X
admet-335	111	22	14	14	NUM
admet-335	111	23	]	]	PUNCT
admet-335	111	24	.	.	PUNCT
admet-335	112	1	whole	whole	ADJ
admet-335	112	2	blood	blood	NOUN
admet-335	112	3	analysis	analysis	NOUN
admet-335	112	4	proved	prove	VERB
admet-335	112	5	consistent	consistent	ADJ
admet-335	112	6	with	with	ADP
admet-335	112	7	expected	expect	VERB
admet-335	112	8	pharmacokinetics	pharmacokinetic	NOUN
admet-335	112	9	of	of	ADP
admet-335	112	10	gemcitabine	gemcitabine	NOUN
admet-335	112	11	1	1	NUM
admet-335	112	12	and	and	CCONJ
admet-335	112	13	2	2	NUM
admet-335	112	14	hours	hour	NOUN
admet-335	112	15	after	after	ADP
admet-335	112	16	dosing	dose	VERB
admet-335	112	17	[	[	X
admet-335	112	18	10,11	10,11	NOUN
admet-335	112	19	]	]	PUNCT
admet-335	112	20	.	.	PUNCT
admet-335	113	1	gemcitabine	gemcitabine	NOUN
admet-335	113	2	levels	level	NOUN
admet-335	113	3	demonstrated	demonstrate	VERB
admet-335	113	4	a	a	DET
admet-335	113	5	rapid	rapid	ADJ
admet-335	113	6	decrease	decrease	NOUN
admet-335	113	7	in	in	ADP
admet-335	113	8	concentration	concentration	NOUN
admet-335	113	9	over	over	ADP
admet-335	113	10	the	the	DET
admet-335	113	11	2	2	NUM
admet-335	113	12	hour	hour	NOUN
admet-335	113	13	time	time	NOUN
admet-335	113	14	period	period	NOUN
admet-335	113	15	corresponding	correspond	VERB
admet-335	113	16	to	to	ADP
admet-335	113	17	an	an	DET
admet-335	113	18	increase	increase	NOUN
admet-335	113	19	in	in	ADP
admet-335	113	20	observable	observable	ADJ
admet-335	113	21	dfdu	dfdu	ADJ
admet-335	113	22	in	in	ADP
admet-335	113	23	agreement	agreement	NOUN
admet-335	113	24	with	with	ADP
admet-335	113	25	an	an	DET
admet-335	113	26	earlier	early	ADJ
admet-335	113	27	pharmacokinetic	pharmacokinetic	ADJ
admet-335	113	28	study	study	NOUN
admet-335	113	29	in	in	ADP
admet-335	113	30	mice	mouse	NOUN
admet-335	113	31	[	[	X
admet-335	113	32	11	11	NUM
admet-335	113	33	]	]	PUNCT
admet-335	113	34	.	.	PUNCT
admet-335	114	1	for	for	ADP
admet-335	114	2	crizotinib	crizotinib	NOUN
admet-335	114	3	,	,	PUNCT
admet-335	114	4	literature	literature	NOUN
admet-335	114	5	reported	report	VERB
admet-335	114	6	admet	admet	PROPN
admet-335	114	7	&	&	CCONJ
admet-335	114	8	dmpk	dmpk	PROPN
admet-335	114	9	4(4	4(4	NUM
admet-335	114	10	)	)	PUNCT
admet-335	114	11	(	(	PUNCT
admet-335	114	12	2016	2016	NUM
admet-335	114	13	)	)	PUNCT
admet-335	114	14	327	327	NUM
admet-335	114	15	-	-	PUNCT
admet-335	114	16	334	334	NUM
admet-335	114	17	tissue	tissue	NOUN
admet-335	114	18	distribution	distribution	NOUN
admet-335	114	19	of	of	ADP
admet-335	114	20	crizotinib	crizotinib	NOUN
admet-335	114	21	and	and	CCONJ
admet-335	114	22	gemcitabine	gemcitabine	NOUN
admet-335	114	23	in	in	ADP
admet-335	114	24	mouse	mouse	NOUN
admet-335	114	25	model	model	NOUN
admet-335	114	26	doi	doi	PROPN
admet-335	114	27	:	:	PUNCT
admet-335	114	28	10.5599	10.5599	NUM
admet-335	114	29	/	/	SYM
admet-335	114	30	admet.4.4.335	admet.4.4.335	NOUN
admet-335	114	31	333	333	NUM
admet-335	114	32	data	datum	NOUN
admet-335	114	33	are	be	AUX
admet-335	114	34	limited	limit	VERB
admet-335	114	35	,	,	PUNCT
admet-335	114	36	but	but	CCONJ
admet-335	114	37	since	since	SCONJ
admet-335	114	38	the	the	DET
admet-335	114	39	methodology	methodology	NOUN
admet-335	114	40	was	be	AUX
admet-335	114	41	adequate	adequate	ADJ
admet-335	114	42	for	for	ADP
admet-335	114	43	blood	blood	NOUN
admet-335	114	44	and	and	CCONJ
admet-335	114	45	tissue	tissue	NOUN
admet-335	114	46	pharmacokinetics	pharmacokinetic	NOUN
admet-335	114	47	of	of	ADP
admet-335	114	48	gemcitabine	gemcitabine	NOUN
admet-335	114	49	as	as	ADV
admet-335	114	50	well	well	ADV
admet-335	114	51	as	as	ADP
admet-335	114	52	blood	blood	NOUN
admet-335	114	53	crizotinib	crizotinib	NOUN
admet-335	114	54	,	,	PUNCT
admet-335	114	55	it	it	PRON
admet-335	114	56	can	can	AUX
admet-335	114	57	be	be	AUX
admet-335	114	58	assumed	assume	VERB
admet-335	114	59	that	that	SCONJ
admet-335	114	60	the	the	DET
admet-335	114	61	crizotinib	crizotinib	NOUN
admet-335	114	62	results	result	NOUN
admet-335	114	63	also	also	ADV
admet-335	114	64	reflect	reflect	VERB
admet-335	114	65	the	the	DET
admet-335	114	66	true	true	ADJ
admet-335	114	67	situation	situation	NOUN
admet-335	114	68	.	.	PUNCT
admet-335	115	1	crizotinib	crizotinib	PROPN
admet-335	115	2	demonstrated	demonstrate	VERB
admet-335	115	3	an	an	DET
admet-335	115	4	elevated	elevated	ADJ
admet-335	115	5	concentration	concentration	NOUN
admet-335	115	6	after	after	ADP
admet-335	115	7	1	1	NUM
admet-335	115	8	hour	hour	NOUN
admet-335	115	9	which	which	PRON
admet-335	115	10	was	be	AUX
admet-335	115	11	maintained	maintain	VERB
admet-335	115	12	after	after	ADP
admet-335	115	13	2	2	NUM
admet-335	115	14	hours	hour	NOUN
admet-335	115	15	indicating	indicate	VERB
admet-335	115	16	a	a	DET
admet-335	115	17	steady	steady	ADJ
admet-335	115	18	state	state	NOUN
admet-335	115	19	condition	condition	NOUN
admet-335	115	20	had	have	AUX
admet-335	115	21	probably	probably	ADV
admet-335	115	22	been	be	AUX
admet-335	115	23	reached	reach	VERB
admet-335	115	24	.	.	PUNCT
admet-335	116	1	crizotinib	crizotinib	NOUN
admet-335	116	2	accumulated	accumulate	VERB
admet-335	116	3	into	into	ADP
admet-335	116	4	all	all	DET
admet-335	116	5	tested	test	VERB
admet-335	116	6	tissues	tissue	NOUN
admet-335	116	7	at	at	ADP
admet-335	116	8	levels	level	NOUN
admet-335	116	9	consistent	consistent	ADJ
admet-335	116	10	with	with	ADP
admet-335	116	11	therapeutic	therapeutic	ADJ
admet-335	116	12	concentrations	concentration	NOUN
admet-335	116	13	,	,	PUNCT
admet-335	116	14	except	except	SCONJ
admet-335	116	15	for	for	ADP
admet-335	116	16	brain	brain	NOUN
admet-335	116	17	.	.	PUNCT
admet-335	117	1	crizotinib	crizotinib	VERB
admet-335	117	2	accumulation	accumulation	NOUN
admet-335	117	3	in	in	ADP
admet-335	117	4	the	the	DET
admet-335	117	5	brain	brain	NOUN
admet-335	117	6	tissue	tissue	NOUN
admet-335	117	7	has	have	AUX
admet-335	117	8	not	not	PART
admet-335	117	9	been	be	AUX
admet-335	117	10	previously	previously	ADV
admet-335	117	11	reported	report	VERB
admet-335	117	12	,	,	PUNCT
admet-335	117	13	but	but	CCONJ
admet-335	117	14	low	low	ADJ
admet-335	117	15	levels	level	NOUN
admet-335	117	16	were	be	AUX
admet-335	117	17	expected	expect	VERB
admet-335	117	18	since	since	SCONJ
admet-335	117	19	it	it	PRON
admet-335	117	20	is	be	AUX
admet-335	117	21	a	a	DET
admet-335	117	22	good	good	ADJ
admet-335	117	23	substrate	substrate	NOUN
admet-335	117	24	for	for	ADP
admet-335	117	25	efflux	efflux	NOUN
admet-335	117	26	pumps	pump	NOUN
admet-335	117	27	[	[	X
admet-335	117	28	18	18	NUM
admet-335	117	29	]	]	PUNCT
admet-335	117	30	.	.	PUNCT
admet-335	118	1	hence	hence	ADV
admet-335	118	2	,	,	PUNCT
admet-335	118	3	crizotinib	crizotinib	PROPN
admet-335	118	4	does	do	AUX
admet-335	118	5	not	not	PART
admet-335	118	6	show	show	VERB
admet-335	118	7	efficacy	efficacy	NOUN
admet-335	118	8	in	in	ADP
admet-335	118	9	patients	patient	NOUN
admet-335	118	10	with	with	ADP
admet-335	118	11	either	either	CCONJ
admet-335	118	12	brain	brain	NOUN
admet-335	118	13	tumors	tumor	NOUN
admet-335	118	14	of	of	ADP
admet-335	118	15	liver	liver	NOUN
admet-335	118	16	metastases	metastasis	NOUN
admet-335	118	17	[	[	X
admet-335	118	18	19	19	NUM
admet-335	118	19	]	]	PUNCT
admet-335	118	20	.	.	PUNCT
admet-335	119	1	the	the	DET
admet-335	119	2	combination	combination	NOUN
admet-335	119	3	of	of	ADP
admet-335	119	4	crizotinib	crizotinib	NOUN
admet-335	119	5	with	with	ADP
admet-335	119	6	gemcitabine	gemcitabine	NOUN
admet-335	119	7	appears	appear	VERB
admet-335	119	8	to	to	PART
admet-335	119	9	enhance	enhance	VERB
admet-335	119	10	crizotinib	crizotinib	ADJ
admet-335	119	11	exposure	exposure	NOUN
admet-335	119	12	in	in	ADP
admet-335	119	13	the	the	DET
admet-335	119	14	tissues	tissue	NOUN
admet-335	119	15	of	of	ADP
admet-335	119	16	the	the	DET
admet-335	119	17	pancreas	pancrea	NOUN
admet-335	119	18	,	,	PUNCT
admet-335	119	19	liver	liver	NOUN
admet-335	119	20	,	,	PUNCT
admet-335	119	21	brain	brain	NOUN
admet-335	119	22	and	and	CCONJ
admet-335	119	23	skin	skin	NOUN
admet-335	119	24	.	.	PUNCT
admet-335	120	1	the	the	DET
admet-335	120	2	accumulation	accumulation	NOUN
admet-335	120	3	of	of	ADP
admet-335	120	4	crizotinib	crizotinib	NOUN
admet-335	120	5	in	in	ADP
admet-335	120	6	the	the	DET
admet-335	120	7	orthotopic	orthotopic	ADJ
admet-335	120	8	tumor	tumor	NOUN
admet-335	120	9	was	be	AUX
admet-335	120	10	about	about	ADV
admet-335	120	11	37.4±30.3	37.4±30.3	NUM
admet-335	120	12	pmol	pmol	PRON
admet-335	120	13	/	/	SYM
admet-335	120	14	mg	mg	NOUN
admet-335	120	15	tissue	tissue	NOUN
admet-335	120	16	,	,	PUNCT
admet-335	120	17	while	while	SCONJ
admet-335	120	18	that	that	PRON
admet-335	120	19	of	of	ADP
admet-335	120	20	gemcitabine	gemcitabine	NOUN
admet-335	120	21	was	be	AUX
admet-335	120	22	about	about	ADV
admet-335	120	23	5.84±2.41	5.84±2.41	NUM
admet-335	120	24	pmol	pmol	PRON
admet-335	120	25	/	/	SYM
admet-335	120	26	mg	mg	NOUN
admet-335	120	27	tissue	tissue	NOUN
admet-335	120	28	,	,	PUNCT
admet-335	120	29	demonstrating	demonstrate	VERB
admet-335	120	30	excellent	excellent	ADJ
admet-335	120	31	tumor	tumor	NOUN
admet-335	120	32	uptake	uptake	ADJ
admet-335	120	33	.	.	PUNCT
admet-335	121	1	c	c	X
admet-335	121	2	-	-	PUNCT
admet-335	121	3	met	meet	VERB
admet-335	121	4	overexpression	overexpression	NOUN
admet-335	121	5	is	be	AUX
admet-335	121	6	observed	observe	VERB
admet-335	121	7	in	in	ADP
admet-335	121	8	tumors	tumor	NOUN
admet-335	121	9	from	from	ADP
admet-335	121	10	many	many	ADJ
admet-335	121	11	different	different	ADJ
admet-335	121	12	tissues	tissue	NOUN
admet-335	121	13	such	such	ADJ
admet-335	121	14	as	as	ADP
admet-335	121	15	brain	brain	NOUN
admet-335	121	16	,	,	PUNCT
admet-335	121	17	kidney	kidney	NOUN
admet-335	121	18	,	,	PUNCT
admet-335	121	19	ovarian	ovarian	ADJ
admet-335	121	20	,	,	PUNCT
admet-335	121	21	breast	breast	NOUN
admet-335	121	22	and	and	CCONJ
admet-335	121	23	gastrointestinal	gastrointestinal	ADJ
admet-335	121	24	cancers	cancer	NOUN
admet-335	121	25	[	[	X
admet-335	121	26	4,20	4,20	NUM
admet-335	121	27	]	]	X
admet-335	121	28	.	.	PUNCT
admet-335	122	1	the	the	DET
admet-335	122	2	use	use	NOUN
admet-335	122	3	of	of	ADP
admet-335	122	4	crizotinib	crizotinib	NOUN
admet-335	122	5	might	might	AUX
admet-335	122	6	be	be	AUX
admet-335	122	7	considered	consider	VERB
admet-335	122	8	as	as	ADP
admet-335	122	9	an	an	DET
admet-335	122	10	additional	additional	ADJ
admet-335	122	11	resource	resource	NOUN
admet-335	122	12	in	in	ADP
admet-335	122	13	these	these	DET
admet-335	122	14	areas	area	NOUN
admet-335	122	15	,	,	PUNCT
admet-335	122	16	especially	especially	ADV
admet-335	122	17	in	in	ADP
admet-335	122	18	combination	combination	NOUN
admet-335	122	19	with	with	ADP
admet-335	122	20	gemcitabine	gemcitabine	NOUN
admet-335	122	21	.	.	PUNCT
admet-335	123	1	crizotinib	crizotinib	PROPN
admet-335	123	2	also	also	ADV
admet-335	123	3	appears	appear	VERB
admet-335	123	4	to	to	PART
admet-335	123	5	enhance	enhance	VERB
admet-335	123	6	the	the	DET
admet-335	123	7	exposure	exposure	NOUN
admet-335	123	8	of	of	ADP
admet-335	123	9	pancreas	pancrea	NOUN
admet-335	123	10	and	and	CCONJ
admet-335	123	11	skin	skin	NOUN
admet-335	123	12	towards	towards	ADP
admet-335	123	13	gemcitabine	gemcitabine	NOUN
admet-335	123	14	,	,	PUNCT
admet-335	123	15	possibly	possibly	ADV
admet-335	123	16	by	by	ADP
admet-335	123	17	inhibiting	inhibit	VERB
admet-335	123	18	the	the	DET
admet-335	123	19	gemcitabine	gemcitabine	NOUN
admet-335	123	20	degradation	degradation	NOUN
admet-335	123	21	enzyme	enzyme	NOUN
admet-335	123	22	cytidine	cytidine	NOUN
admet-335	123	23	deaminase	deaminase	NOUN
admet-335	123	24	[	[	X
admet-335	123	25	3	3	NUM
admet-335	123	26	]	]	PUNCT
admet-335	123	27	.	.	PUNCT
admet-335	124	1	the	the	DET
admet-335	124	2	high	high	ADJ
admet-335	124	3	accumulation	accumulation	NOUN
admet-335	124	4	of	of	ADP
admet-335	124	5	crizotinib	crizotinib	NOUN
admet-335	124	6	in	in	ADP
admet-335	124	7	tissues	tissue	NOUN
admet-335	124	8	might	might	AUX
admet-335	124	9	not	not	PART
admet-335	124	10	reflect	reflect	VERB
admet-335	124	11	the	the	DET
admet-335	124	12	actually	actually	ADJ
admet-335	124	13	accumulation	accumulation	NOUN
admet-335	124	14	in	in	ADP
admet-335	124	15	cells	cell	NOUN
admet-335	124	16	,	,	PUNCT
admet-335	124	17	particularly	particularly	ADV
admet-335	124	18	in	in	ADP
admet-335	124	19	the	the	DET
admet-335	124	20	cytoplasm	cytoplasm	NOUN
admet-335	124	21	.	.	PUNCT
admet-335	125	1	earlier	early	ADV
admet-335	125	2	we	we	PRON
admet-335	125	3	demonstrated	demonstrate	VERB
admet-335	125	4	in	in	ADP
admet-335	125	5	cancer	cancer	NOUN
admet-335	125	6	cell	cell	NOUN
admet-335	125	7	lines	line	NOUN
admet-335	125	8	that	that	PRON
admet-335	125	9	crizotinib	crizotinib	VERB
admet-335	125	10	might	might	AUX
admet-335	125	11	concentrate	concentrate	VERB
admet-335	125	12	in	in	ADP
admet-335	125	13	lysosomes	lysosome	NOUN
admet-335	125	14	[	[	X
admet-335	125	15	18	18	NUM
admet-335	125	16	]	]	PUNCT
admet-335	125	17	,	,	PUNCT
admet-335	125	18	similar	similar	ADJ
admet-335	125	19	to	to	ADP
admet-335	125	20	sunitinib	sunitinib	NOUN
admet-335	125	21	[	[	X
admet-335	125	22	21	21	NUM
admet-335	125	23	]	]	PUNCT
admet-335	125	24	.	.	PUNCT
admet-335	126	1	hence	hence	ADV
admet-335	126	2	,	,	PUNCT
admet-335	126	3	in	in	ADP
admet-335	126	4	tissue	tissue	NOUN
admet-335	126	5	with	with	ADP
admet-335	126	6	a	a	DET
admet-335	126	7	high	high	ADJ
admet-335	126	8	content	content	NOUN
admet-335	126	9	of	of	ADP
admet-335	126	10	lysosomes	lysosome	NOUN
admet-335	126	11	the	the	DET
admet-335	126	12	accumulation	accumulation	NOUN
admet-335	126	13	might	might	AUX
admet-335	126	14	be	be	AUX
admet-335	126	15	a	a	DET
admet-335	126	16	lysosomal	lysosomal	ADJ
admet-335	126	17	accumulation	accumulation	NOUN
admet-335	126	18	.	.	PUNCT
admet-335	127	1	it	it	PRON
admet-335	127	2	is	be	AUX
admet-335	127	3	not	not	PART
admet-335	127	4	clear	clear	ADJ
admet-335	127	5	what	what	PRON
admet-335	127	6	these	these	DET
admet-335	127	7	data	datum	NOUN
admet-335	127	8	mean	mean	VERB
admet-335	127	9	in	in	ADP
admet-335	127	10	view	view	NOUN
admet-335	127	11	of	of	ADP
admet-335	127	12	toxicology	toxicology	NOUN
admet-335	127	13	,	,	PUNCT
admet-335	127	14	however	however	ADV
admet-335	127	15	,	,	PUNCT
admet-335	127	16	in	in	ADP
admet-335	127	17	general	general	ADJ
admet-335	127	18	crizotinib	crizotinib	NOUN
admet-335	127	19	is	be	AUX
admet-335	127	20	tolerated	tolerate	VERB
admet-335	127	21	well	well	ADV
admet-335	127	22	,	,	PUNCT
admet-335	127	23	although	although	SCONJ
admet-335	127	24	the	the	DET
admet-335	127	25	drug	drug	NOUN
admet-335	127	26	may	may	AUX
admet-335	127	27	induce	induce	VERB
admet-335	127	28	gastrointestinal	gastrointestinal	ADJ
admet-335	127	29	toxicity	toxicity	NOUN
admet-335	127	30	,	,	PUNCT
admet-335	127	31	edema	edema	NOUN
admet-335	127	32	and	and	CCONJ
admet-335	127	33	visual	visual	ADJ
admet-335	127	34	impairment	impairment	NOUN
admet-335	128	1	[	[	X
admet-335	128	2	5,22,23	5,22,23	NUM
admet-335	128	3	]	]	PUNCT
admet-335	128	4	.	.	PUNCT
admet-335	129	1	the	the	DET
admet-335	129	2	toxicity	toxicity	NOUN
admet-335	129	3	of	of	ADP
admet-335	129	4	gemcitabine	gemcitabine	NOUN
admet-335	129	5	in	in	ADP
admet-335	129	6	patients	patient	NOUN
admet-335	129	7	is	be	AUX
admet-335	129	8	predominantly	predominantly	ADV
admet-335	129	9	hematological	hematological	ADJ
admet-335	129	10	[	[	X
admet-335	129	11	24	24	NUM
admet-335	129	12	]	]	PUNCT
admet-335	129	13	which	which	PRON
admet-335	129	14	is	be	AUX
admet-335	129	15	in	in	ADP
admet-335	129	16	line	line	NOUN
admet-335	129	17	with	with	ADP
admet-335	129	18	the	the	DET
admet-335	129	19	high	high	ADJ
admet-335	129	20	concentration	concentration	NOUN
admet-335	129	21	observed	observe	VERB
admet-335	129	22	in	in	ADP
admet-335	129	23	the	the	DET
admet-335	129	24	spleen	spleen	NOUN
admet-335	129	25	.	.	PUNCT
admet-335	130	1	these	these	DET
admet-335	130	2	results	result	NOUN
admet-335	130	3	clearly	clearly	ADV
admet-335	130	4	show	show	VERB
admet-335	130	5	that	that	SCONJ
admet-335	130	6	distribution	distribution	NOUN
admet-335	130	7	of	of	ADP
admet-335	130	8	crizotinib	crizotinib	NOUN
admet-335	130	9	and	and	CCONJ
admet-335	130	10	gemcitabine	gemcitabine	NOUN
admet-335	130	11	occurs	occur	VERB
admet-335	130	12	over	over	ADP
admet-335	130	13	a	a	DET
admet-335	130	14	broad	broad	ADJ
admet-335	130	15	range	range	NOUN
admet-335	130	16	of	of	ADP
admet-335	130	17	tissue	tissue	NOUN
admet-335	130	18	types	type	NOUN
admet-335	130	19	achieving	achieve	VERB
admet-335	130	20	therapeutic	therapeutic	ADJ
admet-335	130	21	concentrations	concentration	NOUN
admet-335	130	22	for	for	ADP
admet-335	130	23	both	both	DET
admet-335	130	24	drugs	drug	NOUN
admet-335	130	25	.	.	PUNCT
admet-335	131	1	the	the	DET
admet-335	131	2	accumulation	accumulation	NOUN
admet-335	131	3	in	in	ADP
admet-335	131	4	specific	specific	ADJ
admet-335	131	5	tissues	tissue	NOUN
admet-335	131	6	(	(	PUNCT
admet-335	131	7	spleen	spleen	NOUN
admet-335	131	8	,	,	PUNCT
admet-335	131	9	intestine	intestine	NOUN
admet-335	131	10	)	)	PUNCT
admet-335	131	11	seems	seem	VERB
admet-335	131	12	to	to	PART
admet-335	131	13	be	be	AUX
admet-335	131	14	in	in	ADP
admet-335	131	15	line	line	NOUN
admet-335	131	16	with	with	ADP
admet-335	131	17	the	the	DET
admet-335	131	18	observed	observe	VERB
admet-335	131	19	toxicity	toxicity	NOUN
admet-335	131	20	in	in	ADP
admet-335	131	21	patients	patient	NOUN
admet-335	131	22	.	.	PUNCT
admet-335	132	1	moreover	moreover	ADV
admet-335	132	2	,	,	PUNCT
admet-335	132	3	in	in	ADP
admet-335	132	4	certain	certain	ADJ
admet-335	132	5	tissue	tissue	NOUN
admet-335	132	6	types	type	NOUN
admet-335	132	7	crizotinib	crizotinib	VERB
admet-335	132	8	appears	appear	VERB
admet-335	132	9	to	to	PART
admet-335	132	10	enhance	enhance	VERB
admet-335	132	11	the	the	DET
admet-335	132	12	exposure	exposure	NOUN
admet-335	132	13	to	to	ADP
admet-335	132	14	gemcitabine	gemcitabine	VERB
admet-335	132	15	suggesting	suggest	VERB
admet-335	132	16	the	the	DET
admet-335	132	17	need	need	NOUN
admet-335	132	18	for	for	ADP
admet-335	132	19	further	further	ADJ
admet-335	132	20	development	development	NOUN
admet-335	132	21	of	of	ADP
admet-335	132	22	this	this	DET
admet-335	132	23	combination	combination	NOUN
admet-335	132	24	,	,	PUNCT
admet-335	132	25	especially	especially	ADV
admet-335	132	26	with	with	ADP
admet-335	132	27	regards	regard	NOUN
admet-335	132	28	to	to	ADP
admet-335	132	29	pdac	pdac	NOUN
admet-335	132	30	.	.	PUNCT
admet-335	133	1	acknowledgements	acknowledgement	NOUN
admet-335	133	2	this	this	DET
admet-335	133	3	research	research	NOUN
admet-335	133	4	was	be	AUX
admet-335	133	5	supported	support	VERB
admet-335	133	6	by	by	ADP
admet-335	133	7	a	a	DET
admet-335	133	8	grant	grant	NOUN
admet-335	133	9	of	of	ADP
admet-335	133	10	the	the	DET
admet-335	133	11	cancer	cancer	NOUN
admet-335	133	12	center	center	NOUN
admet-335	133	13	amsterdam	amsterdam	PROPN
admet-335	133	14	to	to	PART
admet-335	133	15	elisa	elisa	VERB
admet-335	133	16	giovannetti	giovannetti	PROPN
admet-335	133	17	and	and	CCONJ
admet-335	133	18	g.j	g.j	PROPN
admet-335	133	19	.	.	PROPN
admet-335	133	20	peters	peters	PROPN
admet-335	133	21	.	.	PUNCT
admet-335	134	1	references	reference	NOUN
admet-335	134	2	[	[	X
admet-335	134	3	1	1	NUM
admet-335	134	4	]	]	X
admet-335	134	5	n.p	n.p	PROPN
admet-335	134	6	.	.	PROPN
admet-335	134	7	van	van	PROPN
admet-335	134	8	erp	erp	PROPN
admet-335	134	9	,	,	PUNCT
admet-335	134	10	h.	h.	PROPN
admet-335	134	11	gelderblom	gelderblom	PROPN
admet-335	134	12	,	,	PUNCT
admet-335	134	13	h.j	h.j	PROPN
admet-335	134	14	.	.	PROPN
admet-335	134	15	guchelaar	guchelaar	NOUN
admet-335	134	16	,	,	PUNCT
admet-335	134	17	cancer	cancer	NOUN
admet-335	134	18	treat	treat	NOUN
admet-335	134	19	.	.	PUNCT
admet-335	135	1	rev	rev	PROPN
admet-335	135	2	.	.	PROPN
admet-335	135	3	35	35	NUM
admet-335	135	4	(	(	PUNCT
admet-335	135	5	2009	2009	NUM
admet-335	135	6	)	)	PUNCT
admet-335	135	7	692	692	NUM
admet-335	135	8	-	-	SYM
admet-335	135	9	706	706	NUM
admet-335	135	10	.	.	PUNCT
admet-335	136	1	[	[	X
admet-335	136	2	2	2	NUM
admet-335	136	3	]	]	PUNCT
admet-335	136	4	c.	c.	PROPN
admet-335	136	5	carmi	carmi	PROPN
admet-335	136	6	,	,	PUNCT
admet-335	136	7	m.	m.	PROPN
admet-335	136	8	mor	mor	PROPN
admet-335	136	9	,	,	PUNCT
admet-335	136	10	p.g	p.g	PROPN
admet-335	136	11	.	.	PROPN
admet-335	136	12	petronini	petronini	PROPN
admet-335	136	13	,	,	PUNCT
admet-335	136	14	r.r	r.r	PROPN
admet-335	136	15	.	.	PROPN
admet-335	136	16	alfieri	alfieri	PROPN
admet-335	136	17	,	,	PUNCT
admet-335	136	18	biochem	biochem	PROPN
admet-335	136	19	.	.	PUNCT
admet-335	137	1	pharmacol	pharmacol	PROPN
admet-335	137	2	.	.	PUNCT
admet-335	138	1	84	84	NUM
admet-335	138	2	(	(	PUNCT
admet-335	138	3	2012	2012	NUM
admet-335	138	4	)	)	PUNCT
admet-335	138	5	1388	1388	NUM
admet-335	138	6	-	-	SYM
admet-335	138	7	1399	1399	NUM
admet-335	138	8	.	.	PUNCT
admet-335	139	1	[	[	X
admet-335	139	2	3	3	NUM
admet-335	139	3	]	]	PUNCT
admet-335	139	4	a.	a.	NOUN
admet-335	139	5	avan	avan	PROPN
admet-335	139	6	,	,	PUNCT
admet-335	139	7	v.	v.	PROPN
admet-335	139	8	caretti	caretti	NOUN
admet-335	139	9	,	,	PUNCT
admet-335	139	10	n.	n.	NOUN
admet-335	139	11	funel	funel	PROPN
admet-335	139	12	,	,	PUNCT
admet-335	139	13	et	et	PROPN
admet-335	139	14	al	al	PROPN
admet-335	139	15	.	.	PROPN
admet-335	139	16	,	,	PUNCT
admet-335	139	17	cancer	cancer	NOUN
admet-335	139	18	res	re	NOUN
admet-335	139	19	.	.	PUNCT
admet-335	140	1	73	73	NUM
admet-335	140	2	(	(	PUNCT
admet-335	140	3	2013	2013	NUM
admet-335	140	4	)	)	PUNCT
admet-335	140	5	6745	6745	NUM
admet-335	140	6	-	-	SYM
admet-335	140	7	6756	6756	NUM
admet-335	140	8	.	.	PUNCT
admet-335	141	1	[	[	X
admet-335	141	2	4	4	NUM
admet-335	141	3	]	]	X
admet-335	141	4	r.e	r.e	PROPN
admet-335	141	5	.	.	PROPN
admet-335	141	6	shackelford	shackelford	PROPN
admet-335	141	7	,	,	PUNCT
admet-335	141	8	m.	m.	PROPN
admet-335	141	9	vora	vora	PROPN
admet-335	141	10	,	,	PUNCT
admet-335	141	11	k.	k.	PROPN
admet-335	141	12	mayhall	mayhall	PROPN
admet-335	141	13	,	,	PUNCT
admet-335	141	14	j.	j.	PROPN
admet-335	141	15	cotelingam	cotelingam	PROPN
admet-335	141	16	,	,	PUNCT
admet-335	141	17	genes	gene	VERB
admet-335	141	18	cancer	cancer	NOUN
admet-335	141	19	5	5	NUM
admet-335	141	20	(	(	PUNCT
admet-335	141	21	2014	2014	NUM
admet-335	141	22	)	)	PUNCT
admet-335	141	23	1	1	NUM
admet-335	141	24	-	-	SYM
admet-335	141	25	14	14	NUM
admet-335	141	26	.	.	PUNCT
admet-335	142	1	[	[	X
admet-335	142	2	5	5	NUM
admet-335	142	3	]	]	X
admet-335	142	4	s.h	s.h	PROPN
admet-335	142	5	.	.	PROPN
admet-335	142	6	ou	ou	PROPN
admet-335	142	7	,	,	PUNCT
admet-335	142	8	drug	drug	PROPN
admet-335	142	9	des	des	PROPN
admet-335	142	10	.	.	PROPN
admet-335	142	11	devel	devel	NOUN
admet-335	142	12	.	.	PUNCT
admet-335	143	1	ther	ther	INTJ
admet-335	143	2	.	.	PUNCT
admet-335	144	1	5	5	NUM
admet-335	144	2	(	(	PUNCT
admet-335	144	3	2011	2011	NUM
admet-335	144	4	)	)	PUNCT
admet-335	144	5	471	471	NUM
admet-335	144	6	-	-	SYM
admet-335	144	7	485	485	NUM
admet-335	144	8	.	.	PUNCT
admet-335	145	1	[	[	X
admet-335	145	2	6	6	NUM
admet-335	145	3	]	]	X
admet-335	145	4	a.t	a.t	PROPN
admet-335	145	5	.	.	PROPN
admet-335	145	6	shaw	shaw	PROPN
admet-335	145	7	,	,	PUNCT
admet-335	145	8	u.	u.	PROPN
admet-335	145	9	yasothan	yasothan	PROPN
admet-335	145	10	,	,	PUNCT
admet-335	145	11	p.	p.	PROPN
admet-335	145	12	kirkpatrick	kirkpatrick	PROPN
admet-335	145	13	,	,	PUNCT
admet-335	145	14	nat	nat	PROPN
admet-335	145	15	.	.	PUNCT
admet-335	145	16	rev	rev	PROPN
admet-335	145	17	.	.	PROPN
admet-335	145	18	drug	drug	PROPN
admet-335	145	19	.	.	PUNCT
admet-335	146	1	discov	discov	NOUN
admet-335	146	2	.	.	PUNCT
admet-335	147	1	10	10	NUM
admet-335	147	2	(	(	PUNCT
admet-335	147	3	2011	2011	NUM
admet-335	147	4	)	)	PUNCT
admet-335	147	5	897	897	NUM
admet-335	147	6	-	-	SYM
admet-335	147	7	898	898	NUM
admet-335	147	8	.	.	PUNCT
admet-335	148	1	[	[	X
admet-335	148	2	7	7	X
admet-335	148	3	]	]	X
admet-335	148	4	m.	m.	NOUN
admet-335	148	5	el	el	PROPN
admet-335	148	6	-	-	PUNCT
admet-335	148	7	naggar	naggar	PROPN
admet-335	148	8	,	,	PUNCT
admet-335	148	9	e.	e.	PROPN
admet-335	148	10	giovannetti	giovannetti	PROPN
admet-335	148	11	,	,	PUNCT
admet-335	148	12	g.j	g.j	PROPN
admet-335	148	13	.	.	PROPN
admet-335	148	14	peters	peters	PROPN
admet-335	148	15	,	,	PUNCT
admet-335	148	16	current	current	ADJ
admet-335	148	17	pharm	pharm	NOUN
admet-335	148	18	.	.	PUNCT
admet-335	149	1	design	design	NOUN
admet-335	149	2	18	18	NUM
admet-335	149	3	(	(	PUNCT
admet-335	149	4	2012	2012	NUM
admet-335	149	5	)	)	PUNCT
admet-335	149	6	2811	2811	NUM
admet-335	149	7	-	-	SYM
admet-335	149	8	2829	2829	NUM
admet-335	149	9	.	.	PUNCT
admet-335	150	1	[	[	X
admet-335	150	2	8	8	NUM
admet-335	150	3	]	]	X
admet-335	150	4	r.	r.	PROPN
admet-335	150	5	honeywell	honeywell	PROPN
admet-335	150	6	,	,	PUNCT
admet-335	150	7	k.	k.	PROPN
admet-335	150	8	yarzadah	yarzadah	PROPN
admet-335	150	9	,	,	PUNCT
admet-335	150	10	e.	e.	PROPN
admet-335	150	11	giovannetti	giovannetti	PROPN
admet-335	150	12	,	,	PUNCT
admet-335	150	13	et	et	PROPN
admet-335	150	14	al	al	PROPN
admet-335	150	15	.	.	PROPN
admet-335	150	16	,	,	PUNCT
admet-335	150	17	j.	j.	PROPN
admet-335	150	18	chromatogr	chromatogr	PROPN
admet-335	150	19	.	.	PUNCT
admet-335	151	1	b.	b.	PROPN
admet-335	151	2	analyt	analyt	PROPN
admet-335	151	3	.	.	PUNCT
admet-335	152	1	technol	technol	PROPN
admet-335	152	2	.	.	PROPN
admet-335	152	3	biomed	biome	VERB
admet-335	152	4	.	.	PUNCT
admet-335	153	1	life	life	PROPN
admet-335	153	2	sci	sci	PROPN
admet-335	153	3	.	.	PROPN
admet-335	154	1	878	878	NUM
admet-335	154	2	(	(	PUNCT
admet-335	154	3	2010	2010	NUM
admet-335	154	4	)	)	PUNCT
admet-335	154	5	1059	1059	NUM
admet-335	154	6	-	-	SYM
admet-335	154	7	1068	1068	NUM
admet-335	154	8	.	.	PUNCT
admet-335	155	1	g.j	g.j	PROPN
admet-335	155	2	.	.	PROPN
admet-335	156	1	peters	peters	PROPN
admet-335	156	2	et	et	PROPN
admet-335	156	3	al	al	PROPN
admet-335	156	4	.	.	PROPN
admet-335	156	5	admet	admet	PROPN
admet-335	156	6	&	&	CCONJ
admet-335	156	7	dmpk	dmpk	PROPN
admet-335	156	8	4(4	4(4	NUM
admet-335	156	9	)	)	PUNCT
admet-335	156	10	(	(	PUNCT
admet-335	156	11	2016	2016	NUM
admet-335	156	12	)	)	PUNCT
admet-335	156	13	327	327	NUM
admet-335	156	14	-	-	SYM
admet-335	156	15	334	334	NUM
admet-335	156	16	334	334	NUM
admet-335	157	1	[	[	X
admet-335	157	2	9	9	NUM
admet-335	157	3	]	]	X
admet-335	157	4	r.j	r.j	PROPN
admet-335	157	5	.	.	PROPN
admet-335	157	6	honeywell	honeywell	PROPN
admet-335	157	7	,	,	PUNCT
admet-335	157	8	e.	e.	PROPN
admet-335	157	9	giovannetti	giovannetti	PROPN
admet-335	157	10	,	,	PUNCT
admet-335	157	11	g.j	g.j	PROPN
admet-335	157	12	.	.	PROPN
admet-335	157	13	peters	peters	PROPN
admet-335	157	14	,	,	PUNCT
admet-335	157	15	nucleosides	nucleoside	VERB
admet-335	157	16	nucleotides	nucleotide	NOUN
admet-335	157	17	nucleic	nucleic	ADJ
admet-335	157	18	acids	acid	NOUN
admet-335	157	19	30	30	NUM
admet-335	157	20	(	(	PUNCT
admet-335	157	21	2011	2011	NUM
admet-335	157	22	)	)	PUNCT
admet-335	157	23	12031213	12031213	NUM
admet-335	157	24	.	.	PUNCT
admet-335	158	1	[	[	X
admet-335	158	2	10	10	NUM
admet-335	158	3	]	]	X
admet-335	158	4	j.r	j.r	PROPN
admet-335	158	5	.	.	PROPN
admet-335	158	6	kroep	kroep	PROPN
admet-335	158	7	,	,	PUNCT
admet-335	158	8	g.j	g.j	PROPN
admet-335	158	9	.	.	PROPN
admet-335	158	10	peters	peters	PROPN
admet-335	158	11	,	,	PUNCT
admet-335	158	12	r.a	r.a	PROPN
admet-335	158	13	.	.	PROPN
admet-335	158	14	nagourney	nagourney	PROPN
admet-335	158	15	,	,	PUNCT
admet-335	158	16	in	in	ADP
admet-335	158	17	:	:	PUNCT
admet-335	158	18	cancer	cancer	NOUN
admet-335	158	19	drug	drug	NOUN
admet-335	158	20	discovery	discovery	NOUN
admet-335	158	21	and	and	CCONJ
admet-335	158	22	development	development	NOUN
admet-335	158	23	:	:	PUNCT
admet-335	158	24	deoxynucleoside	deoxynucleoside	NOUN
admet-335	158	25	analogs	analog	NOUN
admet-335	158	26	in	in	ADP
admet-335	158	27	cancer	cancer	NOUN
admet-335	158	28	therapy	therapy	NOUN
admet-335	158	29	(	(	PUNCT
admet-335	158	30	ed	ed	NOUN
admet-335	158	31	.	.	PUNCT
admet-335	159	1	g.j	g.j	PROPN
admet-335	159	2	.	.	PROPN
admet-335	159	3	peters	peters	PROPN
admet-335	159	4	)	)	PUNCT
admet-335	159	5	,	,	PUNCT
admet-335	159	6	humana	humana	PROPN
admet-335	159	7	press	press	PROPN
admet-335	159	8	inc	inc	PROPN
admet-335	159	9	.	.	PROPN
admet-335	159	10	,	,	PUNCT
admet-335	159	11	(	(	PUNCT
admet-335	159	12	2015	2015	NUM
admet-335	159	13	)	)	PUNCT
admet-335	159	14	253	253	NUM
admet-335	159	15	-	-	SYM
admet-335	159	16	288	288	NUM
admet-335	159	17	.	.	PUNCT
admet-335	160	1	[	[	X
admet-335	160	2	11	11	NUM
admet-335	160	3	]	]	X
admet-335	160	4	g.	g.	PROPN
admet-335	160	5	veerman	veerman	PROPN
admet-335	160	6	,	,	PUNCT
admet-335	160	7	v.w	v.w	PROPN
admet-335	160	8	.	.	PROPN
admet-335	160	9	ruiz	ruiz	PROPN
admet-335	160	10	van	van	PROPN
admet-335	160	11	haperen	haperen	PROPN
admet-335	160	12	,	,	PUNCT
admet-335	160	13	j.b	j.b	PROPN
admet-335	160	14	.	.	PROPN
admet-335	160	15	vermorken	vermorken	VERB
admet-335	160	16	,	,	PUNCT
admet-335	160	17	et	et	PROPN
admet-335	160	18	al	al	PROPN
admet-335	160	19	.	.	PROPN
admet-335	160	20	,	,	PUNCT
admet-335	160	21	cancer	cancer	NOUN
admet-335	160	22	chemother	chemother	PROPN
admet-335	160	23	.	.	PUNCT
admet-335	161	1	pharmacol	pharmacol	PROPN
admet-335	161	2	.	.	PUNCT
admet-335	162	1	38	38	NUM
admet-335	162	2	(	(	PUNCT
admet-335	162	3	1996	1996	NUM
admet-335	162	4	)	)	PUNCT
admet-335	162	5	335	335	NUM
admet-335	162	6	-	-	SYM
admet-335	162	7	42	42	NUM
admet-335	162	8	.	.	PUNCT
admet-335	163	1	[	[	X
admet-335	163	2	12	12	NUM
admet-335	163	3	]	]	X
admet-335	163	4	y.	y.	PROPN
admet-335	163	5	esumi	esumi	PROPN
admet-335	163	6	,	,	PUNCT
admet-335	163	7	k.	k.	PROPN
admet-335	163	8	mitsugi	mitsugi	PROPN
admet-335	163	9	,	,	PUNCT
admet-335	163	10	h.	h.	PROPN
admet-335	163	11	seki	seki	PROPN
admet-335	163	12	,	,	PUNCT
admet-335	163	13	et	et	PROPN
admet-335	163	14	al	al	PROPN
admet-335	163	15	.	.	PROPN
admet-335	163	16	,	,	PUNCT
admet-335	163	17	xenobiotica	xenobiotica	PROPN
admet-335	163	18	24	24	NUM
admet-335	163	19	(	(	PUNCT
admet-335	163	20	1994	1994	NUM
admet-335	163	21	)	)	PUNCT
admet-335	163	22	957	957	NUM
admet-335	163	23	-	-	SYM
admet-335	163	24	964	964	NUM
admet-335	163	25	.	.	PUNCT
admet-335	164	1	[	[	X
admet-335	164	2	13	13	NUM
admet-335	164	3	]	]	X
admet-335	164	4	y.	y.	PROPN
admet-335	164	5	esumi	esumi	PROPN
admet-335	164	6	,	,	PUNCT
admet-335	164	7	k.	k.	PROPN
admet-335	164	8	mitsugi	mitsugi	PROPN
admet-335	164	9	,	,	PUNCT
admet-335	164	10	a.	a.	PROPN
admet-335	164	11	takao	takao	PROPN
admet-335	164	12	,	,	PUNCT
admet-335	164	13	et	et	PROPN
admet-335	164	14	al	al	PROPN
admet-335	164	15	.	.	PUNCT
admet-335	165	1	xenobiotica	xenobiotica	PROPN
admet-335	165	2	24	24	NUM
admet-335	165	3	(	(	PUNCT
admet-335	165	4	1994	1994	NUM
admet-335	165	5	)	)	PUNCT
admet-335	165	6	805	805	NUM
admet-335	165	7	-	-	SYM
admet-335	165	8	817	817	NUM
admet-335	165	9	.	.	PUNCT
admet-335	166	1	[	[	X
admet-335	166	2	14	14	NUM
admet-335	166	3	]	]	X
admet-335	166	4	j.	j.	PROPN
admet-335	166	5	sigmond	sigmond	PROPN
admet-335	166	6	,	,	PUNCT
admet-335	166	7	r.j	r.j	PROPN
admet-335	166	8	.	.	PROPN
admet-335	166	9	honeywell	honeywell	PROPN
admet-335	166	10	,	,	PUNCT
admet-335	166	11	t.j	t.j	PROPN
admet-335	166	12	.	.	PROPN
admet-335	166	13	postma	postma	PROPN
admet-335	166	14	,	,	PUNCT
admet-335	166	15	et	et	PROPN
admet-335	166	16	al	al	PROPN
admet-335	166	17	.	.	PUNCT
admet-335	166	18	ann	ann	PROPN
admet-335	166	19	.	.	PUNCT
admet-335	167	1	oncol	oncol	PROPN
admet-335	167	2	.	.	PUNCT
admet-335	168	1	20	20	NUM
admet-335	168	2	(	(	PUNCT
admet-335	168	3	2009	2009	NUM
admet-335	168	4	)	)	PUNCT
admet-335	168	5	182	182	NUM
admet-335	168	6	-	-	SYM
admet-335	168	7	7	7	NUM
admet-335	168	8	.	.	PUNCT
admet-335	169	1	[	[	X
admet-335	169	2	15	15	NUM
admet-335	169	3	]	]	X
admet-335	169	4	p.e	p.e	PROPN
admet-335	169	5	.	.	PROPN
admet-335	169	6	kristjansen	kristjansen	PROPN
admet-335	169	7	,	,	PUNCT
admet-335	169	8	b.	b.	PROPN
admet-335	169	9	quistorff	quistorff	PROPN
admet-335	169	10	,	,	PUNCT
admet-335	169	11	m.	m.	PROPN
admet-335	169	12	spang	spang	PROPN
admet-335	169	13	-	-	PUNCT
admet-335	169	14	thomsen	thomsen	PROPN
admet-335	169	15	,	,	PUNCT
admet-335	169	16	h.h	h.h	PROPN
admet-335	169	17	.	.	PROPN
admet-335	169	18	hansen	hansen	PROPN
admet-335	169	19	,	,	PUNCT
admet-335	169	20	ann	ann	PROPN
admet-335	169	21	.	.	PROPN
admet-335	169	22	oncol	oncol	PROPN
admet-335	169	23	.	.	PUNCT
admet-335	170	1	4	4	NUM
admet-335	170	2	(	(	PUNCT
admet-335	170	3	1993	1993	NUM
admet-335	170	4	)	)	PUNCT
admet-335	170	5	157	157	NUM
admet-335	170	6	-	-	SYM
admet-335	170	7	60	60	NUM
admet-335	170	8	.	.	PUNCT
admet-335	171	1	[	[	X
admet-335	171	2	16	16	NUM
admet-335	171	3	]	]	X
admet-335	171	4	j.	j.	PROPN
admet-335	171	5	turk	turk	PROPN
admet-335	171	6	,	,	PUNCT
admet-335	171	7	k.	k.	PROPN
admet-335	171	8	bemis	bemis	PROPN
admet-335	171	9	,	,	PUNCT
admet-335	171	10	w.	w.	PROPN
admet-335	171	11	colbert	colbert	PROPN
admet-335	171	12	,	,	PUNCT
admet-335	171	13	et	et	PROPN
admet-335	171	14	al	al	PROPN
admet-335	171	15	.	.	PROPN
admet-335	171	16	,	,	PUNCT
admet-335	171	17	arzneimittelforschung	arzneimittelforschung	VERB
admet-335	171	18	44	44	NUM
admet-335	171	19	(	(	PUNCT
admet-335	171	20	1994	1994	NUM
admet-335	171	21	)	)	PUNCT
admet-335	171	22	1089	1089	NUM
admet-335	171	23	-	-	SYM
admet-335	171	24	92	92	NUM
admet-335	171	25	.	.	PUNCT
admet-335	172	1	[	[	X
admet-335	172	2	17	17	NUM
admet-335	172	3	]	]	X
admet-335	172	4	l.a	l.a	PROPN
admet-335	172	5	.	.	PROPN
admet-335	172	6	shipley	shipley	PROPN
admet-335	172	7	,	,	PUNCT
admet-335	172	8	t.j	t.j	PROPN
admet-335	172	9	.	.	PROPN
admet-335	172	10	brown	brown	PROPN
admet-335	172	11	,	,	PUNCT
admet-335	172	12	j.d	j.d	PROPN
admet-335	172	13	.	.	PROPN
admet-335	172	14	cornpropst	cornpropst	PROPN
admet-335	172	15	,	,	PUNCT
admet-335	172	16	m.	m.	PROPN
admet-335	172	17	hamilton	hamilton	PROPN
admet-335	172	18	,	,	PUNCT
admet-335	172	19	w.d	w.d	PROPN
admet-335	172	20	.	.	PROPN
admet-335	172	21	daniels	daniels	PROPN
admet-335	172	22	,	,	PUNCT
admet-335	172	23	h.w	h.w	PROPN
admet-335	172	24	.	.	PROPN
admet-335	172	25	culp	culp	PROPN
admet-335	172	26	,	,	PUNCT
admet-335	172	27	drug	drug	NOUN
admet-335	172	28	metab	metab	NOUN
admet-335	172	29	.	.	PUNCT
admet-335	173	1	dispos	dispos	PROPN
admet-335	173	2	.	.	PUNCT
admet-335	174	1	20	20	NUM
admet-335	174	2	(	(	PUNCT
admet-335	174	3	1992	1992	NUM
admet-335	174	4	)	)	PUNCT
admet-335	174	5	849	849	NUM
admet-335	174	6	-	-	SYM
admet-335	174	7	55	55	NUM
admet-335	174	8	.	.	PUNCT
admet-335	175	1	[	[	X
admet-335	175	2	18	18	NUM
admet-335	175	3	]	]	X
admet-335	175	4	c.g	c.g	PROPN
admet-335	175	5	.	.	PROPN
admet-335	175	6	da	da	PROPN
admet-335	175	7	silva	silva	PROPN
admet-335	175	8	,	,	PUNCT
admet-335	175	9	r.j	r.j	PROPN
admet-335	175	10	.	.	PROPN
admet-335	175	11	honeywell	honeywell	PROPN
admet-335	175	12	,	,	PUNCT
admet-335	175	13	h.	h.	PROPN
admet-335	175	14	dekker	dekker	PROPN
admet-335	175	15	,	,	PUNCT
admet-335	175	16	g.j	g.j	PROPN
admet-335	175	17	.	.	PROPN
admet-335	175	18	peters	peters	PROPN
admet-335	175	19	.	.	PUNCT
admet-335	175	20	,	,	PUNCT
admet-335	175	21	expert	expert	ADJ
admet-335	175	22	opinion	opinion	NOUN
admet-335	175	23	drug	drug	NOUN
admet-335	175	24	metab	metab	NOUN
admet-335	175	25	.	.	PUNCT
admet-335	176	1	toxicol	toxicol	PROPN
admet-335	176	2	.	.	PUNCT
admet-335	177	1	11	11	NUM
admet-335	177	2	(	(	PUNCT
admet-335	177	3	2015	2015	NUM
admet-335	177	4	)	)	PUNCT
admet-335	177	5	703	703	NUM
admet-335	177	6	-	-	SYM
admet-335	177	7	717	717	NUM
admet-335	177	8	.	.	PUNCT
admet-335	178	1	[	[	X
admet-335	178	2	19	19	NUM
admet-335	178	3	]	]	X
admet-335	178	4	i.b	i.b	PROPN
admet-335	178	5	.	.	PROPN
admet-335	178	6	muller	muller	PROPN
admet-335	178	7	,	,	PUNCT
admet-335	178	8	a.j	a.j	PROPN
admet-335	178	9	.	.	PROPN
admet-335	178	10	de	de	PROPN
admet-335	178	11	langen	langen	PROPN
admet-335	178	12	,	,	PUNCT
admet-335	178	13	r.j	r.j	PROPN
admet-335	178	14	.	.	PROPN
admet-335	178	15	honeywell	honeywell	PROPN
admet-335	178	16	,	,	PUNCT
admet-335	178	17	e.	e.	PROPN
admet-335	178	18	giovannetti	giovannetti	PROPN
admet-335	178	19	,	,	PUNCT
admet-335	178	20	g.j	g.j	PROPN
admet-335	178	21	.	.	PROPN
admet-335	178	22	peters	peters	PROPN
admet-335	178	23	,	,	PUNCT
admet-335	178	24	exp	exp	PROPN
admet-335	178	25	.	.	PROPN
admet-335	178	26	review	review	NOUN
admet-335	178	27	anticancer	anticancer	NOUN
admet-335	178	28	therapy	therapy	NOUN
admet-335	178	29	16	16	NUM
admet-335	178	30	(	(	PUNCT
admet-335	178	31	2016	2016	NUM
admet-335	178	32	)	)	PUNCT
admet-335	178	33	147	147	NUM
admet-335	178	34	-	-	SYM
admet-335	178	35	157	157	NUM
admet-335	178	36	.	.	PUNCT
admet-335	179	1	[	[	X
admet-335	179	2	20	20	NUM
admet-335	179	3	]	]	PUNCT
admet-335	179	4	a.	a.	NOUN
admet-335	179	5	avan	avan	PROPN
admet-335	179	6	,	,	PUNCT
admet-335	179	7	m.	m.	NOUN
admet-335	179	8	maftouh	maftouh	PROPN
admet-335	179	9	,	,	PUNCT
admet-335	179	10	n.	n.	PROPN
admet-335	179	11	funel	funel	PROPN
admet-335	179	12	,	,	PUNCT
admet-335	179	13	et	et	PROPN
admet-335	179	14	al	al	PROPN
admet-335	179	15	.	.	PROPN
admet-335	179	16	,	,	PUNCT
admet-335	179	17	curr	curr	PROPN
admet-335	179	18	.	.	PUNCT
admet-335	179	19	med	med	PROPN
admet-335	179	20	.	.	PROPN
admet-335	179	21	chem	chem	PROPN
admet-335	179	22	.	.	PUNCT
admet-335	180	1	21	21	NUM
admet-335	180	2	(	(	PUNCT
admet-335	180	3	2014	2014	NUM
admet-335	180	4	)	)	PUNCT
admet-335	180	5	975	975	NUM
admet-335	180	6	-	-	SYM
admet-335	180	7	89	89	NUM
admet-335	180	8	.	.	PUNCT
admet-335	181	1	[	[	X
admet-335	181	2	21	21	NUM
admet-335	181	3	]	]	X
admet-335	181	4	k.g	k.g	PROPN
admet-335	181	5	.	.	PROPN
admet-335	181	6	gotink	gotink	PROPN
admet-335	181	7	,	,	PUNCT
admet-335	181	8	h.j	h.j	PROPN
admet-335	181	9	.	.	PROPN
admet-335	181	10	broxterman	broxterman	PROPN
admet-335	181	11	,	,	PUNCT
admet-335	181	12	m.	m.	NOUN
admet-335	181	13	labots	labots	PROPN
admet-335	181	14	,	,	PUNCT
admet-335	181	15	r.r	r.r	PROPN
admet-335	181	16	.	.	PROPN
admet-335	181	17	de	de	PROPN
admet-335	181	18	haas	haas	PROPN
admet-335	181	19	,	,	PUNCT
admet-335	181	20	h.	h.	PROPN
admet-335	181	21	dekker	dekker	PROPN
admet-335	181	22	,	,	PUNCT
admet-335	181	23	r.j	r.j	PROPN
admet-335	181	24	.	.	PROPN
admet-335	181	25	honeywell	honeywell	PROPN
admet-335	181	26	,	,	PUNCT
admet-335	181	27	m.a	m.a	PROPN
admet-335	181	28	.	.	PROPN
admet-335	181	29	rudek	rudek	PROPN
admet-335	181	30	,	,	PUNCT
admet-335	181	31	l.v	l.v	PROPN
admet-335	181	32	.	.	PROPN
admet-335	181	33	beerepoot	beerepoot	PROPN
admet-335	181	34	,	,	PUNCT
admet-335	181	35	r.j	r.j	PROPN
admet-335	181	36	.	.	PROPN
admet-335	181	37	musters	muster	NOUN
admet-335	181	38	,	,	PUNCT
admet-335	181	39	g.	g.	PROPN
admet-335	181	40	jansen	jansen	PROPN
admet-335	181	41	,	,	PUNCT
admet-335	181	42	a.w	a.w	PROPN
admet-335	181	43	.	.	PROPN
admet-335	181	44	griffioen	griffioen	PROPN
admet-335	181	45	,	,	PUNCT
admet-335	181	46	y.g	y.g	PROPN
admet-335	181	47	.	.	PROPN
admet-335	181	48	assaraf	assaraf	PROPN
admet-335	181	49	,	,	PUNCT
admet-335	181	50	r.	r.	PROPN
admet-335	181	51	pili	pili	PROPN
admet-335	181	52	,	,	PUNCT
admet-335	181	53	g.j	g.j	PROPN
admet-335	181	54	.	.	PROPN
admet-335	181	55	peters	peters	PROPN
admet-335	181	56	,	,	PUNCT
admet-335	181	57	h.m.w	h.m.w	PROPN
admet-335	181	58	.	.	PROPN
admet-335	181	59	verheul	verheul	PROPN
admet-335	181	60	,	,	PUNCT
admet-335	181	61	clin	clin	PROPN
admet-335	181	62	.	.	PUNCT
admet-335	182	1	cancer	cancer	NOUN
admet-335	182	2	res	re	NOUN
admet-335	182	3	.	.	PROPN
admet-335	183	1	17	17	NUM
admet-335	183	2	(	(	PUNCT
admet-335	183	3	2011	2011	NUM
admet-335	183	4	)	)	PUNCT
admet-335	183	5	7337	7337	NUM
admet-335	183	6	-	-	SYM
admet-335	183	7	7346	7346	NUM
admet-335	183	8	.	.	PUNCT
admet-335	184	1	[	[	X
admet-335	184	2	22	22	NUM
admet-335	184	3	]	]	X
admet-335	184	4	l.	l.	PROPN
admet-335	184	5	mologni	mologni	PROPN
admet-335	184	6	,	,	PUNCT
admet-335	184	7	expert	expert	NOUN
admet-335	184	8	opin	opin	NOUN
admet-335	184	9	.	.	PUNCT
admet-335	184	10	investig	investig	NOUN
admet-335	184	11	.	.	PUNCT
admet-335	185	1	drugs	drug	NOUN
admet-335	185	2	21	21	NUM
admet-335	185	3	(	(	PUNCT
admet-335	185	4	2012	2012	NUM
admet-335	185	5	)	)	PUNCT
admet-335	185	6	985	985	NUM
admet-335	185	7	-	-	SYM
admet-335	185	8	94	94	NUM
admet-335	185	9	.	.	PUNCT
admet-335	186	1	[	[	X
admet-335	186	2	23	23	NUM
admet-335	186	3	]	]	X
admet-335	186	4	y.p	y.p	PROPN
admet-335	186	5	.	.	PROPN
admet-335	186	6	mosse	mosse	PROPN
admet-335	186	7	,	,	PUNCT
admet-335	186	8	m.s	m.s	PROPN
admet-335	186	9	.	.	PROPN
admet-335	186	10	lim	lim	PROPN
admet-335	186	11	,	,	PUNCT
admet-335	186	12	s.d	s.d	PROPN
admet-335	186	13	.	.	PROPN
admet-335	186	14	voss	voss	PROPN
admet-335	186	15	,	,	PUNCT
admet-335	186	16	et	et	PROPN
admet-335	186	17	al	al	PROPN
admet-335	186	18	.	.	PROPN
admet-335	186	19	,	,	PUNCT
admet-335	186	20	lancet	lancet	PROPN
admet-335	186	21	oncol	oncol	ADJ
admet-335	186	22	.	.	PUNCT
admet-335	187	1	14	14	NUM
admet-335	187	2	(	(	PUNCT
admet-335	187	3	2013	2013	NUM
admet-335	187	4	)	)	PUNCT
admet-335	187	5	472	472	NUM
admet-335	187	6	-	-	SYM
admet-335	187	7	80	80	NUM
admet-335	187	8	.	.	PUNCT
admet-335	188	1	[	[	X
admet-335	188	2	24	24	NUM
admet-335	188	3	]	]	X
admet-335	188	4	j.r	j.r	PROPN
admet-335	188	5	.	.	PROPN
admet-335	188	6	kroep	kroep	PROPN
admet-335	188	7	,	,	PUNCT
admet-335	188	8	g.j	g.j	PROPN
admet-335	188	9	.	.	PROPN
admet-335	188	10	peters	peters	PROPN
admet-335	188	11	,	,	PUNCT
admet-335	188	12	c.j	c.j	PROPN
admet-335	188	13	.	.	PROPN
admet-335	188	14	van	van	PROPN
admet-335	188	15	moorsel	moorsel	PROPN
admet-335	188	16	,	,	PUNCT
admet-335	188	17	et	et	PROPN
admet-335	188	18	al	al	PROPN
admet-335	188	19	.	.	PROPN
admet-335	188	20	,	,	PUNCT
admet-335	188	21	ann	ann	PROPN
admet-335	188	22	.	.	PROPN
admet-335	188	23	oncol	oncol	PROPN
admet-335	188	24	.	.	PUNCT
admet-335	189	1	10	10	NUM
admet-335	189	2	(	(	PUNCT
admet-335	189	3	1999)1503	1999)1503	NUM
admet-335	189	4	-	-	PUNCT
admet-335	189	5	10	10	NUM
admet-335	189	6	.	.	PUNCT
admet-335	190	1	©	©	PROPN
admet-335	190	2	2016	2016	NUM
admet-335	190	3	by	by	ADP
admet-335	190	4	the	the	DET
admet-335	190	5	authors	author	NOUN
admet-335	190	6	;	;	PUNCT
admet-335	190	7	licensee	licensee	PROPN
admet-335	190	8	iapc	iapc	PROPN
admet-335	190	9	,	,	PUNCT
admet-335	190	10	zagreb	zagreb	PROPN
admet-335	190	11	,	,	PUNCT
admet-335	190	12	croatia	croatia	PROPN
admet-335	190	13	.	.	PUNCT
admet-335	191	1	this	this	DET
admet-335	191	2	article	article	NOUN
admet-335	191	3	is	be	AUX
admet-335	191	4	an	an	DET
admet-335	191	5	open	open	ADJ
admet-335	191	6	-	-	PUNCT
admet-335	191	7	access	access	NOUN
admet-335	191	8	article	article	NOUN
admet-335	191	9	distributed	distribute	VERB
admet-335	191	10	under	under	ADP
admet-335	191	11	the	the	DET
admet-335	191	12	terms	term	NOUN
admet-335	191	13	and	and	CCONJ
admet-335	191	14	conditions	condition	NOUN
admet-335	191	15	of	of	ADP
admet-335	191	16	the	the	DET
admet-335	191	17	creative	creative	ADJ
admet-335	191	18	commons	common	NOUN
admet-335	191	19	attribution	attribution	NOUN
admet-335	191	20	license	license	NOUN
admet-335	191	21	(	(	PUNCT
admet-335	191	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-335	191	23	)	)	PUNCT
admet-335	191	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN